Nieuws borstkanker


balk2.jpg (42734 bytes)


Kans op overleving borstkanker groter bij vrouwen met meer sociale connecties

Uit grootschalig onderzoek door Kaiser Permanente blijkt dat bij vrouwen met invasieve borstkanker, sociaal geÔntegreerde vrouwen - met de meeste sociale banden zoals een partner, gemeenschapsbetrekkingen, vriendschappen en familieleden - beduidend minder overlijdensgevallen door kanker en terugkeer van de ziekte voorkomen dan bij sociaal geÔsoleerde vrouwen. Vandaag werd deze studie gepubliceerd in de uitgave Cancer van de American Cancer Society.

Lees verder


Verband hogere vitamine D en betere uitkomsten bij borstkanker

Vrouwen met hogere vitamine D-gehaltes in het bloed na de diagnose borstkanker hadden aanzienlijk betere vooruitzichten op de lange termijn, volgens nieuw onderzoek van Kaiser Permanente en Roswell Park Cancer Institute. Het onderzoek werd online gepubliceerd in JAMA Oncology. Vitamine D is een voedingsstof die het meest bekend staat om zijn rol bij het in stand houden van gezonde botten; andersom staat een tekort aan vitamine D in verband met het risico op verschillende soorten kanker.

Lees verder


Kruisbloemige groente zoals broccolie, boerenkool en borstkanker

Omdat Nederlandse experts zoals hoogleraar Martijn Katan continue zeggen dat voordelen van groente bij ziektes als kanker worden overdreven zullen we keer op keer mensen en studies laten zien die het tegendeel beweren. Onderzoek dus alles en bepaal je eigen waarheid.


De andere kant van Pink Ribbon akties - Pink Washing


Deodorant en borstkanker

Op de website van Pink Ribbon lees ik dat vandaag de dag 1 op de 7 vrouwen borstkanker krijgt en dat er slechts bij 5 tot 8 % van de borstkankerpatiŽnten sprake is van erfelijkheid. Maar ook daar wordt niet gesproken over een mogelijk verband met alu. De borstkanker vereniging noemt dit zelfs een fabeltje, KWF weigert deze info op hun FB pagina te plaatsen, AD bedankte me ('Hai Ellen, dank voor de tip. We kijken er naar. Groet - AD') en verder maar afwachten. Even terzijde: de meeste RVP-vaccins bevatten ook aluminiumzouten.

Lees verder


Eetgewoonten mannelijke rat van invloed op risico borstkanker

Een studie van 60 mannelijke ratten en hun nakomelingen vond dat de voedingsgewoonten van de mannelijke ratten van invloed kan zijn op het risico op borstkanker bij hun dochters. De studie is gepubliceerd in het open access tijdschrift Breast Cancer Research.

Lees verder....


Afname vermoeidheid bij borstkankerpatiŽnten door acupressuur

Acupressuur zorgde voor vermindering van vermoeidheid bij vrouwen die een behandeling hadden ondergaan tegen borstkanker, blijkt uit nieuwe studie. Vermoeidheid is ťťn van de vaakst voorkomende langetermijneffecten van een borstkankerbehandeling. Ongeveer een derde van de vrouwen heeft last van matige tot ernstige vermoeidheid tot 10 jaar na het einde van de behandeling.

Lees verder


Gunstige bacteriŽn kunnen de borsten tegen kanker beschermen

Bepaalde bacteriŽn zijn aanwezig in de borsten van kankerpatiŽnten terwijl gunstige bacteriŽn overvloedig aanwezig zijn in gezonde borsten waarbij zij feitelijk vrouwen kunnen beschermen tegen kanker, volgens Gregor Reid, PhD, en zijn medewerkers. Deze bevindingen kunnen uiteindelijk leiden tot het gebruik van probiotica om vrouwen te beschermen tegen borstkanker.

Lees verder


Hop kan het risico op borstkanker helpen verminderen

Hop, de bloem kegels die gebruikt worden om bier te maken, worden ook gevonden in voedingssupplementen ontworpen om te helpen bij de behandeling van post-menopauzale symptomen en andere klachten. Wetenschappers onderzoeken nu of een uittreksel uit de plant ook zou kunnen helpen ter voorkoming van borstkanker.

Lees verder


Alcohol kan het risico op borstkanker verhogen

Een team aan de universiteit van Houston hebben een belangrijke schakel ontdekt tussen alcohol en borstkanker door het identificeren van een kankerverwekkende gen getriggerd door alcohol. ďIn de Verenigde Staten komt alcoholconsumptie vaker voor bij vrouwen en is een risicofactor voor borstkanker," zegt UH kankerbioloog Chin-Lin Yo. "Ons onderzoek toont aan dat alcohol de werking van oestrogeen verhoogt in het stimuleren van de groei van borstkankercellen en de effecten van het kankermedicijn Tamoxifen op oestrogeen blokkering vermindert door het verhogen van de niveaus van een kankerverwekkend gen genaamd BRAF."

Lees verder


Paradontitis geassocieerd met een verhoogd risico op borstkanker

Parodontitis is een veel voorkomende aandoening die geassocieerd wordt met hartziekten, beroerte en diabetes. Eerder onderzoek heeft verband gevonden tussen parodontitis en orale-, slokdarm,- hoofd - en nek-, pancreas- en longkanker zodat de onderzoekers ook wilden weten of er ook een relatie was met borstkanker.

Lees verder


Samenhang vrouwelijke hormoonsupplementen met oestrogeen en progestageen en borstkankerrisico

Postmenopauzale Afrikaans-Amerikaanse vrouwen die vrouwelijke hormoonsupplementen gebruiken met oestrogeen en progesteron (ďcombinatietherapieĒ) lopen een verhoogd risico op oestrogeenreceptor-positieve borstkanker. Uit de studie, die verschijnt in het Journal of the National Cancer Institute, blijkt dat de toename van het risico over het geheel 50 procent bedroeg, met een nog grotere toename bij recent en/of langdurig gebruik.

Lees verder


Neurotoxische effecten van chemotherapieŽn op cognitie bij borstkankeroverlevenden

De cognitieve beperking gerelateerd aan kanker - vaak een Ďchemobreiní genoemd - is waarschijnlijk groter voor bepaalde cognitieve domeinen en hersennetwerkverbindingen als gevolg van een op anthracycline gebaseerde therapie, vergeleken met behandelingen met een andere soort chemotherapie, zo blijkt uit een artikel dat online bij JAMA Oncology verscheen.

Lees verder


Borstdichtheid niet de enige risicofactor is voor kanker

Volgens een nieuwe studie gepresenteerd tijdens de jaarlijkse bijeenkomst van de ĎRadiological Society of North America (RSNA)í, is borstdichtheid geen sterke onafhankelijke factor voor borstkanker risico.

Lees verder


Chemotherapie kan zorgen voor ontwikkeling van borstkanker tumor

Russische wetenschappers hebben ontdekt dat neo-adjuvante chemotherapie bij patiŽnten met borstkanker de ontwikkeling van de tumor kan stimuleren. De resultaten van het onderzoek, geleid door Nicholay Litvyakov, D.Sc., hoofd van het Tumor Virologie Laboratorium bij het Instituut voor Kankeronderzoek en TSU-onderzoeker Marina Ibragimova, zijn gepubliceerd in Siberian Journal of Oncology.

Lees verder


Mediterraan dieet plus olijfolie geeft minder risico op borstkanker

Volgens een artikel online gepubliceerd door JAMA Internal Medicine wijst een studie onder Spaanse vrouwen uit dat een mediterraan dieet aangevuld met extra ďviergeĒ olijfolie kan geassocieerd worden met een relatief lager risico op borstkanker.

Lees verder


Vals alarm bij borstkanker heeft een negatieve invloed op de gezondheid

De psychologische belasting van de mededeling dat je borstkanker zou kunnen hebben kan zwaar zijn, zelfs als later blijkt dat het een vals alarm geweest is. Dit is het resultaat van nieuw onderzoek van de Universiteit van Kopenhagen, dat recentelijk gepubliceerd is in het wetenschappelijke tijdschrift ďAnnals of Family MedicineĒ.

Lees verder


Gewone hormonen kunnen helpen bij de behandeling van borstkanker

Ongeveer de helft van alle borstkanker patiŽnten zullen op een dag de voordelen ervan kunnen ervaren , wanneer het goedkope en wijdverbreid verkrijgbare progesteron hormoon zal worden toegevoegd aan hun behandeling, aldus het door het Cancer Research UK gesteunde onderzoek, gepubliceerd in Nature afgelopen week donderdag. Tumoren welke hun brandstof uit het vrouwelijke oestrogeen halen worden behandeld met het medicijn Tamoxifen welke de oestrogeen receptoren blokkeert, zodat kankercellen niet verder kunnen groeien.

Lees verder


Borstkanker en regulatiethermografie

Borstkanker is wereldwijd de meest voorkomende kanker bij vrouwen zoals prostaatkanker dat is bij mannen. Er wordt daarom veel geÔnvesteerd in onderzoek naar de oorzaak en effectieve behandelingen. In de reguliere gezondheidszorg worden steeds meer geavanceerde diagnostische systemen en kankercel dodende medicatie toegepast. In de complementaire geneeskunde worden middelen en zienswijzen gepromoot die de oplossing zouden zijn maar naar eigen zeggen worden genegeerd en tegengewerkt door politiek en industrie.

Lees verder


Verstoringen in de biologische klok verhogen het risico op borstkanker

De verstoring van iemands dag en nacht ritme -de 24-uurs biologische klok - is verbonden aan een verhoogd risico op borstkanker, aldus nieuwe University of Georgia onderzoek. De boosdoener, in deze studie in het bijzonder, is kunstlicht. "Blootstelling aan kunstlicht leidt tot een significant hoger risico voor het ontwikkelen van borstkanker," zei Chunla He, een afgestudeerd student in biostatistiek van het UGA College of Public Health. "Om kunstlicht verbruik te verminderen, zou men 's nachts te werken moeten vermijden en de gewoonte aannemen vroeger naar bed te gaan."

Lees verder


Diversiteit van darmbacteriŽn in verband gebracht met een gunstige verhouding van oestrogeen metabolieten

Postmenopauzale vrouwen met verschillende soorten darmbacteriŽn vertonen een gunstiger verhouding tussen oestrogeen metabolieten, die in verband wordt gebracht met een verlaagd risico op borstkanker in vergelijking met vrouwen met minder microbiŽle variatie, volgens een nieuwe studie gepubliceerd in het Endocrine Society's Journal of Clinical Endocrinologie en Metabolisme ( JCEM ).

Lees verder


Borstkanker en wijn

Na de diagnose kunnen vrouwen het risico om te sterven zo goed als halveren door enkele eenvoudige en gemakkelijke veranderingen in levensstijl - 5 of meer porties fruit en groenten per dag en 30 minuten wandelen per dag, 6 dagen in de week. Maar hoe zit het met het voorkomen van borstkanker?

Lees verder


Perzik extract remt uitzaaiing van borstkanker

Laboratoriumtesten aan het Texas A & M AgriLife Research heeft aangetoond dat behandelingen met perzik extract, uitzaaiingen van borstkanker afremt bij muizen. Volgens een studie gepubliceerd in het Journal of Nutritional Biochemistry, zeggen AgriLife Research wetenschappers dat het mengsel van fenolische verbindingen aanwezig in perzikextract verantwoordelijk is voor de remming van metastasen.

Lees verder


Vitamine D verhoogt overlevingskansen van borstkanker patiŽnten

Borstkanker patiŽnten met hoge niveaus van vitamine D in hun bloed hebben twee keer zoveel kans om de ziekte te overleven als vrouwen met lage niveaus van deze voedingsstof, rapporteren de Universiteit van CaliforniŽ, San Diego School of Medicine onderzoekers in het maartnummer van Anticancer Research. In eerdere studies toonden Cedric F. Garland, DrPH, professor in het Department of Family and Preventive Medicine aan dat een lage vitamine D-spiegel werd gekoppeld aan een hoog risico op premeno-pauzale borstkanker. Deze vaststelling, zei hij, bracht hem ertoe de relatie tussen de 25-hydroxyvitamine D - een metaboliet gevormd door het lichaam na de inname van vitamine D - en borstkanker overlevingskansen te onderzoeken.

Lees verder


Een dieet rijk aan tomaten kan het risico op borstkanker verlagen

Deze groenten verhoogden het niveau van hormonen dat betrokken is bij het reguleren van bloedsuiker en vet. Chevy Chase , MD - Uit een nieuw onderzoek geaccepteerd voor publicatie in 'The Endocrine Society's Journal of Clinical Endocrinology & Metabolism' blijkt dat een tomatenrijk dieet kan helpen postmenopauzale vrouwen te beschermen tegen borstkanker.

Het risico op borstkanker stijgt bij postmenopauzale vrouwen als hun 'body mass index' (BMI) verhoogt. De studie vond dat het eten van een dieet rijk aan tomaten een positief effect had op het niveau van hormonen die een rol spelen bij de regulering van vet- en suikerstofwisseling.

Lees verder


Mentale mist door tamoxifen is reŽel; URMC vind mogelijk tegengif

Een team van de Universiteit van Rochester Medical Center (URMC) heeft wetenschappelijk aangetoond wat veel vrouwen anekdotisch melden: dat het borstkanker medicijn tamoxifen giftig is voor cellen van de hersenen en het centrale zenuwstelsel, het produceert mentale mist gelijkaardig aan "chemo brain ."

Echter , in het Journal of Neuroscience melden onderzoekers dat ze een bestaand geneesmiddel hebben ontdekt die lijkt de schadelijke effecten van het borstkankermedicijn tegen te werken.

Auteur Mark Noble , Ph.D. , hoogleraar Biomedische Genetica en directeur van de UR Stem Cell en Regenerative Medicine Institute, zei dat het spannend is om potentieel in staat te zijn om een toxische reactie te voorkomen van ťťn van de oudste en meest gebruikte medicijnen bij borstkanker. Hoewel tamoxifen relatief gunstig is vergeleken met de meeste kankerbehandelingen produceert het toch verontrustende bijwerkingen.

lees verder


Hoe kan zwangerschap het risico op borstkanker verminderen?

Het is bekend dat zwanger zijn als je jong bent een vrouw tegen borstkanker kan beschermen. Onderzoek in 'BioMed Central's open acces journal Breast Cancer Research' constateert dat de Wnt/Notch signaalwegen verhouding wordt verlaagd in het borstweefsel van muizen die bevallen zijn, in vergelijking met maagdelijke muizen van dezelfde leeftijd. Zwangerschap op een jonge leeftijd beschermd tegen borstkanker bij mensen en knaagdieren. Het risico op kanker vermindert bij een mens als ze voor de leeftijd van 20 jaar een kind baart. Zogenaamde 'microarray analysis' onderzoekers uit Basel ontdekten dat genen welke betrokken zijn in het immuunsysteen en differentiatie, werden up-gereguleerd na de zwangerschap, terwijl de activiteit van genen die coderen voor groeifactoren verminderden.  De activiteit van een bepaald Wnt4 werd ook down-gereguleerd na de zwangerschap. Het eiwit van dit gen (Wnt4) is een feminisering eiwit -ontbreken van dit eiwit stuwt een foetus naar de ontwikkeling als een jongen.

Lees verder


Vergelijking van Tamoxifen met eetbare zeewier (Eucheuma cottonii L.) extract bij het onderdrukken van borsttumoren

Institute of Bioscience, University Putra Malaysia, 43400 Serdang, Selangor, MaleisiŽ.

De tropische eetbare rode zeewier (Eucheuma cottonii L.) is rijk aan voedingsstoffen en polyfenolische verbindingen die kanker kunnen onderdrukken door middel van de anti-oxidanten en anti-proliferatieve eigenschappen. De studie rapporteert over het onderdrukken van borsttumoren en weefsel antioxidant statusmodulatie door E. cottonii ethanolextract (ECE). Het effect van oraal toegediend ECE (100 mg / kg lichaamsgewicht) werd vergeleken met die van tamoxifen (10 mg / kg lichaamsgewicht).

Ratten werden langs subcutane injectie met LA-7 cellen (6 x 10 (6) cellen / rat) geÔnduceerd om borstkanker te ontwikkelen . De ECE was werkzamer dan tamoxifen in het onderdrukken van de tumorgroei (27%) met verbetering van weefsels (plasma, lever en nier) malondialdehyde concentraties superoxide dismutase activiteit en erythrocyte glutathione concentraties (P <0,05). In tegenstelling tot tamoxifen keverde de ECE weinig toxiciteit aan lever en nieren. De ECE toonde een sterk antikanker effect met enzym modulerende eigenschappen hetgeen wijst op het potentieel voor het onderdrukken van borstkliertumoren.

Vertaling Andre Teirlinck


Verhoogt uw werk het risico op borstkanker?

Is er een verband tussen het risico op borstkanker en de werkomgeving? Een studie gepubliceerd in het open tijdschrift BioMed Central's Environmental Health levert verder bewijs over dit voorheen verwaarloosde onderzoeksthema; bevestigd wordt dat bepaalde beroepen een hoger risico op borstkanker geven dan anderen, met name die welke de werknemer blootstellen aan potentieel kankerverwekkende stoffen en hormoonontregelaars. Borstkanker is de meest voorkomende vorm van kankerdiagnose bij vrouwen in de geÔndustrialiseerde landen, en de Noord-Amerikaanse cijfers behoren tot de hoogste in de wereld. Hormoonontregelende chemische- en kankerverwekkende stoffen, waarvan sommige nog niet als dusdanig zijn geclassificeerd, zijn aanwezig in veel werkomgevingen en kunnen het risico op borstkanker verhogen. In een recente studie gaan James T Brophy en zijn collega's op zoek naar de mogelijke verbanden tussen borstkanker en beroepen in de landbouw en de industrie. De op de bevolkingsbasis "case-control" studie werd uitgevoerd in het zuiden van Ontario, Canada op 1006 gevallen van borstkanker (aangeduid door het Windsor Cancer Centre) met 1147 willekeurig geselecteerd en afgestemde gemeenschapscontroles. Met behulp van interviews en enquÍtes verzamelde het team gegevens over de deelnemers hun beroeps-en reproductieve geschiedenis. Alle jobs werden gecodeerd voor hun kans op blootstelling aan carcinogene agentia en endocriene verstoorders, en de tumorpathologie van de patiŽnten met betrekking tot de endocriene receptor status werd beoordeeld.

Lees verder


Onderzoek bevindt uit groente afkomstige samenstelling effectief bij behandeling van triple-negatieve borstkanker

Arlington, Va. ó een nieuwe ontwikkelde samenstelling uit een rijke bron van groenten zoals broccoli en spruiten is ontwikkeld ter bestrijding van triple-negatieve borstkanker (TNBC). Dit onderzoek wordt gepresenteerd op de jaarlijkse vergadering en expositie van de Amerikaanse Vereniging van Farmaceutische Wetenschappers (AAPS) 2012, 's werelds grootste conferentie in farmaceutische wetenschappen, in Chicago, Ill., van oktober 14-18, tijdens Borstkanker Awareness Month. TNBC (Triple Negatieve Borstkanker) gaat op voor ongeveer 15-20 procent van alle gevallen van borstkanker in de VS. Het is een van de meest agressieve vormen van borstkanker; het groeit sneller, breidt zich sneller uit naar andere delen van het lichaam, is moeilijker te detecteren op een mammogram en keert vaker terug.

Lees verder


Screenen van borstkanker met mammografie

Wat zijn de voor- en nadelen van het toepassen van borstkankeronderzoek?

Hoeveel mensen hebben er baat bij en hoeveel mensen worden erdoor geschaad?

Wat is het wetenschappelijk bewijs hiervoor?

Wat je altijd al wilde weten over screenen op borstkanker.

Lees verder


Borstkanker effectief behandeld met in selderij en peterselie gevonden chemische stoffen, door MU onderzoekers

Apigenin, een natuurlijke stof die voorkomt in supermarkt goederen, is waarschijnlijk een niet-toxische behandeling voor een agressieve vorm van menselijke borstkanker, dat naar aanleiding van een nieuw onderzoek aan de University of Missouri. MU onderzoekers vonden uit dat apigenin een vorm van een borstkanker tumor verkleinde die gestimuleerd werd door progestin, een synthetisch hormoon dat gegeven wordt aan vrouwen om menopauze symptomen te verlichten. ďDit is de eerste studie die aantoont dat apigenin, dat gewonnen kan worden uit selderij, peterselie en veel andere natuurlijke bronnen, effectief is tegen menselijke borstkanker cellen die beÔnvloed worden door een bepaalde chemische stof die gebruikt wordt in hormonale vervangingstherapie,Ē zegt mede-auteur Salman Hyder, de bijzonder hoogleraar van Zalk in Tumor Angiogenesis Medicine en het Dalton Cardiovascular Research Center.

Lees verder


Daling van borstkanker gevallen rechtstreeks gekoppeld aan verminderde hormonale therapie

In een nieuwe UCSF studie van meer dan 2 miljoen mammogram screenings uitgevoerd op bijna 700.000 vrouwen in de Verenigde Staten, laten wetenschappers voor het eerst een rechtstreeks verband zien tussen verlaagde hormoontherapie en de daling van ductaal carcinoma in situ (DCIS) alsmede invasieve borstkanker. De onderzoekers zagen een dergelijke opvallende daling, zij geloven dat zij ook indirect bewijsmateriaal aan het licht hebben gebracht dat hormonen borsttumorgroei bevordert. De dalingen deden zich voor in de leeftijdsgroepen die het meest op grote schaal vervolgens opgegeven hormoontherapie omarmd. Al bijna een decennium zijn postmenopauzale vrouwen sterk aangeraden om zich te onthouden van lange termijn hormoontherapie of dan de laagst mogelijke dosis voor korte tijd om opvliegers en nachtelijk zweten te verlichten.

Lees verder

John


Nieuwe behandeling borstkanker UMC Utrecht

Het UMC Utrecht begint volgende maand met het testen van een nieuwe behandelmethode van borstkanker door middel van ultrageluid.

Lees verder


MRI-scans 'te gevoelig'

Vrouwen die borstkanker hebben krijgen, vanwege over-gevoelige MRI-scans, overbodige operaties zoals borstamputaties.

Lees verder

Eric van Staalduinen


Breast cancer increasing among Dutch men


Childhood Radiation and Adult Breast Cancer

Dr. James G. Schwade reports on a possible link between childhood radiation treatment in adult breast cancer.


GZ waarschuwt opnieuw voor PIP-implantaten

De Inspectie voor de Gezondheidszorg (IGZ) doet opnieuw een oproep aan alle vrouwen met borstimplantaten van het Franse merk Poly Implant Protheses (PIP) om zich te laten onderzoeken, ook als zij geen klachten hebben.

Lees verder


Effect screening borstkanker klein

Een bevolkingsonderzoek naar borstkanker vermindert de sterfte aan die kanker met ongeveer 3 procent. Er is zelfs een kans dat het effect van de screening nihil is.

Lees verder

Jochem


Waterkers helpt tegen borstkanker

Het dagelijks eten van waterkers zou de kans op het ontwikkelen van borstkanker kunnen verminderen. Dat blijkt uit een onderzoek van de universiteit van Southampton.

Lees verder

Annemarieke (Healthylives.nl)


ProteÔne gemaakt door borstkanker gen reinigt

Een belangrijke stap bij het begrijpen van de oorsprong van borstkanker bij families, is gezet door door twee teams van wetenschappers van de Universiteit van California te Davis. De onderzoekers hebben voor de eerste keer de reinigende werking van proteÔne ontdekt door het borstkankergevoelige gen BRCA2 en gebruikte het in een kankeronderzoek naar het herstel van DNA.

Lees verder

Pieter Tau


Nieuw apparaat helpt borstkanker opsporen

Het kan een revolutie worden bij het opsporen van borstkanker. Het Jeroen Boschziekenhuis heeft een nieuw apparaat dat driedimensionale beelden maakt. Dat moet helpen bij een versnelde opsporing van tumoren in de borst. Het apparaat is nog bijna nergens ter wereld in gebruik. Het Jeroen Bosch Ziekenhuis heeft goede contacten met producent Siemens en krijgt de kans het uit te proberen en mee te werken aan een wetenschappelijk onderzoek. De driedimensionale beelden maken het veel gemakkelijker tumoren op te sporen. Uiteindelijk moet de computer zelf verdachte zaken signaleren die met het blote oog niet te zien zijn.


Dagelijks glas wijn verdubbelt kans op borstkanker

Een glas wijn per dag verdubbelt het risico op een vaak voorkomend type van borstkanker, dat blijkt vandaag uit onderzoek.

Lees verder


Yoga verbetert welzijn bij borstkanker

Iyengar-yoga kan vrouwen helpen beter te herstellen tijdens of na een behandeling bij borstkanker. Dit laat onderzoek van de University of Alberta zien.

Lees verder


Relatief veel borstkankerdoden in Nederland

Nederlandse vrouwen hebben voor Europese begrippen relatief weinig kans borstkanker te overleven.

Link

Zonder al teveel te hoeven nadenken zal een hogere UV-licht belasting met daardoor hogere vitamine D3 spiegels  een rol kunnen spelen...

House


Meer borstkanker in Nederland dan in Afrika

Nederlandse vrouwen hebben meer kans op borstkanker dan vrouwen in Oost-Afrikaanse landen zoals Kenia en Tanzania. Borstkanker komt hier vier keer meer voor dan in Oost-Afrika, zo constateert het Wereld Kanker Onderzoek Fonds.

Link

Amber Kesseler


Screening borstkanker redt ťťn leven per 258 onderzoeken ?

Critici zijn het niet eens met deze cijfers en zeggen dat per gered leven, tien vrouwen onnodig behandelingen ondergaan.

Link


Borstkankerscreening

Amper helft Vlaamse vrouwen laat zich screenen op borstkanker

Ongeveer de helft van de Vlaamse vrouwen heeft sinds 2001 een borstkankerscreening ondergaan. Momenteel bedraagt het gemiddelde
percentage geteste vrouwen 42 procent. [ Link ]

Borstkankerscreening vanaf veertig jaar is risicovol

Bij een screening van borstkanker vanaf veertig jaar zijn de mogelijke nadelen groter dan de voordelen. Belangrijke risico's zijn de straling bij de mammografie, overdiagnose en overbehandeling. [ Link ]

Vooropgesteld dat iedere vrouw de vrijheid hoort te hebben om zich tijdig te laten onderzoeken, wil ik opmerken dat toen ik een tijdje terug het
boek 'Wat artsen je niet vertellen', van de journaliste en schrijfster Lynne McTaggert las, dit schokkende zaken voor mij aan het licht bracht.

Niet alleen in dit kader van borstkanker onderzoek, maar vele manieren van onderzoek, is het goed om te weten wat er in de medische wereld omgaat. Een medaille heeft 2 kanten, en mijn ervaringen zijn dat ik er hooguit maar 1 te zien of te horen krijg en soms zelfs geen. Er is er maar 1 verantwoordelijk en eindverantwoordelijk voor Uw lichaam en dat bent Uzelf. En dat gaat het best, met de beste informatie die er is. Voor mij is dat geen borstkanker onderzoek doen, gerustgesteld worden of accuut in een behandeltraject storten, omdat er iets aan het licht is gekomen. Voor je het weet zit je in de stress en in een fuik, waar je nooit in terecht zou zijn gekomen, als je van te voren je had verdiept.

Amber Kesseler


Visoliecapsules beschermen tegen borstkanker

Vrouwen die visoliecapsules slikken hebben minder kanker op borstkanker. Dat ontdekten onderzoekers van de University of Washington die 35.000 vrouwen van 50-76 jaar zo'n 5 jaar hebben gevolgd. Het is voor de eerste keer dat onderzoekers op die manier hebben gekeken of supplementen beschermen tegen borstkanker.

Link


Minder kans op erfelijke borstkanker door actieve leefstijl

Een actieve leefstijl verkleint mogelijk de kans op erfelijke borstkanker. Dat is de voorlopige conclusie van het proefschrift van Anouk Pijpe, onderzoeker bij het Nederlands Kanker Instituut. Uit het onderzoek blijkt dat vrouwen met een erfelijke aanleg voor borstkanker (BRCA 1/2-mutatiedraagsters) de kans op het krijgen van borstkanker kunnen verkleinen door hun leefstijl aan te passen. Door voldoende te bewegen en een gezond lichaamsgewicht wordt het risico op borstkanker minder.

Link

Anne (Healthylives)


Mammaprint voorkomt soms chemo na kanker

De tijd dat bijna alle vrouwen die geopereerd worden aan borstkanker ook chemotherapie krijgen, is voorbij.

Link

Gerrit


Beter geen screening borstkanker bij 40'ers

De mogelijke nadelen van een screening van borstkanker vanaf veertig jaar zijn groter dan de voordelen. Belangrijke risico's zijn de straling bij de mammografie, overdiagnose en overbehandeling.

Link

Frank op de Beeck


Lynne McTaggart speaking on Breast Cancer

Lynne McTaggart speaking on modern medicine's treatment of breast cancer.


Nieuwe merker voor borstkanker ontdekt

Een multidisciplinair onderzoeksteam van de Universiteit Gent, het National Human Genome Research Institute (VS), het Imperial College London (Groot-BrittanniŽ) en INSERM (Frankrijk) heeft een eiwit ontdekt dat een belangrijke factor is voor de mate waarin borsttumoren kwaadaardig zijn. De ontdekking biedt perspectieven voor nieuwe behandelingen en correctere diagnoses. De resultaten van het onderzoek worden vandaag gepubliceerd in het gezaghebbende tijdschrift Journal of the National Cancer Institute.

Rab-eiwitten coŲrdineren het eiwitverkeer in de cel. Onderzoek naar de biologische functie van Rab27B, een regulator van het uitgaande eiwitverkeer, toonde aan dat deze molecule de groei en invasie stimuleert van hormoonpositieve borstkankercellen. Een hoge Rab27B-expressie in hormoonpositieve tumoren hangt samen met uitzaaiingen in de lymfeklieren en met de tumorgraad.

Sommige vrouwen die het bewuste eiwit aanmaken zijn veel gevoeliger voor de kwaadaardigheid van borsttumoren dan anderen. De conclusies van het onderzoek kunnen belangrijke gevolgen hebben voor de behandeling van tumoren. De nieuwe kennis kan leiden tot betere medicatie om kankercellen onder controle te houden.

Borstkanker is wereldwijd de meest voorkomende kanker. In BelgiŽ worden jaarlijks ongeveer 9.000 diagnoses gesteld. De ernst van de ziekte wordt bepaald door infiltratieve tumorgroei en uizaaiingen in andere weefsels.


Genetische verschillen kunnen gewrichtspijn beinvloeden onder vrouwen die levensreddende borstkankermedicijnen nemen

Aromatase-remmers hebben als grootste bijwerking gewrichtspijn, die zo heftig kan zijn dat bijna 10 procent van de vrouwen met borstkanker die deze medicijnen gebruiken de behandeling met deze levensreddende medicijnen voortijdig onderbreken. Uit nieuw onderzoek van de University of Pennsylvania's Abramson Cancer Center dat tijdens een bijeenkomst van de American Society of Clinical Oncology in 2010 werd gepresenteerd toont een mogelijke genetische basis voor het wel of niet voorkomen van deze bijwerking.

Link

Ingeborg Boucheloukh


Dr. Nitin Tanna Discusses Digital Mammography

Radiologist Dr. Nitin Tanna, Chief of Mammography Services at Lancaster General Health, discusses digital mammography in a video.


Wetenschappers hebben een nieuwe manier gevonden om de gevoeligheid van de borstkankercellen voor behandeling te 'behouden'

Uit een onderzoek van het Georgetown Lombardi Comprehensive Cancer Center van het Georgetown University Medical Center is mogelijk een nieuwe therapiecombinatie ontdekt om de gevoeligheid voor fulvestrant bij borstkankers met positieve estrogene recpetoren te "redden". De bevindingen zijn op 15 mei 2010 gepubliceerd als omslagartikel van het tijdschrift Molecular Cancer Therapeutics

Link

Ignit Bekken


Borstkanker preventie !

Stuur de link door aan elke dame die U kent.....

Link

Ditta


Overleven van metastatische borstkanker is direct verbonden
met rondwarende tumor cellen

Uit een nieuwe studie van metastatische (zich door het lichaam verspreidende) borstkanker blijkt dat het aantal rondwarende tumorcellen dat patienten in hun bloed hebben, rechtstreeks correleert met hun overlevingsduur.

Link

Constans Kootstra


Meldpunt siliconen borstimplantaten

Dit is een officieel meldpunt voor alle vrouwen die klachten ervaren nadat zij siliconen borstimplantaten hebben laten plaatsen ťn voor alle mensen die klachten ervaren door Šnder siliconen materiaal.

Link


Vitamine D supplementen verminderen de kans op borstkanker

Een nieuwe studie van Canadese onderzoekers, gepubliceerd in het American Journal of Clinical Nutrition van 14 april 2010, stelt dat de inname van vitamine D supplementen het risico op borstkanker drastisch vermindert. Anderson L.N. en collega's van het PSSCCO in Ontario leidden het patient-controle-onderzoek (dit is een groep patiŽnten die de aandoening heeft, te vergelijken met een groep patiŽnten die deze niet heeft), en kwamen tot de ontdekking dat vrouwen die 400 IU vitamine D per dag namen, 24% minder kans hadden op borstkanker vergeleken met vrouwen die niets innamen. Anderson vergeleek 3101 borstkanker patiŽnten in de leeftijd van 25 tot 74 met een controle groep van 3471 op hun inname van vitamine D door middel van supplematie en voeding om te kijken of vitamine D van invloed was op het risico op borstkanker.

Eerdere onderzoeken lieten zien dat vitamine D gebrek het risico op kanker verhoogde. Een aantal voedingsmiddelen die van nature vitamine D bevat zijn vette vis, eigeel en champignons. GeÔndustrialiseerde, voorbewerkte voedingsmiddelen en dranken die verrijkt zijn met vitamine D zijn o.a. melk, jus d'orange en nog een aantal vaste voedingsmiddelen. De onderzoekers vonden geen significant verband tussen de inname van calcium supplementen en de vermindering van borstkanker. Ze vonden ook geen wisselwerking tussen vitamine D, calcium en de menopauze die van invloed zou kunnen zijn op het risico op borstkanker.

Een ander patient-controle onderzoek van Japanse wetenschappers, gepubliceerd in het januari nummer van Cancer Science, stelt dat het beschermende effect van vitamine D en calcium inname tegen borstkanker afhangt van de mate van ontvankelijkheid en aanleg hiervoor en het stadium van de menopauze waarin de vrouw verkeert. Voor dit onderzoek werden 1803 borstkanker patiŽnten vergeleken met 3606 andere kankerpatiŽnten. Ze ontdekten een belangrijk inversief verband tussen de inname van vitamine D en calcium supplementen en het risico op borstkanker onder alle patiŽnten. Ze constateerden dat vitamine D de kans op borstkanker alleen verminderde bij vrouwen voor hun menopauze en dat calcium hielp bij vrouwen na hun menopauze. Zonlicht is de beste bron voor vitamine D. 15 to 20 minuten blootstelling aan de zon gedurende het heetste moment van de dag, resulteert in genoeg vitamine D voor de gehele dag (dit is tenminste 10.0000 IU (internationale eenheden)). Experts zeggen dat vitamine supplementen noodzakelijk zijn voor mensen die nauwelijks buiten komen. Zij lopen anders een groot risico op allerlei ziekten zoals kanker, diabetes, hartaandoeningen en andere ziekten.
Dr. John Cannel, een vitamine D expert en directeur van de vitamine D raad, stelt op zijn website dat mensen minstens 4000 tot 5000 IU per dag binnen moeten krijgen om het beschermende niveau te kunnen handhaven. De Canadian Cancer Society beveelt 1000 IU per dag aan om kanker te voorkomen.

Link

Ineke


Kanker eerder te zien via tepelvocht

Een analyse van tepelvocht kan mogelijk in een vroeger stadium aantonen of een vrouw borstkanker heeft

Link


Ah-ha Moment Leads to New Breast Cancer Tumor Testing Standards

In a front-page April 19 story, the New York Times describes the moment of truth that Dr. Edith Perez, a breast cancer oncologist and researcher at Mayo Clinic, Florida, had in 2001 about the quality of tests given around the world to newly diagnosed breast cancer patients. These tests are designed to assess what kind of tumors a woman has, based on proteins on the cancer. Correct treatment depends on that information. As the principal investigator of two large national studies of Herceptin for women with HER2 positive early-stage breast cancer, she knew that women were having these tests at all kinds of places, from community hospitals to major medical centers to central national labs that specialize in these tests. She wondered if the women entering her clinical trials based on a positive HER2 test actually did have that kind of cancer. So she decided to retest the tumor samples in a central lab to confirm the results. As the New York Times reported, the outcome stunned her and her colleagues. Twenty percent of the first 119 women whose initial tests indicated their tumors had excess HER2 turned out not to have it on retesting.


Stof in moedermelk doodt borstkankercellen

Een stof die voorkomt in moedermelk kan kankercellen doden; zo blijkt uit studies gedaan door onderzoekers van de Universiteit van Lund en deUniversiteit van GŲteborg.

Link

Constans Kootstra


Dikke meisjes hebben minder kans op borstkanker

Wanneer meisjes op hun zevende mager en groot zijn, hebben ze na de menopauze een grotere kans op borstkanker dan hun leeftijdsgenootjes met wat meer vet op de botten.

Link

--

Waarom? Vetweefsel absorbeert meer schadelijke toxines, dat is het mechanisme!

Dennis (arts)


Hormoongevoeligheid van borst-stamcellen levert een nieuw aanknopingspunt voor nieuwe medicijnen op

Onderzoekers van het "Walter en Eliza Hall Instituut" hebben ontdekt dat borst-stamcellen zeer gevoelig zijn voor de vrouwelijke hormonen oestrogeen en progesteron. Deze bevinding opent nieuwe wegen voor de ontwikkeling van nieuwe mogelijkheden tot preventie en behandeling van borstkanker.

Link

Cindy Oppers


Onderzoekers hebben een link gevonden tussen borstkanker en hormonen

Er is een sleutelsignaal geidentificeert,die de groei van borst-stamcellen stimuleert. Dit helpt onderzoekers de ontwikkeling van borstkanker beter te begrijpen.

Link

Cindy Oppers


Borstvergrotingsgel maskeert borstkanker

Het borstvergrotingsmiddel Macrolane zou symptomen van borstkanker kunnen maskeren. Daarnaast zouden veel vrouwen na de behandeling klagen over pijn en abnormale bultjes in de borst.

Link


Breast cancer: research to help beat the disease

Professor David Stott is investigating ways to stimulate a patients own immune system to recognise and kill their breast cancer cells. This exciting area of research, called immunotherapy, could open up new possibilities for treating the UKs most common cancer.


Reaktie op Uitzending Netwerk over Simoncini

Reactie aan Netwerk

Jammer dat Netwerk mij niet heeft gevraagd voor in de uitzending. In 2008 is daar samen met Marojein een programma door Netwerk over gemaakt dat ook al zo gekleurd was. Begin vorige jaar (jan. 2009) belde Alje Kamphuis van Netwerk met de vraag of ik weer mee wilde doen. Ik wist dat Marjolein was overleden - overigens had zij een jaar langer geleef door de behandeling van Simoncini dan de artsen haar hier in Nederland konden bieden. Ik heb Alje toen verteld niet mee te willen doen, omdat ik uit ervaring nu wist dat Netwerk alleen maar sensatieprogramma's wil maken; met journalistieke 'waarheid' heeft dit programma niets van doen. Daarnaast ging ik toen net op wintersport.

Wel heb ik in dat telefoongesprek Alje ingelicht over een kennis die in maart 2008 met 2 tumoren in haar borst (1 van 9 en 1 van 6 cm!) naar Rome is geweest. Door de enorme druk heeft zij in okt. 2009 haar borst toch in Duitsland laten verwijderen. Na onderzoek bleek dat er nog 1 ingecapselde tumor van 1,5 cm. was te vinden. De rest van necrotisch weefsel. Alje zei dit aan Patrick Smidt (collega Netwerk) te melden, want Alje ging ook weg. Dat heb ik per email gedaan en nooit meer wat van gehoord.

Nu, 3,5 jaar NA het RECIDIEF (eerder in 2001 regulier behandeld in dezelfde borst) blaak ik van gezondheid. Zo ken ik nog een vrouw uit Nederland die nu, 2,5 jaar na behandeling in Rome nog steeds gezond rondloopt. Haar tumor was ook 6 cm. Dit zou toch aanleiding moeten zij om eens serieus te gaan kijken naar bica. De kosten zijn laag.

De stichting Sergio heeft het KWF in 1999 100.000 gulden aangeboden voor onderzoek naar zout. Het antwoord van het KWF kan men vinden in het boek "Chemo of kan ik zelf kiezen" van Drs. H. Trentelman.

Droevig.

Wat laat Netwerk een kans lopen, of mogen ze niet................! Censuur???

Marion


Borstkanker in eenderde van de gevallen te voorkomen

Volgens deskundigen is ruim dertig procent van de gevallen van borstkanker te voorkomen, door middel van eenvoudige veranderingen in levenswijze.

Link

Jan Slemmer


Twijfels over screening van borstkanker

Van de 175.000 vrouwen die zich vorig jaar vrijwillig lieten screenen op borstkanker kregen 5.000 een brief dat ze zich geen zorgen moeten maken,

Link


Junk DNA kan de aandacht op borst- en darmkanker vestigen

Wetenschappers van de Universiteit van Nottingham hebben gevonden dat een groep van losgeslagen genetisch materiaal, geprocedeerd door DNA strengen die bekend staan als junk DNA, kunnen helpen om borst- en darmkanker te diagnostiseren. Hun onderzoek, gesponsord door het Cancer Research UK, is gepubliceerd in het "Genomics Journal".

Link

Mies Kloos


Radiotherapie bij borstkanker kan vaak goedkoper en beter

Een nieuwe vorm van gecombineerde radiotherapie biedt belangrijke voordelen voor patiŽnten met borstkanker. Gezond weefsel en risico-organen, zoals het hart en de longen, krijgen een lagere dosis straling te verduren. Dat ontdekte UMCG-onderzoeker Hans Paul van der Laan. Ook blijkt de nieuwe
behandeling goedkoper dan de standaardtherapie. Sinds de ontdekking is de gecombineerde bestraling al in veel Nederlandse ziekenhuizen ingevoerd. Op 3 maart promoveert Van der Laan op het onderzoek aan de Rijksuniversiteit Groningen.

De radiotherapie die de meeste borstkankerpatiŽnten tot voor kort volgden, bestond uit een programma van 25 dagen waarin de hele borst werd bestraald en acht dagen waarin een deel van de borst, het operatiegebied, nog een extra dosis straling kreeg. Van der Laan ontdekte dat het gunstig is deze afzonderlijke bestralingen te vervangen door ťťn geÔntegreerde bestraling. Gedurende 28 dagen worden de hele borst en het operatiegebied tegelijk met verschillende doseringen bestraald (SIB –simultaneous integrated boost).

De promovendus toonde aan dat het gezonde weefsel en de organen met SIB minder belast worden. Ook liet hij zien dat er met SIB minder sessies nodig zijn om hetzelfde resultaat te krijgen. Hierdoor zijn patiŽnten een week eerder klaar met de therapie, en worden de kosten gereduceerd. De door Van der Laan beschreven gecombineerde therapie wordt wereldwijd bij steeds meer patiŽnten toegepast. In Nederland wordt ongeveer de helft van de Nederlandse patiŽnten volgens deze methode bestraald.

Dure behandeling niet altijd beter

Van der Laan onderzocht ook welke patiŽnten met borstkanker baat hebben bij een bestralingstechniek die alleen door kostbare computerapparatuur berekend kan worden (intensiteitsgemoduleerde radiotherapie, IMRT). Dit blijken twee patiŽntengroepen te zijn: patiŽnten bij wie het operatiegebied relatief groot is, en patiŽnten bij wie het hart dicht in de buurt van het bestralingsgebied ligt. In andere
gevallen is deze duurdere behandeling niet noodzakelijk beter dan de standaard driedimensionale radiotherapie, zo stelt Van der Laan vast. Ziekenhuizen kunnen met een CT-scan bepalen welke bestralingstechniek het meest geschikt is.

Om de risico’s voor de patiŽnt zoveel mogelijk te beperken, moet er volgens Van der Laan kritisch gekeken worden naar de samenstelling van de stralingsbundels. Zeker wanneer het bestralingsgebied groot is, bijvoorbeeld wanneer ook de lymfeklieren bestraald moeten worden, is dit van groot belang. Een combinatie van gewone rŲntgenstralen en elektronen kan in dat geval uitkomst bieden, zo blijkt uit onderzoek van Van der Laan. Tot slot pleit de onderzoeker voor goed overleg tussen alle betrokken partijen: chirurgen, pathologen en radiotherapeuten. Wanneer deze goed op elkaar zijn ingespeeld, is een betere afstemming van chirurgie en radiotherapie mogelijk.


Medical Marijuana Stops Spread of Breast Cancer

Cannabidiol enhances the inhibitory effects of Delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival: The cannabinoid 1 (CB(1)) and cannabinoid 2 (CB(2)) receptor agonist Delta(9)-tetrahydrocannabinol (THC) has been shown to be a broad-range inhibitor of cancer in culture and in vivo, and is currently being used in a clinical trial for the treatment of glioblastoma. It has been suggested that other plant-derived cannabinoids, which do not interact efficiently with CB(1) and CB(2) receptors, can modulate the actions of Delta(9)-THC. There are conflicting reports, however, as to what extent other cannabinoids can modulate Delta(9)-THC activity, and most importantly, it is not clear whether other cannabinoid compounds can either potentiate or inhibit the actions of Delta(9)-THC. We therefore tested cannabidiol, the second most abundant plant-derived cannabinoid, in combination with Delta(9)-THC. In the U251 and SF126 glioblastoma cell lines, Delta(9)-THC and cannabidiol acted synergistically to inhibit cell proliferation. The treatment of glioblastoma cells with both compounds led to significant modulations of the cell cycle and induction of reactive oxygen species and apoptosis as well as specific modulations of extracellular signal-regulated kinase and caspase activities. These specific changes were not observed with either compound individually, indicating that the signal transduction pathways affected by the combination treatment were unique. Our results suggest that the addition of cannabidiol to Delta(9)-THC may improve the overall effectiveness of Delta(9)-THC in the treatment of glioblastoma in cancer patients.


Borstkankerscreening redt geen levens?

Britse experts beweren in The Journal of Medicine dat de borstkankerscreening geen levens redt en ieder jaar duizenden verkeerde diagnoses stelt.

Link

Een gezonder alternatief voor deze methode is Thermography:


Junk DNA kan indicator zijn voor borst- en darmkanker

Wetenschappers van de Universiteit van Nottingham hebben gevonden dat een groep "losgeslagen" genetisch materiaal, geproduceerd door DNA strengen die gewoonlijk bekend staan als "Junk DNA", kunnen helpen bij het diagnostiseren van Borst- en darmkanker. De resultaten van dit onderzoek, dat werd gefinancieerd door het "Cancer Research UK" in Engeland, is gepubliceerd in het "Genomics Journal" van deze maand.

Link

Vertaling: Mies Kloos


Betere overleving bij borstkanker door radiotherapie

Postoperatieve bestraling ter hoogte van de klierstreken heeft wel degelijk nut bij borstkankerpatiŽnten bij wie minder dan vier lymfeklieren waren aangetast. Dat concluderen onderzoekers van de Vrije Universiteit Brussel uit een vergelijkende studie.

Link


Natuurlijke bestanddelen granaatappel kunnen mogelijk hormoon
gerelateerde groei van borstkanker voorkomen

Het eten van fruit dat anti-aromatase phytochemicals bevat, vermindert de incidentie van hormoon gerelateerde borstkanker, volgens een studie in "Cancer Prevention Research", een tijdschrift van de "American Association for Cancer Research".

Link

Vertaling: Keimpe Wiersma


Tamoxifen Use and Second Breast Cancers

Presentation by Christopher Li, Ph.D. from Fred Hutchinson Cancer Reserach Center on his study of long-term Tamoxifen use and the occurance of second breast cancers.


Leverenzym beÔnvloedt borstkanker

BorstkankerpatiŽnten die een bepaald enzym in de lever missen, hebben minder baat bij behandeling met het geneesmiddel tamoxifen en hebben daardoor een hoger risico om te overlijden aan borstkanker. Het gaat om patiŽnten na de menopauze die het zogenoemde enzym (CYP2D6) in hun lever missen.

Link


Eiwit uit zwangerschapshormonen beschermt tegen borstkanker

Amerikaanse onderzoekers hebben ontdekt dat de hormonen die tijdens de zwangerschap worden geproduceerd de aanmaak stimuleren een eiwit dat de groei van borstkanker remt. Het eiwit, alpha-fetoprotein (AFP), kan volgens de studie gepubliceerd in het Cancer Prevention Research dienen als goed getolereerd middel voor de behandeling en preventie van borstkanker. Volgens hoofdonderzoeker Herbert Jacobson zorgen de hormonen zoals oestrogeen alle voor produktie van dit eiwit. Men gaat nu proberen het eiwit in de vorm van een medicijn op de markt te brengen.

Link


VS volgt borstkankeradvies Erasmus

De VS gaat zijn borstkankeronderzoek naar Nederlands voorbeeld organiseren. Voortaan zullen vrouwen pas vanaf 50 jaar worden opgeroepen om elke twee jaar hun borsten te laten onderzoeken. Nu gebeurt dat al vanaf 40 jaar.

Link


Wetenschappers ontdekten een nieuwe sleutel van de puzzel mbt hormoontherapie en borstkanker

Het gebruik van postmenopauze hormoontherapie is geleidelijk in de Verenigde Staten afgenomen, dit kan volgens onderzoekers een sleutelrol spelen in de afname / achteruitgang van afwijkende melklier hyperplasia, een bekende risico factor voor borstkanker. "Postmenopauze hormoonbehandeling wordt geassocieerd met een toegenomen aantal borst biopsies, en vroegere en latere stadia of kanker. Afwijkende melklier hyperplasia is gerelateerd aan het gebruik van postmenopauze hormoongebruik en haar waarden zijn verlaagd met het afnemen van deze behandeling," zei onderzoeker Tehillah Menes, M.D., hij was het hoofd van de borst service in het Departement van chirurgie in het Elmhorst Ziekenhuis Centrum, New York, toen deze studie werd geleid.

De details van deze bevindingen zijn gepubliceerd in het Cancer Epidemiology, Biomarkers & Prevention, welk een journaal is van de American Associaton voor kanker onderzoek. Afwijkende melkklier hyperplasia zijn abnormale cellen die groeien in de melkklieren van de borst. Vorig onderzoek heeft laten zien dat vrouwen die zijn gediagnosticeerd met afwijkende melkklieren bereiken een drie-tot-vijf maal groot risico op ontwikkeling van borstkanker. Gebruikmakend van data van het Breast Cancer Surveillance Consortium, Menes en collega's onderzoeken de waarden van afwijkende melkklier hyperplasia om de risico factoren en waarden te bepalen voor meer dan 2.4 millioen mammografie studies met en zonder borstkanker.

Link

Vertaling Jana Ilsen


HRT Risks, What Are They If The Woman Has Breast Cancer?

Dr. Heward shares what HRT risks there are for a woman who has breast cancer.


Waarom geen GALVANO THERAPIE?

Waarom kunnen we in Ned. nog steeds niet kiezen voor GALVANO THERAPIE, en worden we gedwongen voor chemo, operatie en bestralingen te kiezen als we borstkanker hebben? GALVANO. Therapie behandelingen zijn nontoxic, de tumoren worden verbrand door middel van een lage gelijkstroom, het gezonde weefsel/cellen worden niet aangetast. Op Oncologische congressen, hebben Chinezen een remissie van 88%. Ik heb in 1994 Galavano Therapie behandelingen met succes in de St. Georg Klinik in Bad Eibling ondergaan. Mijn website: www.choiceinlife.com kan je mijn 8 maanden borstkanker ervaringen lezen.

Alie


Borstkanker eist meer levens

Vorig jaar zijn meer vrouwen overleden aan borstkanker dan in 2007. In totaal overleden vorig jaar 3327 vrouwen aan borstkanker in Nederland

Link

Dennis


New screening tool for breast cancer

The latest screening tool for breast cancer is offered at just one facility in Connecticut. It's called the breast-specific gamma imaging (BSGI) test and it is available at the Hospital of Central Connecticut in Southington .


Borstkanker: veel vrouwen hebben weinig of maar kort psychische problemen

In Nederland krijgt circa een op de negen vrouwen borstkanker. De diagnose is altijd ingrijpend. Maar nu de behandelmogelijkheden toenemen en het "taboe" rond de ziekte verdwenen is, wordt de ziekte minder vaak een levensbedreigende, traumatische ervaring. Dat blijkt uit onderzoek waarop Inge Henselmans op 28 oktober promoveert aan de Rijksuniversiteit Groningen. Met name vrouwen met een sterk gevoel van controle over het eigen leven hebben relatief weinig psychische klachten. Borstkanker wordt veroorzaakt door afwijkingen in het DNA die ervoor zorgen dat een cel ongecontroleerd gaat delen en groeien. Als de ziekte in een vroeg stadium wordt ontdekt, zijn de behandelmogelijkheden relatief goed. In veel gevallen moet de tumor chirurgisch worden verwijderd en moet de patiŽnt bestraald worden, in sommige evallen is ook chemotherapie nodig. Overleving na vijf jaar ligt op 85 procent. Wanneer er geen uitzaaiingen zijn, ligt dit percentage zelfs tussen de 90 en 100 procent.

Langlopend onderzoek

Voor Henselmans' onderzoek naar psychisch welbevinden na de diagnose borstkanker vulden ruim 900 vrouwen meerdere malen vragenlijsten in. Van hen was bij 242 vrouwen borstkanker vastgesteld; 670 gingen naar het ziekenhuis op verdenking van borstkanker, maar bleken geen kanker te hebben. Alle vrouwen werden op meerdere momenten bevraagd: zowel voor als na de diagnose, en zowel voor als na eventuele behandeling. Niet eerder werden vrouwen over zoveel fases in het ziektetraject gevolgd.

Na behandeling weinig klachten

"Vrouwen realiseren zich prima welke risico's de ziekte met zich meebrengt," licht Henselmans haar onderzoek toe, "maar blijken over het algemeen zeer veerkrachtig." Toch doorloopt niet iedereen het ziektetraject zonder problemen. Vooral kort na de diagnose kampt een groot aantal vrouwen die bestraling en/of chemotherapie ondergaan met angst voor wat er komen gaat, en andere psychische klachten “ waaronder slapeloosheid. Over het algemeen herstellen vrouwen zich in de maanden na afronding van de behandeling. Een derde van de vrouwen ervaart zelfs op geen enkel moment na diagnose psychische problemen. Daar staat een kleine groep vrouwen tegenover die pas na de behandeling voor het eerst psychische klachten krijgen, of zelfs gedurende het gehele ziekenhuistraject problemen houden.


miRNA lijkt belangrijke factor in ontstaan borstkanker

miMRNA lijkt een niet onbelangrijke rol te spelen bij het ontstaan van borstkanker.
Nieuwe bewijzen daarvoor draagt patholoog Liqiang Qi aan in zijn promotieonderzoek.

Link


Borstkankerzorg niet in elk ziekenhuis op orde

Voor vrouwen met borstkanker kan het een behoorlijk verschil maken of ze zich laten behandelen in ziekenhuis A of ziekenhuis B. Zo blijkt uit onderzoek dat de Consumentenbond publiceert in de Gezondgids van oktober. Op basis van cijfers over het aantal operaties waarbij in ťťn keer de hele tumor succesvol wordt verwijderd en gegevens over de ervaring van het chirurgenteam raadt de bond in totaal 17 ziekenhuizen aan. Dertien ziekenhuizen hebben de behandelingen voor borstkanker duidelijk minder goed op orde.

Consumentenbond


Octrooirechten op genen verhinderen onderzoek en schaden patiŽnten

Misschien was u net als velen onlangs geschokt te horen dat Myriad, een biomedisch bedrijf, octrooihouder is van twee vormen van het gen dat geassocieerd wordt met borstkanker. Dit octrooi beschermt niet alleen de genetische screeningtest van Myriad, die helpt voorspellen of iemand borstkanker krijgt, maar belemmert ook andere bedrijven om vergelijkbare tests te ontwikkelen. Helaas staan octrooirechten ook basisonderzoek in de weg.

Link

Geert


Zwarte beha gevaar voor gezondheid?

Uit onderzoek door het Duitse consumentenmagazine ÷ko-Test is gebleken dat zwarte beha’s te veel kleurstoffen bevatten die een gevaar zijn voor de gezondheid.

Link


Lifestyle linked to breast cancer risk

Experts have found the strongest evidence yet that a woman's lifestyle is linked to her risk of developing breast cancer..


Lange termijn gebruik Tamoxifen verviervoudigt de kans op een agressievere vorm van borstkanker

Terwijl het lange termijn gebruik van Tamoxifen bij borstkanker patiŽnten normaal het risico op terugkeer van de minder agressieve vorm van borstkanker verkleint blijkt nu uit een nieuwe observatie studie van het Amerikaanse Fred Hutchinson Cancer Research Center dat de kans op de agressievere niet goed behandelbare vorm van borstkanker juist wordt verviervoudigd.

Comparing breast-cancer patients who received the estrogen-blocking drug tamoxifen to those who did not, the researchers found that while the drug was associated with a 60 percent reduction in estrogen receptor-positive, or ER positive, second breast cancer – the more common type, which is responsive to estrogen-blocking therapy – it also appeared to increase the risk of ER negative second cancer by 440 percent. "This is of concern, given the poorer prognosis of ER-negative tumors, which are also more difficult to treat," said Li, an associate member of the Hutchinson Center's Public Health Sciences Division.

 


Babies protect mothers against breast cancer

Having children could reduce the risk of getting breast cancer because cells with strong protective characteristics are transferred from the baby in the womb to the mother, a study showed Tuesday.

Lees verder


Early Xeloda does not help in breast cancer

Older breast cancer patients who got Roche AG's drug Xeloda all by itself were almost twice as likely to relapse and die than women who got standard chemotherapy, U.S. researchers reported on Wednesday.

Lees verder


Second-hand smoke linked to breast cancer, says study

Parents who smoke are putting their daughters at increased risk of breast cancer, according to an expert panel that has unanimously agreed strong enough evidence now exists to link second-hand smoke to breast cancer.

Lees verder


AICR Reminds Mothers Of Additional Breastfeeding Benefit - Cancer Protection

the American Institute for Cancer Research (AICR) urges new mothers to consider one more benefit to breastfeeding their babies: added cancer protection for mother and child.

Lees verder


Active smoking and second-hand smoke linked to breast cancer

There is now enough scientific evidence to link both active smoking and second-hand smoke to breast cancer, according to an international panel convened by the Ontario Tobacco Research Unit, an affiliate of the Dalla Lana School of Public Health, University of Toronto, with support from the Public Health Agency of Canada.

Lees verder


Additional Breastfeeding Benefit - Cancer Protection

The evidence examined by AICR’s international panel of experts showed, convincingly, that breastfeeding protects women against both pre- and postmenopausal breast cancer. The research also finds that breastfeeding probably decreases the likelihood that a child will be overweight (at least during the early years of childhood). Protection from weight gain is of particular importance, as childhood overweight tends to continue into adulthood, where excess body fat is closely linked to cancer development. According to experts, hormonal changes in a woman’s body and physical changes in breast tissue cells are likely responsible for the added protection seen in mothers. Infants’ benefits are gained from the chemical composition of breast milk as well as the promotion of self-regulated feeding that is a natural part of the breastfeeding process.

Lees verder


Ingredient found in green tea significantly inhibits breast cancer growth in female mice

A new study conducted by researchers at the University of Mississippi finds that consuming EGCG, an antioxidant in green tea, significantly inhibits breast tumor growth in female mice. These results bring us one step closer to better understanding the disease and potentially new and naturally occurring therapies.

Lees verder


What You Should Know About Breastfeeding

Hormonal changes associated with breastfeeding delay the return of a new mother’s menstrual periods when she is breastfeeding . Delayed menstruation reduces a woman’s lifetime exposure to hormones like estrogen, which is linked to breast cancer risk . According to researchers, this may be one of the main reasons that breastfeeding protects women.

Lees verder


Breast Cancer Risk and the Dirty Air We Breathe

there are over 200 chemicals in air pollution--called polycyclic aromatic hydrocarbons (PAHs)--that may also lead to cancer, including cancer of the breast. PAHs are the chief component of soot, and enter the air via burning of coal, oil, diesel, gasoline, wood, garbage, tobacco, and even charbroiled meat.

Lees verder


Red wine vs. white? It makes no difference when it comes to breast-cancer risk

The largest study of its kind to evaluate the effect of red versus white wine on breast-cancer risk concludes that both are equal offenders when it comes to increasing breast-cancer risk. The results of the study, led by researchers at Fred Hutchinson Cancer Research Center, were published in the March issue of Cancer Epidemiology, Biomarkers and Prevention. "We were interested in teasing out red wine's effects on breast-cancer risk. There is reason to suspect that red wine might have beneficial effects based on previous studies of heart disease and prostate cancer," said lead author Polly Newcomb, Ph.D., M.P.H., head of the Cancer Prevention Program in the Public Health Sciences Division at the Hutchinson Center. "The general evidence is that alcohol consumption overall increases breast-cancer risk, but the other studies made us wonder whether red wine might in fact have some positive value." Instead, Newcomb and colleagues found no compelling reason to choose Chianti over Chardonnay. "We found no difference between red or white wine in relation to breast-cancer risk. Neither appears to have any benefits," Newcomb said. "If a woman drinks, she should do so in moderation – no more than one drink a day. And if a woman chooses red wine, she should do so because she likes the taste, not because she thinks it may reduce her risk of breast cancer," she said. The researchers found that women who consumed 14 or more drinks per week, regardless of the type (wine, liquor or beer), faced a 24 percent increase in breast cancer compared with non-drinkers. For the study, the researchers interviewed 6,327 women with breast cancer and 7,558 age-matched controls about their frequency of alcohol consumption (red wine, white wine, liquor and beer) and other breast-cancer risk factors, such as age at first pregnancy, family history of breast cancer and postmenopausal hormone use. The study participants, ages 20 to 69, were from Wisconsin, Massachusetts and New Hampshire. The frequency of alcohol consumption was similar in both groups, and equal proportions of women in both groups reported consuming red and white wine.

Lees verder


Fighting breast cancer with garlic

After about five years of research, Thomas and Newell, 33, determined that the flavor component of garlic is the key ingredient in preventing breast cancer. Thomas said studies also have shown that garlic inhibits carcinogens related to colon cancer and cardiovascular diseases.

Lees verder


New technology could revolutionize breast cancer screening

The world's first radar breast imaging system developed at Bristol University that could revolutionise the way women are scanned for breast cancer, is being trialled at North Bristol NHS Trust (NBT). Professor Alan Preece and Dr Ian Craddock from the University of Bristol have been working for a number of years to develop a breast-imaging device which uses radio waves and therefore has no radiation risk unlike conventional mammograms. The team began developing and researching a prototype around five years ago and have received funding from organisations including the Engineering and Physical Sciences Research Council (EPSRC), the trustees of the United Bristol Hospitals and the University of Bristol spin-out company, Micrima Ltd. Dr Ian Craddock from the University's Department of Electrical and Electronic Engineering, said: "This new imaging technique works by transmitting radio waves of a very low energy and detecting reflected signals, it then uses these signals to make a 3D image of the breast. This is basically the same as any radar system, such as the radars used for air traffic control at our airports." Mike Shere, Associate Specialist Breast Clinician at NBT, added: "Currently women are diagnosed in three ways: firstly by a clinician then by using imaging such as mammography and ultrasound and lastly by a needle biopsy. "The radar breast imaging system came to Frenchay in September this year and so far around 60 women have been examined using it. "It takes less time to operate than a mammogram approximately six minutes for both breasts compared with 30-45 minutes for an MRI, and like an MRI it provides a very detailed 3D digital image. "Women love it as they compare it to a mammogram and find the whole experience much more comfortable."

Lees verder


Breast thermography

Breastthermography.com is dedicated to providing information on breast thermography, risk assessment, breast cancer, early detection, prevention and ultimately the preservation of the breast and the survival of women. Current research has determined that the key to breast cancer survival rests upon its earliest possible detection. If discovered in its earliest stages, 95% cure rates are possible. Our center is dedicated to providing one of the most essential tests in breast cancer risk assessment and early detection.

Lees verder


Can dogs give you breast cancer?

Analysis of breast cancer cases by researchers at the University of Munich showed that patients with this type of cancer were significantly more likely to have kept a dog than a cat.

Lees verder


Breast cancers - What if their invasive power were "latent" from the beginning of their development?

Why are some cancers more aggressive than others? This was the question explored by a number of doctors and Inserm research scientists at the Institut Curie when they studied the biological profile of a form of breast cancer. The results were astounding: tumour aggressiveness seems to be determined from the very first tumour cells and the biological diversity observed in invasive cancers already exists in localised forms. These results could make it possible to define subpopulations of localised cancers and adapt the treatment according to the associated risks. But with this work published in the Clinical Cancer Research issue of 1st April, the question remains of the origin of tumour cell aggressiveness: if it does not arise from biological modifications formerly acquired by tumour cells, how is the invasive capacity triggered off?

Lees verder


Twin nanoparticle shown effective at targeting, killing breast cancer cells

Breast cancer patients face many horrors, including those that arise when fighting the cancer itself. Medications given during chemotherapy can have wicked side effects, including vomiting, dizziness, anemia and hair loss. These side effects occur because medications released into the body target healthy cells as well as tumor cells. The trick becomes how to deliver cancer-fighting drugs directly to the tumor cells. Brown University chemists think they have an answer: They have created a twin nanoparticle that specifically targets the Her-2-positive tumor cell, a type of malignant cell that affects up to 30 percent of breast cancer patients. The combination nanoparticle binds to the Her-2 tumor cell and unloads the cancer-fighting drug cisplatin directly into the infected cell. The result: Greater success at killing the cancer while minimizing the anti-cancer drug's side effects."Like a missile, you don't want the anti-cancer drugs to explode everywhere," explained Shouheng Sun, a chemistry professor at Brown University and an author on the paper published online in The Journal of the American Chemical Society. "You want it to target the tumor cells and not the healthy ones." The researchers created the twin nanoparticle by binding one gold (Au) nanoparticle with an iron-oxide (Fe3O4) nanoparticle. On one end, they attached a synthetic protein antibody to the iron-oxide nanoparticle. On the other end, they attached cisplatin to the gold nanoparticle. Visually, the whole contraption looks like an elongated dumbbell, but it may be better to think of it as a vehicle, equipped with a very good GPS system, that is ferrying a very important passenger.

Lees verder


Chemicals and breast cancer Database

The National Toxicology Program has identified 42 chemicals that cause mammary tumors (breast tumors) in laboratory mice. The EnviroChem and Cancer database provides a snapshot of important information about each of those chemicals.

Lees verder


Environmental Chemicals and Breast Cancer Risk

There has been growing interest in whether environmental factors, including exposures to certain chemicals or changes in lifestyle, may increase the risk of breast cancer. This fact sheet will discuss research linking environmental chemicals and the risk of breast cancer. This will include exposures of concern in the home and workplace, and chemicals known to cause mammary (breast tumors) in laboratory animals. The fact sheet will also discuss new emerging data on how exposures to certain chemicals early in life may affect breast development and breast cancer risk, as well as new work identifying important gene-environmental interactions.

Lees verder


flame retardants and breast cancer

Commonly used flame retardants, polybrominated diphenyl ethers (PBDEs), are an emerging concern because some have been identified as endocrine disruptors. They also have been widely detected in the environment, wildlife, and people.

Lees verder


RNA snippet suppresses spread of aggressive breast cancer

A low cellular level of a tiny fragment of RNA appears to increase the spread of breast cancer in mouse models of the disease, according to researchers at Whitehead Institute for Biomedical Research. Measuring levels of this so-called microRNA, which is also associated with metastatic breast cancer in humans, may more accurately predict the likelihood of metastasis (which accounts for 90% of cancer-related deaths) and ultimately help determine patient prognoses. In the study, whose results are reported in the June 12 issue of Cell, Scott Valastyan, a graduate student in Whitehead Member Robert Weinberg's laboratory, screened patient breast cancer samples for microRNAs with potential roles in metastasis. MicroRNAs are single strands of RNA about 21-23 nucleotides long. Within a cell, a single microRNA can fine-tune the expression of dozens of genes simultaneously. This capability could be particularly important in metastasis, a multi-step process that could be influenced by a single microRNA at several points. The screened samples were classified as either metastatic cancer or non-metastatic cancer. After analysis, the microRNA miR-31 stood out because of its inverse correlation with metastasis. In samples where a patient's original tumor had not metastasized, the cancer cells retained high levels of the microRNA. But where the tumor had metastasized, the cancer cells came to possess lower levels of miR-31. The functional role of miR-31 in metastasis regulation was then confirmed in mice. When Valastyan removed miR-31 from normally non-aggressive breast cancer cells and implanted those cells into mice, the cells formed highly aggressive tumors. Mice injected with the cancer cells lacking miR-31 had 6 to 10 times more cancer cells that metastasized to their lungs than did their counterparts implanted with unmodified cancer cells.To see how increasing miR-31 levels could affect metastasis, Valastyan introduced miR-31 into breast cancer cells that readily metastasize. After injecting these altered cells into mice, the mice had four to 40 times fewer metastases than mice injected with the unaltered cells. Valastyan says that quantifying miR-31 levels in a patient's cancer cells could one day support a more accurate prognosis. Currently, breast cancers are divided into three major categories, two of which are typically associated with poor prognoses. "This microRNA seems to be quite unique, in that it seems to provide some prognostic utility across these existing subclassifications [of cancers]," says Valastyan. A better-defined prognosis could help patients determine whether they might benefit from poorly tolerated cancer therapies.

Lees verder


Human breast tumours' 'microenvironment' primes them for metastasis

The environment within primary breast tumours can 'empower' cells that break free and enter the bloodstream to successfully invade other organs, researchers report in the 4th April Cell, a publication of Cell Press.

Lees verder


Biomarkers predict risk for invasive breast cancer years before the tumor develops

A team of scientists from the University of California San Francisco has identified distinct molecular markers that predict whether or not a woman is likely to develop subsequent invasive cancer after initial diagnosis with a noninvasive form of early breast cancer. The research, published by Cell Press in the November issue of Cancer Cell, provides critical information that can be used to determine whether a woman should receive more or less aggressive therapy.

Lees verder


Einstein Researchers Develop a New Way to Study How Breast Cancer Spreads

In a breakthrough study appearing in advance online publication of Nature Methods, researchers at Albert Einstein College of Medicine of Yeshiva University describe for the first time a method of viewing individual breast cancer cells for several days at a time. The study, by scientists in Einstein's Gruss Lipper Biophotonics Center, provides detail on how cancer cells invade surrounding tissue and reach blood vessels. These movements are the first steps of the potentially deadly stage of cancer known as metastasis. The new method of viewing cancer cells over several days in their natural environment is considered significant because prior methods of study only allowed cells to be viewed clearly for several hours at one time. Having a longer and clearer window into how cancer cells move during the early stages of metastasis may help scientists develop more effective cancer therapies. For 2007, the American Cancer Society reported that a woman with metastatic breast cancer had an average survival rate of two years.

Lees verder


Thermography - A Safer Option for Breast Cancer Detection

The occurrence of breast cancer has dramatically increased in the past 50 years and the medical establishment encourages the use of annual mammogram screenings as a woman’s best option for early detection. In fact, for more than 30 years it’s been the unquestioned, standard screening device used by the medical community. While mammography may be useful in certain situations, it has many disturbing drawbacks.

Lees verder


Transforming growth factor-? in breast cancer - too much, too late

The contribution of transforming growth factor (TGF)? to breast cancer has been studied from a myriad perspectives since seminal studies more than two decades ago. Although the action of TGF? as a canonical tumor suppressor in breast is without a doubt, there is compelling evidence that TGF? is frequently subverted in a malignant plexus that drives breast cancer. New knowledge that TGF? regulates the DNA damage response, which underlies cancer therapy, reveals another facet of TGF? biology that impedes cancer control. Too much TGF?, too late in cancer progression is the fundamental motivation for pharmaceutical inhibition.

Lees verder


2 proteins may be survival markers in some breast cancers

New research suggests that the presence or absence of two proteins may be important markers for long-term survival in some breast cancer patients.

Lees verder


Cellular response to stress signals predicts future tumor formation in women diagnosed with common type of pre-breast cancer

A specific biological response to cellular stress may predict the likelihood of future tumor formation of the most common, non-invasive form of pre-malignant breast cancer-- ductal carcinoma in situ, or DCIS.

Lees verder


Vitamin D and breast cancer risk

High blood levels of vitamin D protect post-menopausal women from breast cancer. This connection has been confirmed by research of the German Cancer Research Center. It also shows that a particular gene variant of the vitamin D receptor is associated with an elevated breast cancer risk if the tumor has receptors for the female sex hormone estrogen. German Cancer Aid, Deutsche Forschungsgemeinschaft

Lees verder


Breast cancers behave differently before and after the age of 70

Researchers in Belgium have discovered that increasing age affects the way breast cancer behaves. As women approach the age of 70, they become less likely to be diagnosed with aggressive tumors that have spread to the lymph nodes. But after 70, the cancer is increasingly likely to spread, particularly if the tumors are small. The research was presented on Friday at the 6th European Breast Cancer Conference in Berlin.

Lees verder


Acupuncture relieves hot flushes in breast cancer patients taking tamoxifen

Acupuncture provides effective relief from hot flushes in women who are being treated with the anti-oestrogen tamoxifen following surgery for breast cancer, according to new research presented today (Friday) at the 6th European Breast Cancer Conference (EBCC-6) in Berlin. Mrs Jill Hervik, a physiotherapist and acupuncturist at the Vestfold Central Hospital (TÝnsberg, Norway), told a news briefing that breast cancer patients who received traditional Chinese acupuncture had a 50% reduction in hot flushes, both during the day and the night, and that this effect continued after the acupuncture ceased.

Lees verder


"Two-Headed" Antibody Poses A Double Threat to Breast Cancer Cells, Say Fox Chase Researchers

A small, antibody-like molecule created by researchers at Fox Chase Cancer Center can successfully attack two separate molecules on the surface of cancer cells at the same time, halting the growth of breast cancer cells in laboratory tests, the researchers say. The molecule, nickname "ALM," might be a means of slowing cancer spread or, as the researchers believe, a guidance system for delivering more aggressive drugs directly to cancer cells. Their findings appear in this month’s British Journal of Cancer. Unlike naturally occurring antibodies, which only bind to one specific target at a time, ALM is bispecific, meaning it attaches to two separate targets simultaneously. ALM's targets are two signaling proteins, ErbB2 and ErbB3, which connect to form a growth-promoting complex on the surface of many cancer cells, including head and neck cancer and drug-resistant breast cancer.

Lees verder


Variants of vitamin D receptor linked to increased risk of breast cancer

Genetic variations in the body's receptor for vitamin D could increase the risk of breast cancer in post-menopausal women, according to a study published today in the open access journal Breast Cancer Research.

Lees verder


Traditional Chinese Food Ingredients Prevent Breast Cancer

Two foods commonly eaten as part of the traditional Chinese diet can reduce a woman's risk of breast cancer by as much as 90 percent, according to a study conducted by researchers from the University of Western Australia in Perth, and published in the International Journal of Cancer. Researchers compared consumption of mushrooms and green tea between two groups of Chinese women, one with breast cancer and one without. They found that women who ate at least 10 grams (0.35 ounces) of fresh mushrooms per day had a 64 percent lower risk of developing breast cancer than those who did not eat as much. Those who also regularly drank green tea reduced their risk by a total of 90 percent. Dried mushrooms also reduced breast cancer risk, although they were not as effective as fresh ones.

Lees verder


Mayo researchers identify dangerous 'two-faced' protein crucial to breast cancer spread and growth

Two critical properties of cancer cells are their ability to divide without restraint and to spread away from the primary tumor to establish new tumor sites. Now, researchers from the Mayo Clinic campus in Florida have found a protein they say acts as a deadly master switch, both freeing cancer cells from a tumor while ramping up new growth.

Lees verder


What the Immune System Reveals about Breast Cancer

Researchers working with Dr Marcus Schmidt in the Department of Obstetrics and Gynecology at the University Medical Center Mainz have unlocked the key to the immune system's significance in cases of breast cancer, thus identifying its long-neglected role in the prognosis of the disease. Their research results, published in the renowned Cancer Research journal, show that patients with certain breast tumors have a better prognosis when more immune cells are present in the tumor. These results permitted the scientists to extend the "coordinate system" in case of breast tumors to include the immune system as the third important reference point for the prognosis of this disease, in addition to the long-established prognostic factors of estrogen receptor expression and proliferative activity (Cancer Research, 1 July 2008; Cancer Research, 1 April 2009).

Lees verder


Eating red meat during adolescence might heighten the risk of breast cancer

Many adolescent women shun red meat, driven by the lure of clothes-hanger figures and runway looks. But for those who don't, here's a reason to reconsider: Eating a lot of red meat during adolescence may increase the risk of breast cancer among premenopausal women, a new study reports. The findings are based on a study published in a recent issue of Cancer Epidemiology, Biomarkers and Prevention conducted by Dana-Farber oncologist Lindsay Frazier, MD, Sc M, and colleagues at the Harvard School of Public Health and Harvard Medical School. Red meat consumption during adulthood has been previously shown to spur hormone-fueled breast cancer in women ages 26 to 46. The new study is the first prospective study to show a connection between a diet high in red meat during adolescence and the development of pre-menopausal breast cancer. A prospective analysis is an investigation that follows a group of women over time instead of establishing a link through medical records of past diagnoses.

Lees verder


Researcher shows link between growth hormones and tumors

In the Oct. 15 issue of Cancer Research, Hyder and colleagues published findings about progesterone, a hormone common in birth control and treatments for menopause. Their research shows that progesterone actively promotes the progression of human breast cancer cells in an animal model. Previously such observations had been limited to animal cells.

Lees verder


Comparison of Prognostic Gene Expression signatures for Breast Cancer

During the last years, several groups have identified prognostic gene expression signatures with apparently similar performances. However, signatures were never compared on an independent population of untreated breast cancer patients, where risk assessment was computed using the original algorithms and microarray platforms.Despite the difference in development of these signatures and the limited overlap in gene identity, they showed similar prognostic performance, adding to the still growing evidence that these prognostic signatures are of wide clinical relevance.

Lees verder


Should Breast Tissue Be Screened For Cancer After Cosmetic Surgery?

Young women undergoing cosmetic breast reduction surgery are being screened for cancer without their informed consent, according to a paper published on the British Medical Journal website.

Lees verder


UNC researchers find clue to stopping breast-cancer metastasis

If scientists knew exactly what a breast cancer cell needs to spread, then they could stop the most deadly part of the disease: metastasis. New research from the University of North Carolina at Chapel Hill School of Medicine takes a step in that direction. Carol Otey, Ph.D. and UNC colleagues reduced the ability of breast cancer cells to migrate by knocking down the expression of a protein called palladin. They also found higher levels of palladin in four invasive breast cancer cell lines compared to four non-invasive cell lines. "This study shows that palladin may play an important role in the metastasis of breast cancer cells as they move out of the tumor and into the blood vessels and lymphatics to spread throughout the body," said Otey, associate professor of cell and molecular physiology. To conduct the study, the researchers grew breast cancer cells in an "invasion chamber," in which human tumor cells are placed in a plastic well that is inserted into a larger well. Cells will attempt to move to the bottom of the chamber because it's baited with growth factors that cells find attractive. But first the cells have to migrate through a filter coated with a layer of artificial connective tissue. "The cells have to migrate through that and have to degrade it," Otey said. "It's a useful model system that mimics what happens in the body."

Lees verder


Breast cancer subtypes originate from different biological pathways

There is a biological distinction between breast cancers that depend on hormones and those that do not, according to research published Friday, April 25 in the open-access journal PLoS Genetics. In the largest study of its kind, an international consortium of cancer researchers studied the genetic makeup of over 23,000 breast cancer cases.

Lees verder


Breast cancer and organic foods

When I was first diagnosed with breast cancer and liver disease, I read everything I could find on both subjects. Certain words kept popping up: toxic pesticides, toxic fertilizers, herbicides, hormones, antibiotics, vitamin supplements, mineral supplements. After my mastectomy for the breast cancer, I turned to organic food, which has none of these additives, and I stopped all vitamin and mineral supplements to heal my liver and fight cancer recurrence. After six months, my liver enzymes returned to below normal, my overall cholesterol dropped 40 points, my good cholesterol rose 40 points, and even my bad cholesterol dropped a few points. Since breast cancer is not a one shot deal, I remain on an organic diet to fight cancer recurrence and to keep my liver healthy.

Lees verder


2 new compounds show promise for eliminating breast cancer tumors

Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors. Associate Professor James Turkson’s compounds disrupt the formation and spread of breast cancer tumors in tests on mice. The compounds, S3I-201 and S3I-M2001, break up a cancer-causing protein called STAT3, and researchers have observed no negative side effects so far. "The compounds are very promising," Turkson said. "They’ve worked very well in mice, and now we’re looking for partners to help us take these compounds to the next level of trials."

Lees verder


Chinese food fights breast cancer

Two Chinese dietary staples - mushrooms and green tea - may have the power to ward off breast cancer, mounting evidence suggests.

Lees verder


Positive thinkers 'avoid cancer'

Women who have a positive outlook may decrease their chances of developing breast cancer, say Israeli researchers.

Lees verder


CSHL scientists identify new drug target against virulent type of breast cancer

Tumor cells in a particular subset of breast cancer patients churn out too much of a protein called ErbB2 -- also often called HER2 -- which drives the cells to proliferate unchecked. Patients unlucky enough to be in this group -- about one in four -- have poorer prognoses and clinical outcomes than those who don’t. Senthil K. Muthuswamy, Ph.D. The drugs Herceptin and Lapatinib, prescribed in combination with other chemotherapeutic agents, have improved this picture significantly, but leave plenty of room for improvement: they suppress ErbB2 but are effective against less than half of ErbB2-producing tumors. Moreover, patients with tumors that do respond usually develop resistance to these drugs.A team of scientists at Cold Spring Harbor Laboratory has just published research identifying an enzyme called Brk that may serve as a target for future drugs developed to fight ErbB2-positive tumors. Brk, they report, helps these tumors become virulent and is also implicated in the process through which the tumors develop drug resistance.

Lees verder


BH and breast cancer

Many physicians and researchers now agree that wearing a tight fitting bra can cut off lymph drainage, which can contribute to the development of breast cancer, as your body will be less able to excrete all the toxins you’re exposed to on a daily basis. Aluminum from antiperspirants, for example, is one potentially dangerous source of toxins that can accumulate if your lymph drainage is impaired.

Lees verder


Study identifies causes of bone loss in breast cancer survivors

Osteoporosis is a growing concern among breast cancer survivors and their doctors because certain cancer drugs can cause bone loss. But a new study has found that cancer drugs aren't the only culprits. Among 64 breast cancer patients referred to a bone health clinic, 78 percent had at least one other cause of bone loss, such as vitamin D deficiency and an overactive parathyroid gland.

Lees verder


Type of breast reconstruction impacts radiation therapy outcomes

For breast cancer patients who underwent a mastectomy and who undergo radiation therapy after immediate breast reconstruction, autologous tissue reconstruction provides fewer long-term complications and better cosmetic results than tissue expander and implant reconstruction, according to a study in the Nov. issue of the International Journal of Radiation Oncology, Biology, Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

Lees verder


Penn Researchers Identify New Protein Important in Breast Cancer Gene’s Role in DNA Repair

For years, researchers have known that under normal conditions, the breast cancer protein BRCA1 orchestrates the repair of damaged DNA, but the details of just how BRCA1 moves to the damaged site and recruits the right nuclear repairmen for DNA restoration remains a mystery. Now, a new study from the University of Pennsylvania School of Medicine has identified genes associated with the BRCA1 protein and their involvement in the DNA repair pathway, helping to clear the way for researchers to better understand what goes wrong when the BRCA1 gene is mutated and the repair pathway goes haywire. Identifying patients with mutations in these BRCA1-associated genes may help better fight breast cancer.

Lees verder


Women exposed to negative life events at greater risk of breast cancer

Happiness and optimism may play a role against breast cancer while adverse life events can increase the risk of developing the disease, according to a study by Professor Ronit Peled, at Ben-Gurion University of the Negev in Israel. An article on the study titled "Breast Cancer, Psychological Distress and Life Events among Young Women," was just published in the British journal BMC Cancer (8:245, August 2008). In the study, researchers questioned women about their life experiences and evaluated their levels of happiness, optimism, anxiety, and depression prior to diagnosis. Researchers used this information to examine the relationship between life events, psychological distress and breast cancer among young women. A total of 622 women between the ages of 25 and 45 were interviewed: 255 breast cancer patients and 367 healthy women. "The results showed a clear link between outlook and risk of breast cancer, with optimists 25 percent less likely to have developed the disease. Conversely, women who suffered two or more traumatic events had a 62 percent greater risk," Peled said. "Young women who have been exposed to a number of negative life events should be considered an 'at-risk' group for breast cancer and should be treated accordingly." The researchers indicate that women were interviewed after their diagnosis, which may color their recall of their past emotional state somewhat negatively. However, according to Peled, "We can carefully say that experiencing more than one severe and/or mild to moderate life event is a risk factor for breast cancer among young women. On the other hand, a general feeling of happiness and optimism can play a protective role." "The mechanism in which the central nervous, hormonal and immune systems interact and how behaviour and external events modulate these three systems is not fully understood," Peled states. "The relationship between happiness and health should be examined in future studies and relevant preventative initiatives should be developed."

Lees verder


Study shows gene variations may predict risk of breast cancer in women

According to a recent study, led by Virginia Kaklamani, MD, an oncologist at Northwestern Memorial Hospital and assistant professor of medicine, Northwestern University Feinberg School of Medicine, variations of the adiponectin gene, which regulates a number of metabolic processes, may increase a woman's risk of developing breast cancer. This discovery is an important step forward in cancer genetics research, as it could help experts develop a future genetic testing model to more accurately predict a woman's risk of developing breast cancer.

Lees verder


Genetic testing for breast or ovarian cancer risk may be greatly underutilized

Although a test for gene mutations known to significantly increase the risk of hereditary breast or ovarian cancer has been available for more than a decade, a new study finds that few women with family histories of these cancers are even discussing genetic testing with their physicians or other health care providers. In a report in the Journal of General Internal Medicine, which has been released online, investigators from the Massachusetts General Hospital (MGH) Institute of Health Policy and Dana-Farber Cancer Institute note that their findings illustrate the challenges of bringing genetic information into real-world clinical practice. "Testing for BRCA1 and 2 mutations has been around a long time and should be a good indicator of whether genetic testing is making its way into regular medical practice," says Douglas Levy, PhD, of the MGH Institute for Health Policy, the study's lead author. "When a well-established genetic test is not being incorporated into clinical practice when appropriate, we are a long way from meeting the promise of personalized, genetically-tailored medical care." Most women's lifetime risk of breast cancer is about 13 percent, and the risk for ovarian cancer is less than 2 percent. But women with mutations in the BRCA1 or BRCA2 genes may be 3 to 7 times more likely to develop breast cancer and 9 to 30 times more likely to develop ovarian cancer than women with unaltered forms of the genes. Several organizations have issued clinical guidelines designating who should be screened for BRCA1/2 mutations, and while there have been discrepancies among the guidelines, all of them include a history of breast or ovarian cancer in close relatives among the criteria indicating elevated risk. The authors note that most U.S. health insurers cover at least part of the cost of BRCA1/2 testing for at-risk women. The current study analyzed data from the 2000 and 2005 National Health Interview Surveys, both of which included supplementary questions assessing cancer control. More than 35,000 women participating in those surveys did not have a personal history of breast or ovarian cancer, and around 1 percent of them were determined to be at high risk because a mother, sister or daughter had such a tumor. Among these high-risk women, about half were aware that genetic testing was available, but only 10 percent had discussed it with a physician, less than 5 percent had been advised to have the test, and only 2 percent had done so.

Lees verder


Residual fetal cells in women may provide protection against breast cancer

Fetal cells that persist in a woman's body long after pregnancy -- a common occurrence known in scientific circles as fetal microchimerism -- in some cases may reduce the woman's risk of breast cancer, according to researchers at Fred Hutchinson Cancer Research Center.

Lees verder


Calculating how breast cancers will respond to tamoxifen

A discovery by Australian scientists could help clinicians decide which women with breast cancer will make good candidates for anti-oestrogen therapies, such as tamoxifen, and which will not. Over 12,000 Australian women are diagnosed with breast cancer each year, roughly 70% of which will have cancers treatable with tamoxifen. Unfortunately, 30% or more of these women may not respond well to such anti-hormone therapy long-term.Work done by a research team headed by Associate Professor Liz Musgrove and Professor Rob Sutherland of Sydney’s Garvan Institute of Medical Research has correlated expression of certain functionally-related oestrogen-regulated genes with predictable clinical outcomes. This expanded knowledge about oestrogen action and endocrine resistance should allow clinicians to make better, more informed, choices in the future.

Lees verder


Growth factor predicts poor outcome in breast cancer

The response to insulin-like growth factor 1 (IGF-I) in breast cancer cells predicts an aggressive tumor that is less likely to respond to treatment, said researchers at Baylor College of Medicine in a report that appears in the current issue of the Journal of Clinical Oncology. The finding gives impetus to the movement to tailor cancer treatments to attributes of the various tumors. "These findings come at a critical time," said Dr. Adrian Lee, associate professor in the Lester and Sue Smith Breast Center at BCM. "Our goal is to identify biomarkers that will help predict which patients will respond to therapy against insulin-like growth factor. Several inhibitors of the IGF pathway are in patient studies right now. There's a large movement to understand which patients will respond to these drugs. This is a step toward that goal." In this study, Lee and his colleagues stimulated breast cancer cells with IGF-I in the laboratory and defined how more than 800 genes in the cells responded to the growth factor. They then examined samples of patient breast tumors with this "gene signature" and correlated the gene signatures with the fate of the patients. "We have technology now to allow us to globally assess what IGF is doing in breast cancer at the whole gene expression level," said Lee. "This is one of the first studies to do that. We know that IGF is bad in cancer, but now we can globally understand it in a more comprehensive manner. It could lead to finding biomarkers for patients response" to breast cancer treatments. "We found that IGF-I is a major regulator of cell growth and cell survival," said Lee. "It also regulates DNA repair."

Lees verder


Got Stress? It May Impact Breast Cancer Recurrence

Women diagnosed with metastatic breast cancer who have also endured previous traumatic or stressful events see their cancer recur nearly twice as fast as other women, according to a report by a University of Rochester Medical Center scientist. The small, retrospective study showed that women who faced physical or sexual abuse or life-threatening situations see metastatic tumors return after about 2.5 years, compared with women who have more peaceful lives who see recurrence at about five years. The report was published in this month’s Journal of Psychosomatic Research by scientists from the University of Rochester Medical Center and Stanford University School of Medicine.

Lees verder


Fetal cell 'transplant' could be a hidden link between childbirth and reduced risk of breast cancer

Some benefits of motherhood are intangible, but one has been validated through biostatistical research: women who bear children have a reduced risk of developing breast cancer. In Seattle, researchers at the University of Washington and Fred Hutchinson Cancer Research Center believe they have identified a source of this protective effect: fetal cells "transplanted" to the mother before birth.

Lees verder


Daily aspirin may reduce risk of common type of breast cancer

Taking aspirin on a daily basis may lower women's risk of a particular type of breast cancer, according to results published in BioMed Central's open access journal Breast Cancer Research. In this large study, aspirin use was linked to a small reduction in estrogen receptor-positive breast cancers. However, unlike in some previous research, aspirin and related painkillers were not found to reduce the total risk of breast cancer.

Lees verder


Antiproliferative and cytostatic effects of the natural product eupatorin on MDA-MB-468 human breast cancer cells

The flavone eupatorin is selectively activated in breast cancer cells, but not in normal breast cells, due to CYP1 family metabolism. This provides a basis for selectivity which is desired against breast tumor cells. In this sense, eupatorin is shown by this study to be a very promising chemopreventative candidate, which should be further examined in an in vivo study.

Lees verder


Dietary Calcium Could Possibly Prevent the Spread of Breast Cancer to Bone

A strong skeleton is less likely to be penetrated by metastasizing cancer cells, so a fortified glass of milk might be the way to block cancer's spread, according to researchers at the ANZAC Research Institute in Concord, Australia. Using a mouse model of breast cancer metastasis, the researchers found that a calcium deficiency may increase the tendency of advanced breast cancer to target bone. Dietary calcium, they reason, might help prevent the spread of breast cancer to bone and serve as an adjuvant treatment during therapy.

Lees verder


Getting to the roots of breast cancer

The lesson learned in eradicating dandelions from your yard could apply in treating breast cancer, said researchers from Baylor College of Medicine in Houston in a report that appears online today in the Journal of the National Cancer Institute. "It's not enough to kill the dandelion blossom and stalk that appear above ground," said Dr. Michael Lewis, assistant professor of molecular and cellular biology and a faculty member in the Lester and Sue Smith Breast Cancer Center at BCM. "You have to kill the root beneath the soil as well." In a study involving women with breast cancer, he and colleagues at BCM showed that while conventional anti-cancer drugs can kill the bulk of breast cancer tumors, they leave behind many of the breast cancer stem cells from which tumor cells arise, setting the stage for the tumor to come back.

Lees verder


Menopausal Hormone Therapy Increases Risk of Breast Cancer

As little as three years of using combined estrogen and progestin menopausal hormone therapy substantially increases the risk of developing lobular breast carcinoma, the results of new research indicate. "Previous studies suggest that only women who use these hormones for at least five years have an increase in breast cancer risk, but none have evaluated how shorter durations of use impact risk of lobular breast cancer," lead author Dr Christopher I Li said.

Lees verder


Soy—Cause or Cure?—Things You Must Know about the Link between Soy and Breast Cancer Risk

Expert nutritionist Kaayla T. Daniel, PhD warns consumers about the misleading claims of soy and breast cancer prevention.

Lees verder


Work Stress May Lead to Breast Cancer, Study Finds

Women who feel stressed at work are at a higher risk of developing breast cancer, according to a new study. Researchers found that women in more demanding jobs are 30 percent more likely to develop breast cancer than those who feel they are on top of their work.

Lees verder


Risk of breast cancer mutations underestimated for Asian women, Stanford study shows

Oncologist Allison Kurian, MD, and her colleagues at the Stanford University School of Medicine were perplexed. Computer models designed to identify women who might have dangerous genetic mutations that increase their risk of breast and ovarian cancer worked well for white women. But they seemed to be less reliable for another ethnic group.“We’ve been repeatedly surprised when Asian women who the models predicted would probably not have the mutations do in fact have them,” said Kurian. She recently showed that in a head-to-head comparison between whites and Asians, two of the most commonly used models failed in predicting the presence of mutations in almost half of the Asian women studied.“Doctors and patients should have a higher level of suspicion when using these prediction models in Asian women, because they under-predicted the true number of clinically important mutations,” said Kurian. “We may have to consider more subtle patterns of family cancer history when considering genetic testing in this ethnic group.”

Lees verder


M. D. Anderson-Prevention Poll Finds Women Who Are Close to Someone With Breast Cancer Have Greater Sense of Risk

Women whose lives have been touched by the breast cancer experience of a friend or relative are more acutely attuned to their own risk for the disease and are taking action to protect themselves, according to a new national opinion poll by The University of Texas M. D. Anderson Cancer Center and Prevention magazine. Yet against a backdrop of unprecedented public awareness and despite the fact that an estimated 40,000 America women will lose their lives to breast cancer this year, 69 percent are largely unaware that regular exercise provides protection against the disease and 61 percent do not realize that being overweight or obese increases breast cancer risk. Most women (84 percent) do know, however, that taking hormone therapy increases risk even as it relieves symptoms of menopause. Prevention editor-in-chief Liz Vaccariello said, “We were very surprised to find such low level concern about getting breast cancer. It may be that women feel confident of their ability to beat the disease due to advances in early detection and treatment.”

Lees verder


M. D. Anderson Study Finds Change in HER2 Status After Treatment With Herceptin

Researchers at The University of Texas M. D. Anderson Cancer Center have discovered that when treated with Herceptin prior to surgery, 50 percent of HER2 positive, breast cancer patients showed no signs of disease at the time of surgery. However, of those women who had residual disease, about one-third had tumors that converted from HER2 positive to HER 2 negative status —possibly indicating a resistance to the targeted therapy. The study will be presented today in advance of the American Society for Clinical Oncology Breast Cancer Symposium. Approximately 30 percent of breast cancer cells have an excess amount of the HER2 protein on their surface, which makes the cancer more aggressive. Herceptin, also known as trastuzumab, is a monoclonal antibody that latches on to these proteins and inhibits tumor growth. It was approved in 1998 for women whose advanced, metastatic breast cancer is HER2-positive; it was approved in 2006 for use in the early setting. It’s known that a small percentage of HER2 positive patients develop a resistance to Herceptin during treatment, and there have been several described mechanisms for Herceptin resistance, said Elizabeth Mittendorf, M.D., assistant professor in M. D. Anderson’s Department of Surgical Oncology.

Lees verder


Hip size of mothers linked to breast cancer in daughters

In a study of the maternity records of more than 6,000 women, David J.P. Barker, M.D., Ph.D., and Kent Thornburg, Ph.D., of Oregon Health & Science University discovered a strong correlation between the size and shape of a woman's hips and her daughter's risk of breast cancer. Wide, round hips, the researchers postulated, represent markers of high sex hormone concentrations in the mother, which increase her daughter's vulnerability to breast cancer.

Lees verder


Researchers find new gene linked to breast cancer

Researchers in a multicenter international study have identified a new gene that, if mutated, may increase a woman's risk of breast cancer by more than a third.

Lees verder


Stem cells may solve mystery of early pregnancy breast cancer protection

The answer to why an early pregnancy seems to protect against breast cancer could rest with a decrease in stem cells found after animals have given birth, said researchers at Baylor College of Medicine in a report that appears in the current issue of the journal Stem Cell. Women who have children young, at least before the age of 30, reduce their risk of developing breast cancer, said Dr. Yi Li, a professor in the Lester and Sue Smith Breast Center at BCM. The most dramatic reduction in risk occurs in women who have their first children before the age of 24. However, the mechanism by which these early pregnancies provided protection has proved elusive. The promise of such work is important. "If we can figure out the mechanism behind this, we could develop a pill that we could offer young women in high school and college that could significantly reduce their risk of breast cancer," he said. However, he said, there are many steps to be taken before he and his colleagues can determine how best to do that. Understanding why stem cells decrease in women who have their children young could prove an important advance. In studies in mice, Li and his colleagues compared the numbers of mammary or breast stem cells (early cells that can differentiate into breast tissue) found in mice that had had babies at an age equivalent to the teens to mice that had never had babies.

Lees verder


Too much iron may raise breast cancer risk

High levels of free iron either released from iron reservoirs in the body or from dietary intake may increase risk of developing breast cancer, according to a review article published in the October 2007 issue of Cancer Causes Control.

Lees verder


Gene mutation linked to early-onset breast cancer

An international study that included Israelis has identified a new breast cancer gene that may increase the risk of the tumor by more than a third. The gene, named HMMR, follows the discoveries years ago of the breast cancer gene mutations known as BRCA1, BRCA2, APTM and CHEK2.

Lees verder


New Test May Predict Breast Cancer Metastasis

Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have identified a new marker for breast cancer metastasis called TMEM, for Tumor Microenvironment of Metastasis. As reported in the March 24 online edition of the journal Clinical Cancer Research, density of TMEM was associated with the development of distant organ metastasis via the bloodstream — the most common cause of death from breast cancer. The National Cancer Institute (NCI)–funded translational study could lead to the first test to predict the likelihood of breast cancer metastasis via the bloodstream — a development that could change the way breast cancer is treated. An estimated 40 percent of breast cancer patients relapse and develop metastatic disease. About 40,000 women die of metastatic breast cancer every year. "Currently, anyone with a breast cancer diagnosis fears the worst — that the cancer will spread and threaten their lives. A tissue test for metastatic risk could alleviate those worries, and prevent toxic and costly measures like radiation and chemotherapy," says senior author Dr. Joan G. Jones, professor of clinical pathology and laboratory medicine at Weill Cornell Medical College and director of Anatomic Pathology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. "If patients can be better classified as either low risk or high risk for metastasis, therapies can be custom tailored to patients, preventing over-treatment or under-treatment of the disease," adds first author Dr. Brian D. Robinson, resident in Anatomic Pathology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The Weill Cornell investigators set out to build on previous research by co-author Dr. John S. Condeelis of the Albert Einstein College of Medicine. Working in animal models, he identified a link between blood-borne or systemic metastasis and a three-part association between invasive carcinoma cells, perivascular white blood cells (macrophages) and the endothelial cells that line vessel walls. To confirm this finding in humans, Drs. Jones and Robinson developed a triple immunostain for human breast cancer samples that simultaneously labels the three cell types that together they named TMEM (Tumor Microenvironment of Metastasis).

Lees verder


Vaccine against HER2-positive breast cancer offers complete protection in lab

Researchers at Wayne State University have tested a breast cancer vaccine they say completely eliminated HER2-positive tumors in mice - even cancers resistant to current anti-HER2 therapy - without any toxicity.The study, reported in the September 15 issue of Cancer Research, a journal of the American Association for Cancer Research, suggests the vaccine could treat women with HER2-positive, treatment-resistant cancer or help prevent cancer recurrence. The researchers also say it might potentially be used in cancer-free women to prevent initial development of these tumors.HER2 receptors promote normal cell growth, and are found in low amounts on normal breast cells. But HER2-positive breast cells can contain many more receptors than is typical, promoting a particularly aggressive type of tumor that affects 20 to 30 percent of all breast cancer patients. Therapies such as trastuzumab and lapatinib, designed to latch on to these receptors and destroy them, are a mainstay of treatment for this cancer, but a significant proportion of patients develop a resistance to them or cancer metastasis that is hard to treat.This treatment relied on activated, own-immunity to wipe out the cancer, says the study's lead investigator, Wei-Zen Wei, Ph.D., a professor of immunology and microbiology at the Karmanos Cancer Institute.

Lees verder


Eating Mushrooms Slashes Risk of Breast Cancer by Two-Thirds

Regular mushroom consumption can decrease a woman's risk of breast cancer by two thirds, researchers have found.

Lees verder


Expanding cell girth indicates seriousness of breast cancer

How fat cells become after being exposed to a specialized electrical field is helping researchers determine whether cells are normal, cancerous or a stage of cancer already invading other parts of the body. Purdue University scientists tested the electrical process and found cells that expanded the most were metastatic cancer, the term used when the disease has spread beyond its point of origin. The technique allows screening of single cells 300 times faster - five cells per second compared with the one cell per minute of previous methods, said Chang Lu, senior and corresponding author of the study currently online in the journal Analytic Chemistry. This rapid cell inspection permits testing of enough cells for diagnosis and determination of the disease's level, he said.

Lees verder


PET scan can noninvasively measure early assessment of treatment for common type of breast cancer

Non-invasive imaging can measure how well patients with the most common form of breast cancer - estrogen receptor positive type - respond to standard aromatase inhibitor therapy after only two weeks and shows similar findings that more invasive needle sampling identifies, according to a poster presentation to be presented at the ASCO annual meeting next week. Using Positron Emission Tomography (PET) scanning and a glucose analogue called FDG, a research team led by Hannah Linden, M.D. and David Mankoff M.D., of the Seattle Cancer Care Alliance and the University of Washington, scanned 21 patients before and after two weeks of aromatase inhibitor therapy. Many of the patients also underwent a needle biopsy as a control measure to compare the two techniques. The results – 16 of the 21 patients had a greater than 20 percent decline in FDG values – "paralleled perfectly" earlier work done by UK-based researchers who used needle biopsies to measure whether the proliferation of cancer cells was slowed by therapy, according to Linden, who is a breast cancer oncologist. "Our findings are exciting because they suggest that we can measure a patient's response to therapy noninvasively, and PET scanning provides us simultaneous quantitative metabolic measurements at multiple tumor sites," Linden said. "PET has the potential to be a powerful tool to help doctors make important treatment decisions in as little as two weeks instead of two or more months."

Lees verder


New 'seed' therapy helps pinpoint breast tumors with more accuracy

Physicians at UT Southwestern Medical Center are the first in Texas to use a new technique in which a small radioactive pellet, or "seed," is implanted into a mass or suspicious lesion in the breast to pinpoint its exact location for surgical removal.

Lees verder


Light reveals breast tumor oxygen status

Light directed at a breast tumor through a needle can provide pathologists with biological specifics of the tumor and help oncologists choose treatment options that would be most effective for that individual patient. Duke University bioengineers have developed a light-based system that can quickly and easily provide important information about oxygen levels within a tumor while it is still in place. The new system, based on diffuse reflectance spectroscopy, gives researchers important clues about the tumor by interpreting how the light is either reflected back from the tumor or absorbed. Oxygen status is important, the researchers said, since past studies have shown that low levels of oxygen, or hypoxia, are more often associated with malignant tissue than healthy normal tissue. Tumors that thrive in these low-oxygen environments tend to be more difficult to treat, the researchers said. "We developed an easy-to-use fiber-optic probe that can provide immediate and non-destructive measurements of tumor oxygenation," said J. Quincy Brown, a fourth-year post-doctoral fellow in the laboratory of Nirmala Ramanujam, associate professor of biomedical engineering at Duke's Pratt School of Engineering. The results of the Duke experiments were published April 1 in the journal Cancer Research. "This new approach could be an important new tool for physicians in determining the aggressiveness of a specific tumor and which therapies might work best against it," Brown said. "Since this system is compatible with commonly used biopsy needles, we could make oxygen measurements at the time of a needle biopsy, providing immediate feedback about the tumor's oxygen concentration."

Lees verder


Cancer conflict with chemotherapy treatment

Young women suffering from breast cancer do not necessarily benefit from chemotherapy treatment. Women under the age of forty with breast cancer who are given drugs in addition to lumpectomies or radiotherapy, known as adjuvant chemotherapy, may not be benefiting from these drugs. This is especially true if their tumors respond to changing levels of hormones such as estrogen, according to research published in the online journal, Breast Cancer Research. "Developing breast cancer at a young age is very worrying in terms of survival," explained lead researcher Dr J van der Hage. "But some young women may be undergoing not only unpleasant but also unnecessary chemotherapy, which can be avoided."

Lees verder


New Study Reveals the Vitamin You Can't Ignore

A recent study from US Framingham indicated that one in every four adults in the US is deficient in Vitamin B12, which is known as the energy vitamin. Vitamin B12 can help with energy production, formation of blood, myelin formation and DNA synthesis. Because Vitamin B12 has such an important role when it comes to DNA synthesis, low levels can cause DNA damage. Cervical cancers and breast cancers are linked to low levels of vitamin B12.

Lees verder


Alcohol As a Breast Cancer Risk

According to the latest report on diet and cancer risk published by the American Institute for Cancer Research (AICR), there is convincing evidence that alcohol intake raises risk for breast cancer.

Lees verder


New cancer drug 'shows promise'

Researchers say a new type of cancer treatment has produced highly promising results in preliminary drug trials.

Lees verder


Breast Cancer Linked To Pesticide DDT, Study Suggests

At a time when the pesticide DDT is once again being promoted to combat malaria, researchers have found new evidence linking DDT to breast cancer, according to a study to be published in the scientific journal "Environmental Health Perspectives."

Lees verder


UC Davis researchers identify a protein that may help breast cancer spread, beat cancer drugs

New research from UC Davis Cancer Center shows that a protein called Muc4 may be the essential ingredient that allows breast cancer to spread to other organs and resist therapeutic treatment. The study, which appears in the April 1 issue of Cancer Research, is one of the first to characterize the role of Muc4 in the disease. Kermit Carraway, senior author of the study, knew that Muc4 was not always expressed in primary breast cancer tumors, yet it could be present in lymph node metastases. He suspected that it may have a specialized function in the process of metastasis. "Breast cancer deaths are caused by metastasis, not by the primary tumor," explained Carraway, an associate professor of biochemistry and molecular medicine. "It's at that point that the disease also becomes difficult to treat. We think that Muc4 may be packing a one-two punch by promoting the release of breast cancer cells from the primary tumor and then inhibiting their death." Muc4 is member of a group of proteins called mucins, which are commonly found in fluids such as tears and mucus. They have a known role in protecting epithelial cells, from which breast cancer cells are derived. When separated from their surrounding cell matrix, epithelial cells tend to die. Metastasizing breast cancer cells, however, can survive this detachment. "Because breast cancer cells can lose their adhesive properties and still thrive, we suspected that Muc4 may be somehow allowing them to leave their cellular framework, travel to secondary sites and withstand treatment," Carraway explained. To test his suspicions, Carraway and his team conducted two experiments. They started by comparing breast cancer cells that express Muc4 with those for which Muc4 production is blocked. The researchers then exposed both types of cells to chemotherapy drugs. The Muc4-producing cells survived. They repeated the experiment with breast cancer cells and epithelial cells that do not naturally express Muc4 but were engineered to do so. Both sets of cells avoided cell death and effectively resisted chemotherapy."Our results lead us to believe that Muc4 is somehow disrupting normal links between epithelial cells," said UC Davis graduate student Heather Workman, lead author of the study. "We now need to refine our understanding of this disruption process in order to find ways to interfere with it. There currently are no drugs that target Muc4, and this research will help change that."

Lees verder


Acupuncture Reduces Side Effects of Breast Cancer Treatment As Much As Conventional Drug Therapy

Acupuncture is as effective and longer-lasting in managing the common debilitating side effects of hot flashes, night sweats, and excessive sweating (vasomotor symptoms) associated with breast cancer treatment and has no treatment side effects compared to conventional drug therapy, according to a first-of-its-kind study presented September 24, 2008, at the American Society for Therapeutic Radiology and Oncology’s 50th Annual Meeting in Boston. Findings also show there were additional benefits to acupuncture treatment for breast cancer patients, such as an increased sense of well being, more energy, and in some cases, a higher sex drive, that were not experienced in those patients who underwent drug treatment for their hot flashes. “Our study shows that physicians and patients have an additional therapy for something that affects the majority of breast cancer survivors and actually has benefits, as opposed to more side effects. The effect is more durable than a drug commonly used to treat these vasomotor symptoms and, ultimately, is more cost-effective for insurance companies,” Eleanor Walker, M.D., lead author of the study and a radiation oncologist at the Henry Ford Hospital Department of Radiation Oncology in Detroit, said.

Lees verder


Environmental estrogens affect breast development in male rats

A five-generation rat study provides the clearest evidence to date that exposure to low levels of environmental estrogens can increase the risk of abnormal cell growth in the male breast. Abnormalities which could have the potential to become cancerous developed in the mammary gland tissue of male rats that were exposed to either the soy-based phytoestrogen genistein or ethinyl estradiol – an estrogen used in birth control pills. The findings support a growing concern that exposure to low levels of estrogen in the environment might increase the risk of breast cancer.

Lees verder


Vitamin D Deficiency in Premenopausal Women with Breast Cancer

Despite recent data indicating that vitamin D may have a preventive effect against cancer, 74% of premenopausal women with early-stage breast cancer are deficient in the vitamin, according to the results of a study published in the Journal of Clinical Oncology. Furthermore, daily supplementation of 400 IU of vitamin D does not appear to correct the deficiency.

Lees verder


Enhanced DNA-repair mechanism can cause breast cancer

Although defects in the "breast cancer gene," BRCA1, have long been known to increase the risk for breast cancer, exactly how the defects lead to tumor growth has remained a mystery. Now scientists provide insight into how the normal BRCA1 gene suppresses the growth of tumors as well as the nature of the genetic instability that leads to cancer when BRCA1 is defective.

Lees verder


More Women Scared Into Double Mastectomy as Way to "Prevent" Cancer

Increasing numbers of women are choosing to have both breasts removed in order to avoid breast cancer -- but doctors warn that many of these procedures may expose women to serious risk without providing the promised benefit.

Lees verder


Contrast Agent Trials in Swine

Mammography continues to be the method of choice for the early detection of breast cancer. However, because this technique is not as selective or specific as one would wish, and does not deliver reliable results for every level of tissue density, alternatives are being sought. Near-infrared fluorescence mammography, which works with rays of near-infrared (NIR) light instead of X-rays, is a highly promising technique—although effective contrast agents have thus far been lacking. A team led by John V. Frangioni at the Beth Israel Deaconess Medical Center of the Harvard Medical School in Boston, Massachusetts, has developed a contrast agent that makes visible the microcalcifications related to malignant breast tumors. The researchers report in the journal Angewandte Chemie that in validation trials in swine their new contrast agent distinguishes specific calcium salts in soft tissues, as well as depicting bones.

Lees verder


Hormone Therapy Speeds Breast Cancer

Postmenopausal women face increased risk of lobular breast cancer when they take combined estrogen/progestin hormone-replacement therapy (HRT) for three years — not five years or more as suggested by previous studies, say researchers at the Fred Hutchinson Cancer Research Center in Seattle.

Lees verder


Hypofractionated Radiation in Breast Cancer Has Fewer Adverse Effects

In early-stage breast cancer, delivery of a lower total radiation dose in fewer but larger fractions reduces effects on normal tissue with no loss in tumor control, according to results of two large randomized trials.

Lees verder


LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies

Combined hormone therapy appears to increase the risk that women will have abnormal mammograms and breast biopsies, and it may decrease the effectiveness of both methods for detecting breast cancer, according to a report in the Feb. 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Lees verder


Gene helps protect tumor suppressor in breast cancer

Scientists at The University of Texas M. D. Anderson Cancer Center have discovered a gene that protects PTEN, a major tumor-suppressor that is reduced but rarely mutated in about half of all breast cancers. The gene Rak helps protect and regulate PTEN, which also is important in several other types of cancer, the team reports in the April edition of Cancer Cell. Causes for diminished PTEN protein levels in breast cancer absent a mutation of the PTEN gene have eluded researchers, who knew for several years that a piece of the puzzle was missing. "We've clearly discovered the missing link that explains how Rak can stabilize PTEN protein to prevent breast cancer development," said lead author Shiaw-Yih Lin, Ph.D., an assistant professor in the Department of Systems Biology at M. D. Anderson. "Our research explains why PTEN is defective in breast cancer and provides important clues for the development of effective therapy in Rak- or PTEN-defective breast cancers." In addition to breast cancer, PTEN frequently is mutated or inactivated in glioblastoma, melanoma, and cancers of the prostate and endometrium. The severity of PTEN irregularities strongly correlates with the tumor stage and grade. For example, complete loss of PTEN expression is found more frequently in metastatic cancer than in primary tumors. In the laboratory, researchers found Rak can stabilize PTEN protein and function as a tumor suppressor gene to prevent breast cancer development.

Lees verder


Conflicting Data on Breast Cancer, Tamoxifen and Antidepressants

Researchers think some popular antidepressants may keep the anti-cancer drug Tamoxifenfrom working as well as it should.

Lees verder


Dairy consumption linked to breast, prostate cancer

A South Carolina doctor claims that consumption of dairy products can increase your risk of acquiring breast and prostate cancer. Dr. Robert Bibb of Myrtle Beach is working on a book, Death by Dairy, about the dangers of a dairy-consuming diet. According to Bibb, a growing body of evidence supports his contention that the hormones found in dairy products increase the body's risk of cancer. "There's an association between dairy [consumption] and hormonally sensitive cancers," he said. "I looked, but I can't find any other factors that fit epidemiologically."

Lees verder


Vitamin-A Derivative Provides Clues to Better Breast Cancer Drugs

Retinoic acid, a derivative of vitamin A, could lead researchers to a new set of drug targets for treating breast cancer, researchers from the University of Chicago report in the June 25, 2009, issue of the journal Cell. The most common forms of breast cancer are fueled by the female hormone estrogen. By comparing the effects of estrogen and retinoic acid on the entire genome, the researchers found that they have a "yin-yang" effect. They alter the expression of many of the same genes, with estrogen tipping the scales towards cell proliferation and retinoic acid restoring the balance by inhibiting cellular growth. This balanced control of gene expression regulates fundamental cellular processes, say the authors. When it is dysregulated, it can lead to cancer. "Understanding all the components of this process could be used against breast cancer care in three ways," said study leader, Kevin White, PhD, professor of human genetics and director of the Institute for Genomics and System Biology at the University of Chicago. "It suggests new ways to think about preventing the disease in those at high risk. It offers molecular tools that could provide a more precise diagnosis and predict outcomes. It could also be used to enhance current therapies, making existing drugs, such as tamoxifen, that selectively block estrogen's effects even more powerful, or even to develop new anti-cancer drugs."

Lees verder


Exposure to sunlight may decrease risk of advanced breast cancer by half

A research team from the Northern California Cancer Center, the University of Southern California, and Wake Forest University School of Medicine has found that increased exposure to sunlight -- which increases levels of vitamin D in the body -- may decrease the risk of advanced breast cancer.

Lees verder


'Major breakthrough' in fight against breast cancer

A "major breakthrough" in the fight against breast and ovarian cancers has been achieved, after British scientists identified the genetic process which stops the body repairing faulty DNA.

Lees verder


Korean Scientists Make Breast Cancer Breakthrough

A team of researchers has discovered a method to more accurately predict the spread of breast cancer.

Lees verder


New predictive tool can help determine treatment of breast cancer patients

A new predictive measurement, called a PEPI score, could bring good news to many women diagnosed with early stage breast cancer — a low PEPI (preoperative endocrine prognostic index) score could show that they have little risk of relapse and can safely avoid chemotherapy after surgery. For others, a high PEPI score could warn that the risk of relapse after breast surgery is large and indicates that careful follow-up and aggressive therapy may be needed, say researchers at Washington University School of Medicine in St. Louis and collaborating institutions in Europe.

Lees verder


Weill Cornell team identifies potential new drug targets against hormone-dependent breast cancer

The identification of two cellular receptors that likely contribute to the genesis of hormone-dependent breast cancer points the way to new, highly targeted therapies against the disease, says a team led by scientists at Weill Cornell Medical College in New York City.

Lees verder


Parents told chips can cause cancer

Serving under-fives chips just once a week raises their risk of breast cancer by 27 per cent, shocking new research has shown.

Lees verder


New MRI technique could mean fewer breast biopsies in high-risk women

A University of Wisconsin-Madison biomedical engineer and colleagues have developed a method that, applied in MRI scans of the breast, could spare some women with increased breast cancer risk the pain and stress of having to endure a biopsy of a questionable lump or lesion.The universal technology will give radiologists greater confidence in visually classifying a lesion as malignant or benign. The American Cancer Society recommends that women with certain breast cancer risk factors — including inherited genetic mutations, family or personal history of breast cancer, or previous radiation therapy to the chest — receive an annual MRI screening in addition to their yearly mammogram.During a breast MRI, which lasts about a half hour, the technician injects a contrast agent into a vein in the patient's arm. Over time, the contrast agent flows throughout the body, including the breasts. Because they are growing quickly, cancerous lesions often have immature vasculature, and the contrast agent flows in and "leaks" out quickly. Conversely, benign lesions show more gradual in and out flow. "The tricky ones are the ones that enhance quickly and then fall off more slowly," says Wally Block, a UW-Madison associate professor of biomedical engineering and medical physics. "Many of these lesions turn out to be difficult to classify and lead to biopsy."Yet, it turns out that with the right kind of MRI scan, radiologists can visually identify a cancerous lesion based on characteristics about its shape. For example, breaks or interruptions in a lesion can indicate a benign fibroadenoma. Lumps with smooth edges often are benign, while those with jagged edges can signal cancer. To generate the kind of crisp, three-dimensional images necessary for such a diagnosis, Block, UW-Madison radiology associate professor Fred Kelcz and graduate student Catherine Moran are capitalizing on their unique MRI data-acquisition method. An MR image is made up of thousands of smaller pieces of information. The conventional data-acquisition method gathers that information slowly, and it's designed to be viewed from a single imaging plane. "What people do now is they compromise," says Block. "They don't get resolution in the other planes to make it a reasonable scan time. We found a way around that."

Lees verder


The dietary supplement genistein can undermine breast cancer treatment

Women taking aromatase inhibitors to treat breast cancer or prevent its recurrence should think twice before also taking a soy-based dietary supplement, researchers report. Genistein, a soy isoflavone that mimics the effects of estrogen in the body, can negate the effectiveness of aromatase inhibitors, which are designed to reduce the levels of estrogens that can promote tumor growth in some types of breast cancer. The new study, which included researchers from the University of Illinois, Virginia Polytechnic and State University and the National Center for Toxicological Research, appears in the journal Carcinogenesis. Aromatase inhibitors are a mainstay of breast cancer treatment in post-menopausal women. These drugs work by interfering with the enzyme aromatase, which catalyzes a crucial step in converting precursor molecules to estradiol, the main estrogen in the body. About two-thirds of all cases of breast cancer diagnosed in the U.S. are estrogen dependent or estrogen sensitive, which means that the tumors grow more rapidly in the presence of estrogen.

Lees verder


Soy Industry Promotes Health Myths to Sell More Soy Products, Says Author

Author Kaayla T. Daniel is challenging what she calls the myth that soy prevents breast cancer. "The truth is that soy protein contains dangerous levels of plant estrogens. Although not identical to human estrogens, these have been proven to increase breast cell proliferation, a widely accepted marker of breast cancer risk." said Daniel, author of "The Whole Soy Story; The Dark Side of America's Favorite Health Food."

Lees verder


Revelation on breast cancer research

Tumor cell lines - living cells taken from tumors and cultured in the laboratory - are the mainstay of cancer research at the most fundamental level, and are used as the model for studying tumor behavior and response to treatment. For the past 25 years, most of the laboratory research into metastatic breast cancer has been based on a single breast tumor cell line known as MDA-MB-435. At least 650 papers have been published on studies involving this cell line. Yet it has been revealed that this supposed breast cancer cell line may in fact not be composed of breast cancer cells at all. Instead, it appears that the cells are derived from melanoma. For 25 years, therefore, breast cancer research using this cell line - and it is one of the most widely used - has been based on an incorrect model. Melanoma-derived tumor cells are not biologically equivalent to breast cancer cells; they have different molecular and genetic characteristics.

Lees verder


Antibiotic use raises breast cancer risk

study led by researchers from King Saud bin Abdulaziz University for Health Sciences in Riyadh, Saudi Arabia showed use of antibiotics increased risk of breast cancer by 50 to 79 percent, depending upon the number of prescriptions an individual received during one to 15 years prior to the diagnosis of the disease.

Lees verder


Male breast cancer and Camp Lejeune - Pollution or coincidence?

Some scientists, however, have noted suspicious increases in male breast cancer at other sites polluted with the same compounds found at Camp Lejeune.

Lees verder


Wet ear wax and unpleasant body odors signal breast cancer risk

If having malodorous armpits (called osmidrosis) and goopy earwax isn't bad enough, a discovery by Japanese scientists may add a more serious problem for women facing these cosmetic calamities. That's because they've found that a gene responsible for breast cancer causes these physical symptoms. The report describing this finding is featured on the cover of The FASEB Journal's June 2009 print issue (http://www.fasebj.org), and should arm physicians with another clue for detecting breast cancer risk. "We do strongly hope that our study will provide a new tool for better predication of breast cancer risk by genotyping," said Toshihisa Ishikawa, Ph.D., a professor from the Department of Biomolecular Engineering at the Tokyo Institute of Technology and the senior researcher involved in the work. "Using a rapid and cost-effective typing method presented in this study would provide a practical tool for pharmacogenomics-based personalized medicine." To draw their conclusions, Ishikawa and colleagues monitored the activities of a protein created by a gene associated with breast cancer, called "ABCC11." By studying this gene and its complex cellular and molecular interactions in the body, the researchers discovered a distinct link between the gene and excessively smelly armpits and wet, sticky earwax. Specifically, the researchers expressed the ABCC11 gene and variant proteins in cultured human embryonic kidney cells and showed exactly how the ABCC11 gene produces the wet-type earwax and excessive armpit odor. This discovery could lead to practical tools for clinicians—especially those in developing nations—to rapidly identify who may have a higher risk for breast cancer. "Wet, sticky earwax might not be easily noticed, but most people can't miss unpleasant body odors," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal, "As it turns out, the type of ear wax one has is linked to a gene that leads to bad odors from one's armpit. These may become lifesaving clues to the early detection and treatment of breast cancer."

Lees verder


Omega-6 fatty acid intake tied to breast cancer

However, low intake of these substances combined with high consumption of omega-6 polyunsaturated fatty acids (PUFAs), which are found in most types of vegetable oil, may indeed increase the likelihood that postmenopausal women will develop breast cancer, Dr. Emily Sonestedt, of Lund University, Malmo, and her colleagues found.

Lees verder


External beam partial breast irradiation most cost-effective treatment

External beam partial breast irradiation (EB-PBI) is the most cost-effective method for treating postmenopausal women with early-stage breast cancer based on utilities, recurrence risks and costs when compared to whole breast radiotherapy (WBRT) and brachytherapy partial breast irradiation (brachy-PBI), according to a study in the June 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO). PBI is a newer form of radiation therapy for breast cancer where only part of the breast is treated twice a day for four to five days. Radiation oncologists have been studying different methods to deliver the radiation to the tumor. EB-PBI uses high-energy external X-rays to deliver radiation to the breast after a lumpectomy and brachy-PBI delivers radiation through either implanted needles or a small sphere placed into the post-lumpectomy cavity in the breast. Whole breast radiation therapy is currently the standard of care, but it is a more time-consuming treatment, as it involves five to seven weeks of daily treatments using a linear accelerator to deliver X-rays to the tumor site. While the convenience of receiving radiation for one week instead of five to seven weeks is obvious, the cost-effectiveness of the different methods of treatment has never been analyzed. Doctors are also still examining long-term data to see whether partial breast irradiation is as effective at curing the cancer as whole breast radiation. In a previous study, researchers at the Harvard Radiation Oncology Program, the Dana-Farber Cancer Institute and Brigham and Women's Hospital Department of Radiation Oncology, and the Massachusetts General Hospital Department of Radiation Oncology, all in Boston, and the Brandeis University Heller School for Social Policy and Management in Waltham, Mass., determined that under most circumstances, the quality-adjusted life expectancy was higher in patients receiving PBI than WBRT. In this study, they sought to determine if PBI is better from a cost standpoint. "According to the American Cancer Society, almost 200,000 women will be diagnosed with breast cancer in 2009. Given this high prevalence, resource-conscious healthcare systems may want to consider cost-effectiveness when deciding on appropriate adjuvant therapies for patients with early-stage breast cancer," Rinaa Punglia, M.D., M.P.H., senior author of the study and a radiation oncologist at Dana-Farber Cancer Institute and Brigham and Women's Hospital, said.

Lees verder


Researchers identify new genetic marker for breast cancer

An international group of investigators led by scientists at Memorial Sloan-Kettering Cancer Center and the National Cancer Institute has identified a new genetic marker of risk for breast cancer. Women with this DNA variation are at a 1.4 times greater risk of developing breast cancer compared to those without the variation. The findings are to be published online on March 3, 2008 in the journal Proceedings of the National Academy of Sciences.

Lees verder


I-SPY trial offers key insights into locally advanced breast cancer

Scientists are reporting two findings that could influence the way researchers screen for, treat and assess prognosis for women with locally advanced breast cancer, an aggressive form of the disease. One finding offers a critical message regarding treatment strategy, they say. "Women with locally advanced breast cancer and their clinicians need to be aware that a growing breast mass should not be ignored even if someone has had a recent normal mammogram," says Laura Esserman, MD, UCSF professor of surgery and radiology and director of the UCSF Carol Franc Buck Breast Care Center. The findings emerged from I-SPY, a multi-center clinical trial designed to evaluate the impact of chemotherapy before surgery on patients with locally advanced breast cancer. Assessments in the trial focus on biological markers as predictors of pathological complete response and survival. Locally advanced breast cancer tumors develop in younger patients, have a worse prognosis and are large (min. 3 cm.). The results were reported in the scientific session "Oral Abstract Session-Breast Cancer -- Local-Regional and Adjuvant Therapy (Esserman) and the Oral Abstract Session- Cancer Prevention,(Lin 4pm)" at the American Society of Clinical Oncology annual meeting on Saturday, May 30, 2009. One study revealed that most locally advanced breast cancers are discovered in the interval between routine mammogram exams, which are conducted every one or two years. Of the women who were receiving regular screening mammograms, 83 percent had developed such so-called interval cancers. "This finding suggests that the growth rate of locally advanced breast cancers precludes early detection by conventional screening," says the senior author of the study, Laura Esserman, MD, UCSF professor of surgery and radiology and director of the UCSF Carol Franc Buck Breast Care Center. "We need to develop a better understanding of the molecular signatures of these tumors. Understanding their biology will be important for developing better strategies for prevention and early detection."

Lees verder


Light therapy offers 'non-invasive' treatment for breast cancer

A groundbreaking treatment for breast cancer which uses light to target and kill tumours without the need for surgery is being pioneered by a British doctor.

Lees verder


Evaluation of the current knowledge limitations in breast cancer research

Gaps were identified in all seven themes. General barriers to progress were lack of financial and practical resources, and poor collaboration between disciplines. Critical gaps in each theme included (1) genetics: knowledge of genetic changes, their effects and interactions; (2) initiation of breast cancer: how developmental signalling pathways cause ductal elongation and branching at the cellular level and influence stem cell dynamics, and how their disruption initiates tumour formation; (3) progression of breast cancer: deciphering the intracellular and extracellular regulators of early progression, tumour growth, angiogenesis and metastasis; (4) therapies and targets: understanding who develops advanced disease; (5) disease markers: incorporating intelligent trial design into all studies to ensure new treatments are tested in patient groups stratified using biomarkers; (6) prevention: strategies to prevent oestrogen-receptor negative tumours and the long-term effects of chemoprevention for oestrogen-receptor positive tumours; (7) psychosocial aspects of cancer: the use of appropriate psychosocial interventions, and the personal impact of all stages of the disease among patients from a range of ethnic and demographic backgrounds.

Lees verder


Birth size is a marker of susceptibility to breast cancer later in life

The findings from a study by a team based at the London School of Hygiene & Tropical Medicine (LSHTM) are published today in PLoS Medicine. Associations between birth size, perhaps as a marker of the pre-natal environment, and subsequent breast cancer risk have been identified before, but the findings from epidemiological studies have been inconsistent. The team re-analysed data from published and unpublished studies to obtain more precise estimates of the extent to which birth size affects the risk of breast cancer later in life and to investigate whether they could be explained by associations with other risk factors. They examined 32 studies, comprising 22,058 breast cancer cases among a total of more than 600,000 women, the large majority of whom lived in developed countries. They found that birth weight was positively associated with breast cancer risk in studies where the size at birth information was based on birth records (although not in those based on adult self-reports, which tend to be less accurate). Analyses of women with data from birth records showed that a 0.5 kg increment in birth weight was associated with an estimated 7% increase in the risk of breast cancer. Birth length and head circumference were also positively associated with breast cancer risk when studies with data from birth records were analysed. Of the three birth size measures examined, birth length appeared to be the strongest independent predictor of risk. The estimated magnitude of the birth size association with breast cancer risk was not affected when the effects of established breast cancer risk factors were accounted for. Isabel dos Santos Silva, Professor of Epidemiology at LSHTM and lead author of the study, commented ‘Our study indicates that birth size is a marker of susceptibility to breast cancer in adulthood, at least in developed countries. The birth size - breast cancer association appeared to be largely independent of known risk factors. Little is known on how the pre-natal environment may affect breast cancer risk later in life. Further research is needed to unravel the biological mechanisms underlying the birth size - breast cancer association’.

Lees verder


Breast cancer cells recycle to escape death by hormonal therapy

Many breast cancer cells facing potentially lethal antiestrogen therapy recycle to survive, researchers say. About 70 percent of breast cancer cells have receptors for the hormone estrogen, which acts as a nutrient and stimulates their growth. Patients typically get an antiestrogen such as tamoxifen for five years to try to starve them to death, says Dr. Patricia V. Schoenlein, cancer researcher in the Medical College of Georgia Schools of Medicine and Graduate Studies. "About 50 to 60 percent of these women really benefit from hormonal therapy," says Dr. Schoenlein. Why others don't has been asked for at least two decades. One reason may be breast cancer cells switch into a survival mode that normal cells also use when faced with starvation, according to research published in the September issue of Molecular Cancer Therapeutics. Dr. Schoenlein also is reporting on the research during the 2nd World Conference on Magic Bullets (Ehrlich II) Oct. 3-5 in NŁrenberg, Germany.

Lees verder


Researchers identify risk factors for contralateral breast cancer

A preventive procedure to remove the unaffected breast in breast cancer patients with disease in one breast may only be necessary in patients who have high-risk features as assessed by examining the patient's medical history and pathology of the breast cancer, according to researchers at The University of Texas M. D. Anderson Cancer Center. Their findings, published in the March 1, 2009 issue of Cancer, may help physicians predict the likelihood of patients developing breast cancer in the opposite breast (contralateral breast cancer), stratify risk and counsel patients on their treatment options. "Women often consider contralateral prophylactic mastectomy (CPM) not because of medical recommendation, but because they fear having their breast cancer return," said Kelly Hunt, M.D., professor in the Department of Surgical Oncology at M. D. Anderson and lead author on the study. "Currently it is very difficult to identify which patients are at enough risk to benefit from this aggressive and irreversible procedure. Our goal was to determine what characteristics defined these high-risk patients to better inform future decisions regarding CPM." According to the researchers, approximately 2.7 percent of women diagnosed with breast cancer choose to have CPM. Recent statistics have shown that the rate of CPM in women with stage I-III breast cancer increased by 150 percent from 1998 to 2003 in the United States. Potential reasons breast cancer patients choose to undergo CPM include risk reduction, difficult surveillance and reconstructive issues such as symmetry and/or balance. To begin to classify such risk factors, researchers reviewed the cases of 542 women with breast cancer only in one breast who received CPM to remove the second breast at M. D. Anderson from January 2000 to April 2007. Out of this group, 435 patients had no abnormal pathology identified in the opposite breast, 25 patients had contralateral breast cancer identified at surgery, and 82 patients had abnormal cells (atypical ductal hyperplasia, atypical lobular hyperplasia and lobular carcinoma in situ) that indicate a moderate to high-risk for breast cancer development in the contralateral breast found at the time of surgery.

Lees verder


Metabolic factors may play a role in risk for breast cancer

Physiological changes associated with the metabolic syndrome may play a role in the risk of postmenopausal breast cancer, according to study results published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. The metabolic syndrome, or insulin resistance syndrome, consists of a constellation of factors including abdominal obesity, high blood glucose levels, impaired glucose tolerance, abnormal lipid levels and high blood pressure. Affecting roughly 47 million Americans, the metabolic syndrome is also associated with poor diet and lack of physical activity. It can also increase the risk for diabetes and heart disease. The metabolic syndrome is characterized by elevated insulin levels, and in recent years scientists have proposed that insulin may contribute directly or indirectly to the development of breast cancer. Researchers suspect that the metabolic syndrome could influence the risk for breast cancer by affecting interrelated hormones, such as insulin, estrogen, cytokines and growth factors. "This study suggests that having the metabolic syndrome itself or some of its components may increase a woman's risk of postmenopausal breast cancer. However, much more work is needed to understand the role of these metabolic factors and their interplay with better established breast cancer risk factors, such as reproductive and hormonal factors," said researcher Geoffrey C. Kabat, Ph.D., senior epidemiologist in the department of epidemiology and population health at Albert Einstein College of Medicine, New York. Studies to date have evaluated individual components of the metabolic syndrome and breast cancer, with inconsistent results, according to Kabat. For the first time, Kabat and colleagues assessed whether women who met the criteria of having the metabolic syndrome were at greater risk for postmenopausal breast cancer.

Lees verder


Newly appreciated membrane estrogen receptor important therapeutic target for breast cancer

New research at Rhode Island Hospital has uncovered the biological effects of a novel membrane estrogen receptor, a finding that has potential implications for hormonal therapy for breast cancer. The study is published in the July edition of the journal Molecular Endocrinology. This new study by Edward Filardo, MD, and his research team further supports earlier published work by the group that linked the transmembrane receptor, GPR30/GPER-1, to specific estrogen binding, rapid estrogen signaling and breast cancer metastasis. "What is exciting about this new work," says Filardo, "is that it provides some insight into the influence of GPR30 at the cellular level. It shows that estrogen action through GPR30 allows for breast tumor cell survival, and not breast tumor cell proliferation." Prior studies by Filardo's group showed that estrogen acts through GPR30 to promote the rapid release of preformed growth factors that are tethered to the surface of breast cancer cells. Their latest study was conducted in an effort to better understand the mechanism by which GPR30 triggered the release of epidermal growth factor (EGF) polypeptides from the surface of breast cancer cells.The investigator's found that the "growth factors" did not promote cellular growth, which by itself is not a novel finding. It has long been appreciated that EGF-related factors are also important in other cellular activities such as cellular survival. Filardo and the research team, however, found that estrogen action through GPR30 had a more profound effect on tumor cell survival. They found that GPR30 promoted the assembly of what is called a "provisional extracellular matrix" -- a crucial event in cellular survival. More specifically, they found that release of growth factor by GPR30 required the activation of a latent adhesion receptor (known as integrin a5b1). Filardo says, "Activation of integrin a5b1 by GPR30 is a significant event because it provides a way for invading cells to gain hold once they metastasize to tissues distant to the primary breast cancer. This happens because activated integrin a5b1 can convert soluble plasma protein fibronectin into an insoluble cage. The breast cancer cells can use this to adapt to a new environment."

Lees verder


Tissue Proteomics Technology to Identify Protein Biomarkers of Metastasis

Over 200,000 cases of early-stage breast cancer present for treatment decisions each year in North America. Proteins make up the molecular pathways which control cell functions and are the targets of drug action. This protein-based approach may yield valuable tissue biomarkers of breast cancer metastasis as well as potential new cancer drug targets.

Lees verder


"False" cancer results exposed

Scans given to women who have a high risk of inheriting breast cancer falsely give a positive result for the disease in five out of six cases, new research shows.

Lees verder


Enviro-toxins, radiation may be tied to breast cancer

Produced by the Breast Cancer Fund, a nonprofit group whose mission is to identify environmental links to breast cancer, "The State of the Evidence: 2008" concludes toxic chemicals in the environment, along with increased radiation exposure, are the main culprits in the sharp rise of breast cancer incidence.

Lees verder


MU researcher links hormone replacement therapy to breast cancer

In a recent University of Missouri study, researchers found that one of the hormones used in HRT could be a major factor in promoting breast cancer. At the same time, the researchers have compelling evidence that using an antibody that prevents new blood vessel formation in tumors, or a small molecular drug, known as PRIMA, with similar properties as the antibody may be effective in treating or preventing the negative effects of progestin.

Lees verder


Chemotherapy-induced anemia increases risk of local breast cancer recurrence

Patients with breast cancer who developed anemia during chemotherapy had nearly three times the risk of local recurrence as those who did not, according to a study published in the April 1 issue of Clinical Cancer Researchł a journal of the American Association for Cancer Research. “We speculate that there may be an interaction between chemotherapy/radiotherapy and anemia,” said lead researcher Peter Dubsky, MD, a senior consultant in the department of surgery at the Medical University of Vienna, Austria. “Both treatment modalities have been shown to be less effective in anemic patients. Since we do not see the effect in terms of relapse-free survival, the interaction with local adjuvant treatment may play a more important role.”Dubsky and his colleagues from the Austrian Breast and Colorectal Cancer Study Group examined data from a randomized, clinical trial comparing adjuvant hormonal treatment and tamoxifen with the standard treatment of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). All women in the trial were premenopausal and had positive estrogen and/or progesterone receptor status. Patients who underwent breast-conserving surgery received mandatory radiation. Radiation was optional in women who underwent modified radical mastectomy.

Lees verder


Study identifies potential 'safe period' for hormone replacement use

A new study makes important new findings on the role of hormone use on the risk of breast cancer, confirming that the use of estrogen plus progesterone increases the risk of both ductal and lobular breast cancer far more than estrogen-only; suggesting a two-year "safe" period for the use of estrogen and progesterone; and finding that the increased risk for ductal cancers observed in long-term past users of hormone replacement therapy drops off substantially two years after hormone use is stopped. The study appears in CANCER, a peer-reviewed journal of the American Cancer Society. Previous studies have shown that hormone replacement therapy after menopause increases the risk of breast cancer and that use of a regimen that includes both estrogen and progesterone is more detrimental for the breast than the use of estrogen alone. But more data from large prospective studies are needed to fully characterize the impact of exogenous hormones on breast cancer incidence by type of hormone preparation and histology of the cancer. To investigate the association in more detail, American Cancer Society epidemiologists led by Eugenia E. Calle, PhD, did a prospective study of 68,369 postmenopausal women who were cancer-free at baseline in 1992. They examined the use of estrogen-only and estrogen and progesterone in current and former users of varying duration, and the subsequent risk of developing invasive ductal and lobular carcinoma of the breast. They also looked at whether the risk for each type of breast cancer and each type of hormone regimen varied by body mass index (BMI), stage of disease at diagnosis, and estrogen receptor (ER) and progesterone receptor (PR) status. For the present study, the follow-up period ended on June 30, 2005.

Lees verder


New technique images tumor vessel leakiness to predict breast cancer chemotherapy outcome

Chemotherapy is an integral part of modern cancer treatment, but it's not always effective. Successful chemotherapy depends on the ability of anticancer drugs to escape from the bloodstream through the leaky blood vessels that often surround tumors. Predicting chemotherapy's efficacy could save thousands of individuals from unnecessary toxicity and the often difficult side effects of the treatments. In a study published in the February issue of the journal Radiology, researchers describe a technique for determining the "leakiness" of tumor blood vessels using a simple digital mammography unit. The researchers designed nanometer-sized capsules containing a contrast agent that could only leak into tumors with blood vessels that were growing and therefore leaky. The digital mammography-based quantification of "leakiness" is closely correlated to the ability of a clinically approved chemotherapy agent to enter the tumor, allowing the researchers to predict the agent's therapeutic efficacy. We developed a quantitative way to measure the leakiness of the blood vessels, which is directly linked to the amount of drug that gets to the cancer and in turn determines effectiveness," said Ravi Bellamkonda, a professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. "By simply measuring how much contrast agent reaches the tumor, we can predict how much of a clinically approved chemotherapeutic will reach the tumor, allowing physicians to personalize the dose and predict effectiveness."In some cases, one chemotherapy drug may not be effective in treating the tumor, but this new technique allows oncologists to investigate other drugs sooner since they know the drug is reaching the tumor. Studies are currently underway to determine if mammography can predict the optimal dose of a wide range of breast cancer chemotherapeutics.

Lees verder


New technology discovery at Mount Sinai Hospital holds promise for improved breast cancer treatment

In a study published by Nature Biotechnology online on February 1, 2009, Mount Sinai Hospital researchers have unveiled a new technology tool that analyzes breast cancer tumours to determine a patient's best treatment options. The tool can predict with more than 80 per cent accuracy a patient's chance of recovering from breast cancer. "Breast cancer is the most common cancer in Canadian women," said Dr. Jeff Wrana, Senior Investigator and the Mary Janigan Research Chair in Molecular Cancer Therapeutics at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, and an International Scholar of the Howard Hughes Medical Institute. "Our hope with this technology is to eventually provide individualized analysis to breast cancer patients and their oncologists so that they are better informed and empowered to select a treatment best suited to them." The technology, called 'DyNeMo' analyzes networks of proteins in cancer cells. Analysis of more than 350 patients found that those who survive breast cancer have a different organization of the network of proteins within the tumour cells, compared with patients who succumbed to the illness. DyNeMo can be used to predict the outcome in a newly diagnosed breast cancer patient and then assist clinicians and patients in making informed decisions on treatment. The study was led by the Mount Sinai Hospital team and co-authored by researchers at the University of Toronto and London, England's The Institute for Cancer Research. In the future, this tool may be used to analyze other types of cancer and could be used to predict an individual's response to particular drugs.

Lees verder


Instead of fighting breast cancer, immune cell promotes its spread

Researchers at the UC San Diego School of Medicine and the Moores UCSD Cancer Center have new evidence that a type of immune system cell thought to be part of the first line of defense against breast cancer may also help promote its spread. They have found that when these cells, known as lymphocytes, make an inflammatory protein called RANKL (RANK ligand), breast cancer is more likely to spread to the lungs. They have also shown that blocking a cascade of cellular signals that follow RANKL's docking to its receptor (RANK) on tumor cells can halt cancer progression, or metastasis, and may be a possible target for drug therapy. The scientists, led by first author Wei Tan, PhD, a postdoctoral fellow in the Department of Pharmacology at the UC San Diego School of Medicine and Michael Karin, PhD, professor of pharmacology in UCSD's Laboratory of Gene Regulation and Signal Transduction, say that the findings establish RANKL as a potential marker that can be used to help determine breast cancer prognosis and adds further proof to the potentially important role of inflammation in cancer development and spread. They reported their findings April 22, 2009 at the AACR 100th Annual Meeting 2009 in Denver. According to Tan, the role of lymphocytes in breast cancer progression has been controversial for the last 20 years. Such cells are supposed to detect and eliminate cancer cells, but paradoxically, the infiltration of lymphocytes such as B cells and T cells into breast cancer is sometimes an indicator of poor prognosis, including cancer recurrence and metastasis. RANKL has been shown in previous studies to be an important inflammatory protein that can lead to bone loss by activating cells that help break down bone. Along with another protein, IKK alpha, it has been implicated both in tumor formation and metastasis. The researchers created two types of mice that developed breast tumors. One group had lymphocytes in the tumors and expressed RANKL while the other group did not. They found that the group lacking RANKL had significantly fewer lung metastases than those mice with RANKL. They then took tumor cells from both types of mice and injected them into mice with the same genetic background to avoid rejection and monitored the ability of the mice to form tumors and metastases to the lung. The researchers didn't find any lung tumor metastases in mice without lymphocytes. Yet, when RANKL was injected into the animals, the same potential for the cancer to spread was restored, indicating that the lymphocytes, which make RANKL, are critically important to the process. "Without lymphocytes, there is no metastasis," said Tan. "If we treat the mice with RANK ligand, there are metastases, which indicate that RANK ligand can compensate for the function of lymphocytes." The study establishes the role of RANKL-expressing lymphocytes as a promoting factor in breast cancer metastasis and provides a potentially good marker for breast cancer prognosis, the researchers said.

Lees verder


Test for hormones in blood not reflective of hormones in breast tissue; breast cancer risk

Many studies determine hormone levels in the blood as a marker of breast cancer risk. But it hasn't been known whether these blood tests reflect what is happening in the breast tissue, where certain hormones fuel cancer. Researchers at Georgetown University Medical Center's (GUMC) Lombardi Comprehensive Cancer Center found that measuring the levels of four hormones in blood known to be linked to breast cancer doesn't necessarily reflect the levels of these hormones in the breast tissue itself. In fact, the scientists say that blood tests used in research studies that measure these hormones could give a false impression of both the real breast cancer risk women face, and an imprecise picture of how these hormones affect breast cancer development. The findings are being presented at the Annual Meeting of the American Association for Cancer Research. "We know from this study that measuring the hormones in a patient's blood is not sufficient but that is how many research studies looking at breast cancer risk are being conducted," says the study's lead author, Adana Llanos, a graduate student in genetics at GUMC. "Understanding how cancers develop in breast tissue is the key to prevention, and we need to understand how these hormones affect breast tissue." The research team, led by Llanos and under the guidance of senior investigator, Peter G. Shields, MD, head of Lombardi's Cancer Genetics and Epidemiology Program, did something that has not been done before: They tested normal breast tissue for the levels of IGF-1, IGFBP-3, adiponectin, and leptin. High levels of IGF-1 has been linked to breast cancer development, while low levels of IGFBP-3 is linked to increased risk. High levels of adiponectin and leptin are both related to obesity, which is, in itself, a risk factor for breast cancer. "By understanding these hormones in the normal breast environment, we will have some insight into how early changes in the breast lead to breast cancer," Llanos says. The researchers asked 15 women who were undergoing breast reduction surgery to participate in the study, and then collected three samples of discarded tissue from each breast, as well as blood, and extensive epidemiological data. They first assessed whether levels of these hormones were the same in each of the three tissue samples taken from the women, which represented different areas of the breast. "We found that the hormones were distributed in the same way across the breast, which is a good thing to know because it means that a tissue biopsy taken from one part of the breast will likely represent the breast as a whole," says Llanos. They then tested the blood to see if levels of the hormones matched those found in the breast tissue, and found that leptin, adiponectin, and IGFBP-3 correlated, whereas IGF-1 did not. But even that may be misleading, Llanos says, because hormone levels may differ between a woman's two breasts. "Breast cancer usually develops in a single breast, so it is not clear that looking at these hormones in the blood is sufficient," she says.

Lees verder


Test for Hormones in the Blood Not Reflective of Hormones in Breast Tissue; Breast Cancer Risk

Many studies determine hormone levels in the blood as a marker of breast cancer risk. But it hasn’t been known whether these blood tests reflect what is happening in the breast tissue, where certain hormones fuel cancer. Researchers at Georgetown University Medical Center’s (GUMC) Lombardi Comprehensive Cancer Center found that measuring the levels of four hormones in blood known to be linked to breast cancer doesn’t necessarily reflect the levels of these hormones in the breast tissue itself. In fact, the scientists say that blood tests used in research studies that measure these hormones could give a false impression of both the real breast cancer risk women face, and an imprecise picture of how these hormones affect breast cancer development. The findings are being presented at the Annual Meeting of the American Association for Cancer Research. “We know from this study that measuring the hormones in a patient’s blood is not sufficient but that is how many research studies looking at breast cancer risk are being conducted,” says the study’s lead author, Adana Llanos, a graduate student in genetics at GUMC. “Understanding how cancers develop in breast tissue is the key to prevention, and we need to understand how these hormones affect breast tissue.” The research team, led by Llanos and under the guidance of senior investigator, Peter G. Shields, MD, head of Lombardi’s Cancer Genetics and Epidemiology Program, did something that has not been done before: They tested normal breast tissue for the levels of IGF-1, IGFBP-3, adiponectin, and leptin. High levels of IGF-1 has been linked to breast cancer development, while low levels of IGFBP-3 is linked to increased risk. High levels of adiponectin and leptin are both related to obesity, which is, in itself, a risk factor for breast cancer.

Lees verder


High levels of estrogen associated with breast cancer recurrence

Women whose breast cancer came back after treatment had almost twice as much estrogen in their blood than did women who remained cancer-free – despite treatment with anti-estrogen drugs in a majority of the women –according to researchers in a study published in the March issue of Cancer Epidemiology, Biomarkers and Prevention, a journal of the American Association for Cancer Research.

Lees verder


Occupational Exposure to Polychlorinated Biphenyls and Risk of Breast Cancer

Overall, the breast cancer SIR was 0.81 (95% confidence interval, 0.72–0.92 ; n = 257) , and regression modeling showed little effect of employment duration or cumulative exposure. However, for the 362 women of questionnaire-identified races other than white, we observed positive, statistically significant associations with employment duration and cumulative exposure ; only smoking, birth cohort, and self- or proxy questionnaire completion had statistically significant explanatory power when added to models with exposure metrics.

Lees verder


New clues to breast cancer development in high-risk women

Physicians who treat women with the breast cancer susceptibility gene BRCA1 often remove their patients' ovaries to eliminate the source of estrogen they believe fuels cancer growth. Yet they also know that anti-estrogen therapies don't work to treat breast or ovarian cancer that might develop. That paradox has led scientists to question exactly how, or if, estrogen is involved in cancer development and whether removal of ovaries makes sense.

Lees verder


Phenolics in peaches and plums preferentially suppress the growth of estrogen-independent MDA-MB-435 breast cancer cells

All extracts, dissolved in culture medium at various concentrations expressed as mg chlorogenic acid equivalent/L (mg/L) were tested for their growth-suppression activity on the estrogen-dependent MCF-7, the estrogen-independent MDA-MB-435 breast cancer cells and one non-cancerous breast cell line MCF-10A. The peach RL extract effectively inhibited the proliferation of the estrogen-independent MDA-MB-435 breast cancer cell line. The IC50 was ~30 mg/L for this cell line as compared to IC50 of ~120 mg/L and ~ 515 mg/L for non cancerous breast line MCF-10A and the estrogen dependent breast cancer line MCF-7 respectively. In general BS extracts were less effective although they still affected the MDA-MB-435 to a greater degree than the other breast cancer cell line or the normal breast cell line. Within the three cells lines tested, the order of sensitivity to RL and BS extracts follows MDA-MB-435 > MCF-10A > MCF-7. Among RL and BS fractions, F3 and F4 have shown the highest potency against MDA-MB-435 cell proliferation but their effect on the non-cancerous MCF-10A cells remain to be investigated. In conclusion, peaches and plums may be added to the family of plants with potential anti-tumor activities.

Lees verder


New Women’s Imaging Technique Allows for a More Accurate Diagnosis of Breast Cancer

Breast elastography allows physicians to give a more accurate diagnosis of breast cancer, according to a study performed at Singapore General Hospital in Singapore. Breast elastography is a new technique which looks at the mechanical properties of tissues (relative stiffness) as opposed to conventional ultrasound which looks at the backscatter of transmitted ultrasound waves through tissues. Ninety-nine women with 110 sonographically visible lesions were evaluated with ultrasound, elastography and combined ultrasound and elastography. 26 lesions were malignant and 84 were benign on histology. “All breast cancers (100%) in the study were diagnosed correctly by elastography alone compared to 88.5% by conventional ultrasound,” said Llewellyn Sim, MD, lead author of the study. “The use of breast elastography alone or combined with ultrasound provides a more accurate diagnosis of breast cancer,” said Dr. Sim. “Breast elastography improves the sonographic diagnosis of breast cancer. It also potentially reduces unnecessary work-up i.e. biopsies of benign breast lesions and patient anxiety,” he said.

Lees verder


Study identifies how tamoxifen stimulates uterine cell growth and cancer

UCSF researchers have identified a new "feed-forward" pathway linking estrogen receptors in the membrane of the uterus to a process that increases local estrogen levels and promotes cell growth. The research is significant in helping determine why tamoxifen and other synthetic estrogens are linked to increased rates of endometriosis and uterine cancer, and identifies a pathway that could be targeted in drug therapies for those diseases, researchers say. Findings are published in the July 1, 2009 issue of "Cancer Research," the journal of the American Association for Cancer Research. The research found that when activated by estrogens, endometrial cells obtained from patients suffering from endometriosis or human uterine cancer cells initiate a previously unknown cascade of signals that leads to cellular replication and further estrogen production, the paper says. The ensuing cycle leads to abnormal growth of the cells lining the uterus, or endometrium, which occurs in endometriosis and uterine cancer, according to senior author Holly A. Ingraham, PhD, a professor in the UCSF School of Medicine's Department of Cellular and Molecular Pharmacology. "It turns out that displaced endometrial cells, such as those used in this study, are estrogen factories," said Ingraham, who also is affiliated with the UCSF Helen Diller Family Comprehensive Cancer Center and the UCSF Center for Reproductive Sciences. "They pump out estrogen in a feed-forward pathway, so the more estrogen they produce, the more estrogen they're capable of producing." While this pathway was previously unknown, Ingraham said a June 2009 paper led by researchers at the University of New Mexico and published in the journal "Nature Chemical Biology" showed that blocking the GPR30 receptor in this pathway decreases uterine proliferation in a mouse. The two together, she said, validate what researchers now think may be a key area in addressing both uterine cancer and endometriosis.

Lees verder


Painkillers 'cut breast cancer'

Regular use of common painkillers such as aspirin and ibuprofen reduces the risk of breast cancer, according to an international study.

Lees verder


Spanish scientists confirm extra virgin olive oil helps to combat breast cancer

UGR News Researchers of the Catalonian Institute of Oncology (Spain) and the University of Granada (Spain) have discovered that extra virgin olive oil may help to combat breast cancer, according to a paper published in the last issue of the renowned scientific journal ‘BMC Cancer’. The scientists have confirmed the bioactivity of polyphenols (this is, natural antioxidants) present in olive oil in breast cancer cell lines. The study has proved the anti-HER2 effect of fractions of phenolic compounds directly extracted of extra virgin olive oil in breast cancer cell lines. They have used solid-phase extraction methods of semi-preparative liquid chromatography to isolate fractions of commercial oils and, later, separation techniques (capillary electrophoresis and liquid chromatography connected to mass spectrometry) to check the purity and composition of the fractions. Such fractions were tested in their anti-cancer capacity both against positive HER2 and negative HER2 breast cancers, using in Vitro models and evaluating the effect of polyphenolic fractions in the expression and activation of HER2 oncoprotein through ELISA specific methods for HER2. Fractions containing polyphonels such as hydroxitirosol, tirosol, elenolic acid, lignans, pinoresinol and acetopinoresinol, and secoiridoids, diacetox oleuropein aglycone, ligustrosid aglycone and oleuropein aglycone were able to induce important tumoricid effects in a range of micromolar and in a selective way against HER2 oncogene.

Lees verder


Radiation device in the breast reduces complications for early stage breast cancer patients

A new study shows that the SAVI™ applicator, a small, expandable device inserted inside the breast to deliver partial breast irradiation, carries a low infection risk, a potential complication of such devices. The research, led by radiation oncologists and surgeons at the Moores UCSD Cancer Center and Fort Myers, Florida-based 21st Century Oncology, also indicates that other complications – such as seromas, pockets of fluid that build with the use of internal radiation devices – are unlikely to occur. That's good news for those women with early-stage breast cancer who opt to have such devices inserted for their radiation therapy after breast-sparing lumpectomy surgery, said Cate Yashar, MD, associate professor of radiation oncology at the UC San Diego School of Medicine and chief of breast and gynecological radiation services at the Moores UCSD Cancer Center. Their use is increasing, she added, noting that the Moores UCSD Cancer Center was one of the first medical facilities in the country to offer SAVI. SAVI, which consists of flexible catheters through which radiation is given, provides customized radiation therapy and minimizes exposure to healthy tissue after a woman has undergone a lumpectomy to remove a cancerous tumor. Radiation specialists sometimes decide to give women internal radiation – a process called brachytherapy – with the goal of giving concentrated doses of radiation to areas of concern while avoiding healthy tissue.

Lees verder


Statin therapy ineffective in breast cancer prevention

Laboratory work in animals showed limited activity when statins were given to prevent breast cancer, according to a report in the February issue of Cancer Prevention Research, a journal of the American Association for Cancer Research. Statins, sold under brand names like Lipitor and Zocor, are primarily given to lower cholesterol and prevent heart disease, and prominent cardiologists almost universally agree that their use has changed the landscape. The use of these drugs in cancer prevention has been more controversial. Results of epidemiology studies, which rely on looking backward rather than forward and thus are subject to confounding factors, have yielded mixed results when examining breast cancer. Scientists under the auspices of the NCI, including Ronald Lubet, Ph.D., an NCI program director, and Clinton Grubbs, Ph.D., director of the Chemoprevention Center at the University of Alabama at Birmingham conducted laboratory work in animals to determine if statins actually prevent both ER-positive and ER-negative breast cancer.

Lees verder


New evidence of hormone therapy causing breast cancer, Stanford professor says

Postmenopausal women who take combined estrogen plus progestin menopausal hormone therapy for at least five years double their annual risk of breast cancer, according to new analyses from a major study that clearly establishes a link between hormone use and breast cancer, Stanford researchers say. The multi-center study also found that women on hormones can quickly reduce their risks of cancer simply by stopping the therapy. The study is a follow-up to the landmark Women's Health Initiative report of 2002, which found that postmenopausal women taking estrogen plus progestin were at far greater risk of developing breast cancer and other serious conditions than women on placebo. After publication of the WHI data, use of hormone therapy plummeted in the United States - from 60 million prescriptions in 2001 to 20 million in 2005. Breast cancer rates also declined significantly within the year, suggesting a strong link between hormone use and cancer risk. But some scientists still questioned the connection, saying the dip in breast cancer rates could not have occurred so rapidly and may have been related to patterns of mammogram use. The latest study, however, should put those questions to rest, said Marcia Stefanick, PhD, professor of medicine at Stanford University School of Medicine and a co-author of the study. "This is very strong evidence that estrogen plus progestin causes breast cancer," said Stefanick, chair of the WHI executive committee. "You start women on hormones and within five years, their risk for breast cancer is clearly elevated. You stop the hormones and within one year, their risk is essentially back to normal. It's reasonably convincing cause-and-effect data." The results, she cautioned, do not apply to women taking estrogen alone. The large WHI trial of estrogen-only did not find an increase in breast cancer for the majority of women assigned to estrogen-only therapy.

Lees verder


Link Found Between Vegetables and Decreased Risk of Breast Cancer

When your mother told you to eat your vegetables it appears that maternal wisdom had a scientific basis. Researchers with Vanderbilt-Ingram Cancer Center and the Shanghai Cancer Institute in China have discovered a possible link between a diet rich in certain vegetables and a decreased risk for breast cancer. The study appears in the March issue of the American Journal of Clinical Nutrition. Corresponding author Jay Fowke, Ph.D., assistant professor of Medicine at Vanderbilt-Ingram, said 3,035 women diagnosed with breast cancer were identified through the Shanghai Cancer Registry. They were closely matched with 3,037 women randomly chosen from the general population there. The women filled out questionnaires about their diet, including consumption of cruciferous vegetables like Chinese cabbage, bok choi and turnips. Americans typically eat more broccoli, kale and cauliflower in the cruciferous vegetable family. "Cruciferous vegetables contain some compounds that may have a cancer-inhibitory effect," explained Fowke. "Here we were able to identify a group of women who seem to particularly benefit from a high intake of these vegetables." While there was only a small positive relationship between a diet high in these vegetables and a reduction in breast cancer risk for the overall study population, there was a striking risk reduction – 50 percent – among women with a certain genetic profile. Researchers identified three forms of the GSTP1 genotype among the cancer patients: Ille/Ile, Ile/Val and Val/Val.

Lees verder


Linchpin gene may be useful target for new breast cancer therapies

University of Iowa researchers have discovered a gene that plays a linchpin role in the ability of breast cancer cells to respond to estrogen. The finding may lead to improved therapies for hormone-responsive breast cancers, and may explain differences in the effectiveness of current treatments.

Lees verder


Researchers find genetic key to breast cancer's ability to survive and spread

New research led by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) sheds light on a genetic function that gives breast cancer cells the ability to survive and spread to the bone years after treatment has been administered. The findings support the study of therapies that target this survival capacity and force the death of latent breast cancer cells before they get a chance to metastasize, or spread – a problem that accounts for a majority of breast cancer–related deaths. The research will be published in the July 7 issue of Cancer Cell. Using gene-expression profiling techniques, researchers found that breast cancer cells that infiltrate the bone marrow can survive over time if they contain the gene product Src, which has known effects on cell mobility, invasion, and survival. The investigators discovered that genetically disabling Src activity in human breast cancer cells inhibits these cells from surviving in the bone marrow and forming metastases in mice. They also observed that treatment with the drug dasatinib inhibits the formation of bone metastasis by human breast cancer cells inoculated into mice. "Our results should encourage oncologists to consider the study of Src inhibitors to attack reservoirs of disseminated, latent cancer cells and prevent metastasis in breast cancer patients after their tumor has been removed," said the study's senior author, Joan Massaguť, PhD, Chair of the Cancer Biology and Genetics Program at MSKCC and a Howard Hughes Medical Institute investigator. Breast tumors may shed cancer cells from the outset, and some of these cells may infiltrate vital organs, including the bones, lungs, and brain. When a tumor is diagnosed and removed, chemotherapy is administered with the goal of eliminating these residual cancer cells. However, metastasis may still emerge in some patients and may take years or decades to occur, suggesting that these cells may not inherently possess – and need some time to acquire – all of the molecular characteristics needed to metastasize. According to the study, nearly one-third of cases of breast cancer relapse emerge three or more years after diagnosis, with some cases developing decades later. At present, the major clinical benefits from postoperative drug therapies are observed in the first few years after treatment, which may mean that latent cancer cells are at least partially resistant to conventional therapy.

Lees verder


Breast cancer testing puts women at risk - study

A team of Danish medical researchers has published a paper arguing that women are not being properly informed about the potential harms of breast cancer screening.

Lees verder


Acrylamide exposure and incidence of breast cancer among postmenopausal women in the Danish Diet

After adjustment for smoking behavior, however, a positive association was seen between acrylamide-hemoglobin levels and estrogen receptor positive breast cancer with an estimated incidence rate ratio (95% CI) of 2.7 (1.1-6.6) per 10-fold increase in acrylamide-hemoglobin level. A weak association between glycidamide hemoglobin levels and incidence of estrogen receptor positive breast cancer was also found, this association, however, entirely disappeared when acrylamide and glycidamide hemoglobin levels were mutually adjusted.

Lees verder


Yoga Decreases Menopausal Symptoms in Breast Cancer Survivors

Breast cancer survivors often have more severe hot flashes and other menopausal symptoms than other women, yet they have limited treatment choices. Hormone replacement therapy, for example, is not an option for cancer survivors because it may increase their risk for disease recurrence. Therapies widely used to prevent cancer recurrence, such as tamoxifen, also tend to induce or exacerbate menopausal symptoms However, new research from Duke University Medical Center and Oregon Health and Science University offers an untraditional source of relief: a tailored yoga program.

Lees verder


Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds

Despite the huge publicity generated by a 2002 study on the potential dangers of hormone therapy for postmenopausal women, new research from the Stanford University School of Medicine found that only 29 percent of women surveyed knew about the study two years later.

Lees verder


Mother-daughter breast density study points way to earlier cancer risk assessment

A unique mother-daughter study that used magnetic resonance to measure breast density in younger women shows that percent of breast water could be linked to the risk of breast cancer in middle age and older. The findings, published online today in Lancet Oncology, add another key piece to the puzzle of understanding more about breast density, an inheritable characteristic known to be a cancer risk factor, that could aid in developing prevention methods, says principal investigator Dr. Norman Boyd, a scientist at The Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital. Dr. Boyd initially verified breast density (mammographic density, or MD) as a strong risk factor for breast cancer in middle aged and older women in a landmark study published in the New England Journal of Medicine in 2007. Until now, little was known about the development of breast density in early life, or how it relates to a young woman's height, weight and age, and the breast density of their mothers. The findings of the current study indicate that risk assessment using less harmful techniques such as magnetic resonance imaging (MRI) instead of X-ray should start much earlier in life. Says Dr. Boyd "It is known that the breast is most susceptible to the effects of carcinogens at early ages. Our findings suggest that differences in breast tissue composition in early life may be a potential mechanism for this increased susceptibility. By identifying the environmental and genetic factors that influence breast tissue composition in early life we may be able to develop safe and effective methods of prevention." In this study, between 2003-2006, the researchers recruited 400 mother-daughter pairs and used MRI to examine breast tissue in daughters, aged 15-30-years, and a random sample of 100 of the mothers. In the young women, MRI was used to measure breast water concentration to avoid exposure to radiation from mammograms. Blood was obtained from each woman within 10 days of the start of the most recent menstrual period. Mothers underwent mammography and a random sample of 100 also consented to have a breast MRI.Results show that percent breast water variation is higher in 15-19 year olds than in 20-30 year olds, and decreases with age, as backed by analysis of the 100 mother-daughter pairs who both had MRI.

Lees verder


Breast cancer rates tied closely to hormone use

Researchers, including a scientist from Oregon Health & Science University, reported this month that a decline in hormone use -- not a decrease in mammography screening -- has contributed to the reduction in breast cancer incidence.

Lees verder


Genetic 'hotspot' for breast cancer risk

Vanderbilt-Ingram Cancer Center investigators have identified a new genetic hotspot for breast cancer. Reporting this week in Nature Genetics, Wei Zheng, M.D., Ph.D, and colleagues have identified a region on chromosome 6 that is strongly associated with breast cancer susceptibility in Asian women. This genetic "locus" may help guide efforts to find the specific genes linked with sporadic – or non-inherited – forms of the disease, the authors suggest. Breast cancer is one of the most common cancer types among women worldwide. Genetics plays an important role in the disease, and a handful of breast cancer susceptibility genes – such as BRCA1 and BRCA2 – have been identified. Mutations in these genes increase risk of inherited forms of breast cancers. "But the genetic factors identified so far explain only a small percent of all the cases in the general population," said Zheng, an Ingram Professor of Cancer Research, professor of Medicine and the director of the Vanderbilt Epidemiology Center. The genetic factors responsible for the vast majority of cases are unclear, "so there has been a lot of interest to identify additional genetic factors for breast cancer," said Zheng, the senior author on the study. To date, most breast cancer susceptibility genes have been studied primarily in Caucasian or European populations, but women of other ethnic backgrounds may have important genetic differences from these groups, Zheng noted. So the researchers turned to a population of Asian women in Shanghai, China, which they had been studying for more than a decade to identify nutritional, environmental and genetic factors associated with disease risk. Using an approach called "genome-wide association," Zheng and colleagues began looking for genetic variations in Asian women with breast cancer compared to healthy controls. The investigators analyzed more than 600,000 genetic markers – called SNPs (single nucleotide polymorphisms) – for differences between the groups. From the first group of more than 3,000 women, they selected 29 of the most promising SNPs associated with breast cancer. Through two more rounds of validation in two independent groups of women, the researchers narrowed down these 29 candidate SNPs to a single SNP that exhibited strong and consistent association with breast cancer. The researchers also found a similar association in an independent group of American women, indicating that the results might be relevant for other ethnic populations.The influence of the SNP on breast cancer risk appears very large, Zheng noted.

Lees verder


Gene variant increases breast cancer risk

An international research consortium under the leadership of scientists of the German Cancer Research Center has shown that a common gene variant increases the risk of developing breast cancer.

Lees verder


Breast Cancer More Aggressive Among Obese Women

Women with breast cancer have more aggressive disease and lower survival rates if they are overweight or obese, according to findings published in the March 15 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research. "The more obese a patient is, the more aggressive the disease," said Massimo Cristofanilli, MD, associate professor of medicine in the Department of Breast Medical Oncology at The University of Texas M.D. Anderson Cancer Center. "We are learning that the fat tissue may increase inflammation that leads to more aggressive disease."

Lees verder


Body Mass Index may serve as prognostic tool for advanced, aggressive breast cancers

Body Mass Index, the measure of a person's fat based on their height and weight, may be an effective prognostic tool for specific types of breast cancer, according to research from The University of Texas M. D. Anderson Cancer Center.

Lees verder


Possible Drug Target Found for One of the Most Aggressive Breast Cancers

Van Andel Research Institute (VARI) investigators have identified a gene that could be an important therapeutic target in the treatment of the most aggressive forms of breast cancer. Currently, patients with these cancers have few treatment options. “Breast cancer mortality rates are actually declining, but the cancers that don’t respond to traditional treatments tend to be more aggressive and have decreased survival rates,” said VARI Research Scientist Carrie Graveel, Ph.D., lead author of the study published this week in Proceedings of the National Academy of Sciences U.S.A. Researchers found that the Met gene may play a critical role in the development of an aggressive form of breast cancer known as basal breast cancer. “Met has already been associated with decreased survival in breast cancer, but this study identifies its importance in specific types that can be distinguished at the molecular level,” said VARI Distinguished Scientific Fellow George Vande Woude, Ph.D., who heads the laboratory that conducted the research.

Lees verder


In flurry of studies, researcher details role of apples in inhibiting breast cancer

Six studies published in the past year by a Cornell researcher add to growing evidence that an apple a day -- as well as daily helpings of other fruits and vegetables -- can help keep the breast-cancer doctor away. In one of his recent papers, published in the Journal of Agricultural and Food Chemistry (57:1), Rui Hai Liu, Cornell associate professor of food science and a member of Cornell's Institute for Comparative and Environmental Toxicology, reports that fresh apple extracts significantly inhibited the size of mammary tumors in rats -- and the more extracts they were given, the greater the inhibition. "We not only observed that the treated animals had fewer tumors, but the tumors were smaller, less malignant and grew more slowly compared with the tumors in the untreated rats," said Liu, pointing out that the study confirmed the findings of his preliminary study in rats published in 2007.

Lees verder


Molecular fingerprint of breast-cancer drug resistance can predict response to treatment

A way of predicting which patients will respond well to treatment with a common chemotherapy drug used in breast cancer was unveiled at the European Cancer Conference (ECCO 14) today

Lees verder


Cancer cells in blood can identify risk of recurrence in breast cancer

Cancer cells circulating in the blood are known to be associated with a bad prognosis in metastatic breast cancer. Now, for the first time, scientists have shown they can also detect the cells before and after chemotherapy and hence may be able to identify in the future those patients likely to have a recurrence after treatment.

Lees verder


Enzyme linked to high incidence of breast cancer

An enzyme found in some breast tissue is a strong indicator that a woman develop the cancer later in life.

Lees verder


3-D Doppler Ultrasound Helps Identify Breast Cancer

Three-dimensional (3-D) power Doppler ultrasound helps radiologists distinguish between malignant and benign breast masses, according to a new study being published in the November issue of Radiology. "Using 3-D scans promises greater accuracy due to more consistent sampling over the entire tumor," said lead author, Gerald L. LeCarpentier, Ph.D., assistant professor in the Department of Radiology at University of Michigan in Ann Arbor. "Our study shows that 3-D power Doppler ultrasound may be useful in the evaluation of some breast masses."

Lees verder


Novel gene predicts local recurrence in early onset breast cancer

A newly discovered gene known as DEAR1 is mutated in breast cancer and is an independent predictor of local recurrence-free survival in early-onset breast cancer, a research team headed by scientists at The University of Texas M. D. Anderson Cancer Center reports in the journal PLoS Medicine. "The correlation with local recurrence is significant because so many young women have recurrences in the breast, and cancers that do recur tend to be more aggressive," said senior author Ann McNeill Killary, Ph.D., professor in M. D. Anderson's Department of Genetics. "Young age has been considered a risk factor for local recurrence and metastasis. It is important to understand the genetic mechanisms operating in early-onset breast cancer and to determine whether there is a way to identify young women who might be at a higher risk of recurrence." After Killary's laboratory research discovered DEAR1 (ductal epithelium-associated ring chromosome 1) and implicated it in breast cancer, the team examined a tumor tissue microarray from 123 women whose breast cancer began between ages 25 and 49, all of whom advanced to invasive disease. Of these, 56 percent lacked DEAR1 expression in their tumors, which was associated with 58 percent local recurrence-free survival 15 years after surgery. For those with DEAR1 expression, local recurrence-free survival was 95 percent at 15 years. "Immunohistochemical staining for DEAR1 could potentially be performed in any hospital setting, and such an assay might predict which women are at a high risk of recurrence and potentially help guide treatment decisions" Killary said, noting the results will need to be validated in a larger cohort of patients. Breast cancer that develops before age 50 tends to be more aggressive and more likely to recur even in the absence of invasion of the lymph nodes at diagnosis. "Approximately one-fourth of women without nodal involvement will experience a recurrence up to 12 years after surgery," Killary said. Of the 123 early-onset patients, 72 percent had no lymph node involvement at diagnosis.

Lees verder


PET scans can accurately detect a breast tumor's response to chemotherapy

Researchers in Australia have shown that positron emission tomography that uses a radioactive sugar molecule is more useful than mammography and ultrasound in predicting a breast tumor's response to chemotherapy and, therefore, the patient's ultimate likelihood of survival. The research was presented at the European Cancer Conference in Barcelona today

Lees verder


Einstein Scientists Link Elevated Insulin to Increased Breast Cancer Risk

Elevated insulin levels in the blood appear to raise the risk of breast cancer in postmenopausal women, according to researchers at Albert Einstein College of Medicine of Yeshiva University. Their findings are published in the online version of the International Journal of Cancer.Increased breast cancer risk for postmenopausal women has previously been linked to obesity and diabetes. Both conditions involve insulin resistance, which causes increases in circulating levels of insulin. Since insulin is known to promote cell division and enhance breast tumor growth in animal models, the Einstein scientists reasoned that relatively high insulin levels may contribute to breast cancer risk in women. "Up to now, only a few studies have directly investigated whether insulin levels are associated with breast cancer risk, and those studies have yielded conflicting results," says Geoffrey Kabat, Ph.D., senior epidemiologist in the department of epidemiology and population health at Einstein and the lead author of the paper. "Those other studies were based on just a single baseline measurement of insulin, while our study involved analyzing repeated measurements of insulin taken over several years — which provides a more accurate picture of the possible association between insulin levels and breast cancer risk."

Lees verder


Breast Cancer Treatment May Fail Most Women

The research, from Dr. Dennis Slamon, chief of oncology at the University of California, Los Angeles, suggests that the most widely used chemotherapy drugs may not benefit most women. Although the research hasn’t been published or peer-reviewed yet, it is expected to be soon.

Lees verder


Got stress? It could impact breast cancer recurrence

Women diagnosed with metastatic breast cancer who have also endured previous traumatic or stressful events see their cancer recur nearly twice as fast as other women, according to a report by a University of Rochester Medical Center scientist.

Lees verder


Researchers identify four new targets for breast cancer

Four suspects often found at the scene of the crime in cancer are guilty of the initiation and progression of breast cancer in mice that are resistant to the disease, a team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the June edition of Cancer Cell."We have a smoking gun" that shows it's no coincidence the three protein receptors and the enzyme that makes them are abnormally expressed in many types of cancer, said Gordon Mills, M.D., Ph.D., professor and chair of M. D. Anderson's Department of Systems Biology and senior author of the paper. "We've compiled lots of evidence that they are associated with cancer, what's been missing is proof that they could cause cancer," Mills said. "There are no questions left, they should be targeted." The four are three lysophosphatidic acid (LPA) receptors (LPA1, LPA2, and LPA3) and the LPA-producing enzyme, autotaxin. "Lysophosphatidic acid", Mills said, "is the single most potent known cellular survival factor." LPA binds to a series of G protein-coupled receptors to spark normal cell proliferation, viability, production of growth factors and survival. The Cancer Cell paper shows this powerful network is hijacked to initiate breast cancer and fuel tumor growth, invasion and metastasis. The team took a strain of mice that is highly resistant to breast cancer and then created four transgenic strains, each strain expressing one of the receptors or autotaxin. At 24 months, none of the 44 original cancer-resistant mice developed mammary gland cancer. Only one case of inflammation and two cases of a potentially precancerous accumulation of cells known as hyperplasia were noted.

Lees verder


Women with breast cancer have less dermatitis when treated with IMRT

All women treated with radiation therapy for breast cancer are at risk of developing dermatitis -- a sometimes-painful skin condition caused by radiation as it makes its way through the skin to the tumor area and tissue within the breast. But researchers at Fox Chase Cancer Center say women being treated with intensity-modulated radiation therapy are less likely to have serious dermatitis.

Lees verder


Wine, women and... spirits, beer and breast cancer risk

One of the largest individual studies of the effects of alcohol on the risk of breast cancer has concluded that it makes no difference whether a woman drinks wine, beer or spirits -- it is the alcohol itself and the quantity consumed that is likely to trigger the onset of cancer.

Lees verder


1 in 3 Breast Cancer Patients Overtreated

One in three breast cancer patients identified in public screening programs may be treated unnecessarily, a new study says.

Lees verder


Fifty-one genes predict breast cancer survival

It may be possible in the future to use a specimen from the tumour to determine which patients with breast cancer have a good chance of overcoming the disease, and which patients should be given more intensive treatments. Fifty-one genes may together provide information about the prognosis for an individual patient. These are the conclusions of a thesis presented at the Sahlgrenska Academy, University of Gothenburg, Sweden.The research group has analysed specimens from a number of breast tumours, both from patients that died from the disease and from patients surviving at least 10 years from diagnosis. The levels of expression of 51 genes differed between the two groups. It should be possible to use the differences in order to classify the patients into one of two groups: a favourable prognosis group and a poor prognosis group. "Many breast cancer patients are currently overtreated, while some are undertreated. If it was possible to identify patients with poor prognosis, it would be possible to use greater treatment resources on these patients. At the same time, patients with a favourable prognosis could avoid unnecessary treatment", says Elin Karlsson who successfully defended her thesis on June 5.

Lees verder


'New' estrogen receptor found to be key player in tamoxifen resistance

Researchers at Georgetown University Medical Center have discovered a novel way in which breast cancer cells become resistant to tamoxifen, the world's largest-selling breast cancer prevention and treatment drug. They say the findings could provide a way to identify tamoxifen users who are no longer benefiting from the drug, allowing doctors to try another therapy option sooner. In the November 1 issue of the journal Cancer Research, the researchers show that breast cancer cells that are resistant to tamoxifen display few of the "alpha" estrogen receptors that the drug is designed to bind on to and inhibit, but many more "gamma" estrogen-related receptors, which tamoxifen seems to activate. These two receptors are not closely related – they are more like distant cousins than siblings, researchers say, adding that understanding how these gamma estrogen-related receptors work may— eventually— help in designing new, more effective drugs targeting these receptors.In fact, they track how, as resistance develops over time, breast cancer cells gradually lose the alpha receptors while gaining the estrogen-related receptor gamma subtype. The study offers two new insights, according to lead author Rebecca Riggins, Ph.D., a research assistant professor of oncology at GUMC's Lombardi Comprehensive Cancer Center. One is a clearer understanding of the importance of the gamma estrogen-related receptor in breast cancer. "Until now, this receptor has not been viewed to be of much importance in any type of breast cancer," Riggins says. "All that was known is that there were more of these receptors in breast cancer than in normal breast tissue, we hadn't gone much further than that." A second important insight is that the discovery could help explain why invasive lobular carcinoma – the sub-type of breast cancer in which these findings were made – may not respond as well to tamoxifen as perhaps other subtypes do, she says.

Lees verder


Jefferson researchers uncover new evidence of prolactin's possible role in breast cancer

Scientists at the Kimmel Cancer Center at Jefferson in Philadelphia have discovered new molecular evidence of the role of the hormone prolactin in breast cancer. They have found that prolactin, a pituitary hormone that normally stimulates breast development and milk production, initiates a new

Lees verder


Mayo Clinic study shows drug could effectively treat, prevent the spread of breast cancer

A Mayo Clinic study of a drug that has shown promise in treating sarcoma, lung and brain cancers, demonstrates that the drug may also be effective in treating breast cancer, in particular the spread of breast cancer.

Lees verder


"Glycemic load" of diet tied to breast cancer risk

The amount of carbohydrates a woman eats, as well as the overall "glycemic load" of her diet, impact her chances of developing breast cancer, Swedish researchers report.

Lees verder


Asian Spice Could Reduce Breast Cancer Risk in Postmenopausal Women Exposed to Hormone Replacement Therapy, MU Study Finds

Previous studies have found that postmenopausal women who have taken a combined estrogen and progestin hormone replacement therapy have increased their risk of developing progestin-accelerated breast tumors. Now, University of Missouri researchers have found that curcumin, a popular Indian spice derived from the turmeric root, could reduce the cancer risk for women after exposure to hormone replacement therapy. "Approximately 6 million women in the United States use hormone replacement therapy to treat the symptoms of menopause," said Salman Hyder, the Zalk Endowed Professorship in Tumor Angiogenesis and professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center. "This exposure to progestin will predispose a large number of post-menopausal women to future development of breast cancer. The results of our study show that women could potentially take curcumin to protect themselves from developing progestin-accelerated tumors."

Lees verder


New tumor inhibitor for treatment of hereditary breast cancer shows promising results in mouse model

Researchers of the Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital used the novel inhibitor AZD2281 to target breast cancer, in which the BRCA1-gene plays a role, in a genetically engineered mouse model. Treatment resulted in tumor regression and a strong increase in survival without signs of toxicity. The inhibitor, which recently entered trials in human cancer patients, thus seems to have therapeutic potential for BRCA-defective tumors. Sven Rottenberg, Piet Borst and Jos Jonkers publish their results this week in PNAS Online Early Edition.

Lees verder


UC Davis researchers discover a key to aggressive breast cancer

In trying to find out why HER2-positive breast cancer can be more aggressive than other forms of the disease, UC Davis Cancer Center researchers have surprisingly discovered that HER2 itself is the culprit. By shutting down its own regulator gene, HER2 creates a permissive environment for tumor growth. Building on recent research showing that the regulator — labeled LRIG1 and commonly called "Lig-1" — limits the growth-promoting signals of HER2, the research team set out to clarify the role of Lig-1 in breast cancer. They found that, when compared to healthy breast tissue, the regulator is significantly suppressed. "This suppression assists HER2 in its own over-expression and in driving the growth of cancer cells," said Colleen Sweeney, associate professor of biochemistry and molecular medicine and senior author of the study, which appears in this month's issue of Cancer Research. "HER2 is clearly taking an active role its own ability to be successful in promoting cancer." Sweeney added that the study results could lead to new treatments aimed at restoring or replacing functions of the regulator. This is good news for patients because, in addition to being more aggressive, HER2-positive breast cancer tends to be less responsive to currently available treatments. The gene is over-expressed in about one-quarter to one-third of breast cancer cases. Sweeney and colleagues began by studying mouse models of breast cancer with genomes that carry extra copies of HER2. They noticed an excess of HER2 protein in the resulting tumors, but it was not over-expressed in adjacent healthy tissues that also carried extra copies of the HER2 gene. "That suggested to us that extra copies of HER2 alone are not enough to explain its over-expression. If it was, HER2 would have been over-expressed in both normal and tumor tissues from these mice," she said.

Lees verder


UNC study identifies genetic cause of most common form of breast cancer

The discovery of tumor-suppressor genes has been key to unlocking the molecular and cellular mechanisms leading to uncontrolled cell proliferation – the hallmark of cancer. Often, these genes will work in concert with others in a complex biochemical system that keeps our cells growing and dividing, disease free. Now researchers at the University of North Carolina at Chapel Hill School of Medicine and UNC Lineberger Comprehensive Cancer Center have found that defects in one gene, called p18, may override the rest, eventually leading to cancer. This discovery, combined with new laboratory techniques, will help scientists identify and test new treatments for luminal-type tumors, which account for between 70 and 80 percent of all breast cancers, but are generally slower growing than other types. The results of the research appear in the May 2009 issue of Cancer Cell. Defects in the p18 gene have been observed in different types of human cancer. Senior study author Yue Xiong, Ph.D., William R. Kenan Jr. Distinguished Professor of biochemistry and biophysics, observes, "When this gene is not expressed or is deleted, cells have no braking mechanism. They will continue to grow and divide until they turn into cancer."

Lees verder


Protein Linked to Change in Tissue That Surround and Support Breast Tumors

A protein known to be overly active in breast cancer can exist in a form that seems to change the structural composition of mammary tissue, potentially making it more conducive to tumor progression, say researchers from the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC). At the annual meeting of the Endocrine Society in Washington, DC, the scientists report that the protein, AIB1 (Amplified in Breast Cancer 1), has a shorter form known as AIB1delta3 which turns breast tissue more fibrous. The researchers say this shorter form may contribute to the dense breast tissue that is a known risk factor for breast cancer. “We found that AIB1delta3 alters the stroma, or environment that surrounds and supports cancer cells, producing excessive fibrosis,” says the study’s lead author, Priscilla Furth, MD, Professor of Oncology and Medicine. “This is significant, because disordered interactions between the epithelial and stromal compartments are being increasingly recognized as an important component of breast cancer risk.”

Lees verder


Campaigners urge politicians to act on chemicals-breast cancer link

Health campaigners are urging politicians to act on the growing body of scientific evidence that links exposure to certain chemicals to spiralling rates of breast cancer. Scientists have known for decades that a woman's risk of developing breast cancer is influenced both by the levels of oestrogen produced by her own body and her use of drugs containing man-made oestrogens, such as hormone replacement therapy (HRT).

Lees verder


Radiation Treatment for Breast Cancer Causes Cancer in the Other Breast

Young women who receive radiation treatment after breast cancer surgery are significantly more likely to later develop cancer in the other breast than women who did not undergo such radiation. The findings come from a study, published online in the Journal of Clinical Oncology, on more than 7,000 women who were treated for breast cancer in Netherlands between the years of 1970 and 1986. All study participants were diagnosed with breast cancer before the age of 71.

Lees verder


A molecular switch is linked to a common breast cancer

Researchers have discovered that a molecular switch in the protein-making machinery of cells is linked to one of the most common forms of lethal breast cancer worldwide. The discovery by researchers at NYU School of Medicine could lead to new therapies for the cancer, called locally advanced breast cancer.

Lees verder


Common Organic Compound Found In Many Household Products May Pose Health Risk To Breast Cells

Bisphenol A, a chemical that leaches into food and beverages from many consumer products, causes normal, non-cancerous human breast cells to express genes characteristic of aggressive breast cancer cells.

Lees verder


NYU Langone Medical Center researchers identify key gene in deadly inflammatory breast cancer

Aggressive, deadly and often misdiagnosed, inflammatory breast cancer (IBC) is the most lethal form of primary breast cancer, often striking women in their prime and causing death within 18 to 24 months. Now, scientists from The Cancer Institute at NYU Langone Medical Center have identified a key gene—eIF4G1—that is overexpressed in the majority of cases of IBC, allowing cells to form highly mobile clusters that are responsible for the rapid metastasis that makes IBC such an effective killer. The new findings, Essential Role for eIF4G1 Overexpression in Inflammatory Breast Cancer Pathogenesis, scheduled for advance online publication on Nature Cell Biology's website (Embargoed for June 14th, 2009 at 1:00PM EST) could lead to the identification of new approaches, therapies and a new class of drugs to target and treat IBC. This would be a critical development in the fight against IBC, which respond poorly to chemotherapy, radiation or any other current treatments for breast cancer, according to the study's lead authors Dr. Robert Schneider, associate director for translational research at The Cancer Institute, co-director of breast cancer research, and the Albert B. Sabin Professor of Molecular Pathogenesis at NYU School of Medicine, and Dr. Deborah Silvera, a postdoctoral research fellow. "The tragedy of IBC is that it is often misdiagnosed and misclassified. Rather than presenting as a 'typical' lump, IBC looks like an inflammation of the breast and is frequently mistaken for an infection. Physicians often prescribe antibiotics, losing valuable time for treating this fast-moving killer," says Dr. Schneider, noting that IBC accounts for several percent of all breast cancer cases but takes a high toll on mortality, with an incidence that is 50 percent higher in African American women. He adds that there has been little progress in treating IBC over the past two decades, and there are no drugs specifically for this form of cancer. "In fact, IBC has only recently been recognized as a unique, genetically distinct form of breast cancer."

Lees verder


T-cadherin affects blood vessel growth in breast cancer, hormone from fat cells may play a role

Researchers at the Burnham Institute for Medical Research may have found a new option for targeted breast cancer therapy by showing the link between a certain protein and the development of blood vessels that feed breast tumors. The Burnham team developed the first living model to study the effect of the protein called T-cadherin on tumor angiogenesis by creating a strain of mice that develops spontaneous mammary gland tumors in the absence of T-cadherin.

Lees verder


Should Parents Share the Results of BRCA1/2 Genetic Testing with Their Children?

If you learned that you were at high risk of cancer because you carry the hereditary BRCA1/2 gene mutation, would you tell your children? A recent study at Fox Chase Cancer Center not only considered that question, but also took it to the next level and studied the parent perceptions of the impact of such a decision on children. The study will be presented at the 2009 Annual Meeting of the American Society of Clinical Oncology. BRCA1/2 are hereditary gene mutations that indicate an increased risk of developing breast cancer. "We know that many people who carry the BRCA1/2 gene mutation share their genetic test results with their children," explained Angela Bradbury, MD, medical oncologist at Fox Chase and lead author on the study. "What we did not know was the impact this communication has on their children." In order to learn the impact this has on children, researchers evaluated results from 163 parents who had BRCA1/2 testing. Of those, 52 tested positive for BRCA1/2. Just over 100 parents (66 percent) shared their results with at least one of their children, which totaled 323 children who were between the ages of 5 – 25. The child's age and parent cancer history had a direct correlation to whether or not they shared the results. Not surprising, those without a BRCA1/2 mutation were more likely to communicate test results than parents with a mutation. Among parents who disclosed their results, few reported negative reactions from their children (9 percent) or that their child did not understand the information (11 percent). Overall, most parents reported that their children handled the information well, although negative reactions were more frequent among certain subgroups (younger children and those of parents with a mutation or a variant of uncertain significance).

Lees verder


Flight attendants, and their risk of breast cancer

A number of international studies show that flame retardants sprayed on the cabin's interior give off fumes containing chemical hormones. When inhaled or absorbed into the body, these fat- loving chemicals travel to a person's fat cells, especially to a woman's fatty breast cells.

Lees verder


Breastfeeding reduces risk of breast cancer

Breastfeeding is a way to reduce the risk of breast cancer, even if women first become mothers at a relatively old age, according to a new American-European meta-analysis of clinical studies disclosed at a Israel Cancer Association (ICA) workshop.

Lees verder


Therapy may block expansion of breast cancer cells

Breast cancer stem cells are known to be involved in therapy resistance and the recurrence of cancerous tumors. A new study appearing in Clinical and Translational Science shows the mechanisms governing stem cell expansion in breast cancer (called Notch activity), and finds that therapy targeting a protein called cyclin D1 may block the expansion of cancerous stem cells. The study, conducted by Dr. Richard Pestell and colleagues at Thomas Jefferson University, was the first to show that cyclin d1 is required for breast cancer growth in mice. As cyclin d1 is known to be over-expressed in human breast cancer, the findings may explain how cyclin d1 contributes to breast tumor growth, and provide the rationale for targeted therapies at cancerous stem cells in humans. "Breast and other cancers are maintained through a population of cancer stem cells. By specifically targeting cancer stem cells we hope to reduce recurrence and improve therapy responses," says Pestell.

Lees verder


Lower Breast Cancer Risk for Women Who Were Breastfed as Children

Women who were breastfed as infants have a lower risk of breast cancer as adults, according to a new study conducted by researchers from the University of Wisconsin at Madison and published in the journal Epidemiology.

Lees verder


Lights at Night Are Linked to Breast Cancer

Women who live in neighborhoods with large amounts of nighttime illumination are more likely to get breast cancer than those who live in areas where nocturnal darkness prevails, according to an unusual study that overlaid satellite images of Earth onto cancer registries.

Lees verder


Three Week Radiation Therapy as Effective as Five Weeks for Early-stage Breast Cancer

Early-stage breast cancer patients who receive a more intensive course of radiation to their whole breast over three weeks is as effective as the standard, less intensive five-week whole breast radiation and offers patients more convenience at a lower cost, thereby providing a better quality of life, according to a randomized, long-term study presented September 22, 2008, in the plenary session at the American Society for Therapeutic Radiology and Oncology’s 50th Annual Meeting in Boston. The cost of this shorter treatment, called accelerated hypofractionated whole breast irradiation, is two-thirds of the cost of the standard whole breast radiation. It is also less expensive then other new approaches such as partial breast irradiation.

Lees verder


Study suggests some breast cancer patients facing radiation after a mastectomy may be over-treated

A new study suggests standard radiation therapy for some breast cancer patients may not be medically required and may, therefore, be causing unnecessary serious side effects such as lymphedema and pulmonary problems. The research conducted at Fox Chase Cancer Center involved women who got a mastectomy, but whose lymph nodes were negative. "When a woman has a tumor greater than 5 centimeters and negative lymph nodes, a mastectomy followed by radiation is recommended," said Penny Anderson, M.D., attending physician in the radiation oncology department at Fox Chase. "We typically irradiate the chest wall because it's been shown to improve survival. Out of an abundance of caution, many radiation oncologists also treat the surrounding lymph nodes, but there is little evidence that this improves outcome." Irradiation of axillary (under arm) and supraclavicular (above the collarbone) lymph nodes can lead to lymphedema, a swelling of the extremities caused by fluid build up because the nodes which allow the fluids to drain have been damaged by radiation. There are also pulmonary radiation risks including pneumonitis, inflammation, scarring and fibrosis.

Lees verder


Breast cancer 'linked to use of deodorants'

Higher content of aluminium in the outer breast might be explained by this region's closer proximity to the underarm where the highest density of application of antiperspirant could be assumed.

Lees verder


Essential nutrient found in eggs reduces risk of breast cancer by 24 percent

Choline, an essential nutrient found in foods such as eggs, is associated with a 24 percent reduced risk of breast cancer, according to a study supported by a grant from the US National Institutes of Health, to be published in The FASEB Journal's print issue in June.

Lees verder


Disappearing Breast Cancer?

A new study found that in some women, breast cancer went away on its own. Maggie Rodriguez talks with Dr. Holly Phillips about what this revelation could mean.


Voldoende Vitamine D kan aantal kankerdoden met 75% verlagen !

In a new study, researchers at the Moores Cancer Center and Department of Family and Preventive Medicine, UC San Diego used a complex computer prediction model to determine that intake of vitamin D3 and calcium would prevent 58,000 new cases of breast cancer and 49,000 new cases of colorectal cancer annually in the US and Canada. The researchers model also predicted that 75% of deaths from these cancers could be prevented with adequate intake of vitamin D3 and calcium. Dr. Cedric Garland, UCSD School of Medicine, lead researcher on the study discusses the implications of this finding and the proposed actions.


Galvano therapie of chemo?

Beste Ron

Wat mij verbaasd, is dat er nog niemand vanuit de media in Nederland iets heeft geschreven over GALVANO therapie, die ik met succes in 1994 heb ondergaan tijdens mijn BORSTKANKER, en ben het levende bewijs dat deze therapie ook genezend werkt, zonder mijn lichaam te belasten met al de CHEMICALIEN van de CHEMO therapie behandelingen en dergelijke!

Voor zwangere vrouwen die tijdens hun zwangerschap BORSTKANKER hebben, zou GALVANO therapie een heel goed alternatief kunnen zijn, voor zowel de moeder als het ongeboren kind. Het ongeboren kind wordt al vergiftigd door de CHEMO therapie met de nodige lichamelijke gevolgen, misschien wel tot de dood erop volgt,  want de moeder moet een keuze maken, CHEMO? helaas kan ze niet zelf kiezen er wordt haar meestal geen andere (GALVANO) therapie aangeboden nu ze zwanger is en BORSTKANKER heeft.

Misschien kan de Pink Ribbon in het a.s oktober nummer er aandacht aan besteden? We lezen nu al jaren in de media wat de vreselijke ervaringen zijn van de patienten die borst/kanker hebben, het immuunsysteem meestal niet genoeg weerstand kan bieden, en de kwaliteit van het leven mega achteruit gaat, tot helaas in veel gevallen de veel te vroege dood erop volgt, meestal als gevolg van de CHEMO, OPERATIES &-BESTRALINGEN.

Voor meer GALVANO therapie info, zijn er diverse websites. IN de ST. Georg Klinik Bad Aibling daar heb ik mijn GALVANO therapie behandelingen met succes ondergaan.Hopelijk kan in de nieuwe Pink Ribbon meer aandacht besteed worden aan COMPLEMENTAIRE therapien, waardoor de borst/kanker patient misschien eindelijk THERAPIEVRIJHEID heeft.

Groeten Alie uit AustraliŽ
http://www.kankervoorbij.com/mijn-nieuwe-leven-na-borstkanker.html
http://de.wikipedia.org/wiki/Robert_Remak_(Arzt)
http://www.galvano-therapie.de/eng/index.php
http://www.krebstherapie-beratung.com/allgemein/705,galvanotherapie/


Verloop borstkanker beter te voorspellen

(NKI-AVL) heeft het mede mogelijk gemaakt beter te voorspellen hoe hoog het risico is dat vrouwen met borstkanker de ziekte na 5 jaar weer terug krijgen. Deze zogenaamde Mammaprint wordt nu nog in onderzoeksverband aan een bepaalde groep vrouwen met borstkanker aangeboden. Vrouwen met een hormoongevoelige tumor en waarvan de lymfeklieren niet zijn aangetast komen over het algemeen in aanmerking voor een zogenaamde Mammaprint. Het NKI-AVL doet samen met 19 andere ziekenhuizen in Nederland mee aan een grote studie (Mindact). In deze studie wordt aan de hand van het tumorweefsel dat bij de patiŽnt is weggenomen, bekeken welke kenmerken de tumor heeft en hoe de patiŽnt zal reageren op een vervolgbehandeling met medicijnen. Steeds duidelijker blijkt dat beter te voorspellen is of de patiŽnt baat heeft bij een behandeling met chemotherapie. “Als standaard behandeling wordt vaak chemotherapie voorgeschreven, nu we gerichter kunnen behandelen zullen minder vrouwen met chemotherapie behandeld hoeven worden, aldus internist dr. Sabinne Linn. Als vrouwen met borstkanker willen weten of zij in aanmerking komen voor een Mammaprint, kunnen zij dit het beste bespreken met de eigen behandelend arts.

--

Kwart borstkankerpatiŽnten krijgt onnodig chemotherapie (Link)

House


New study suggests Concord grape juice may provide protection against breast cancer

According to a new study, published in the current issue of the Journal of Medicinal Foods, natural compounds in Concord grape juice protected healthy human breast cells from DNA damage. Healthy human breast cells were exposed in a test tube to an environmental carcinogen, benzo(a)pyrene, that is able to initiate a chain of events leading to breast cancer. However, the introduction of Concord grape juice compounds blocked the connection of the carcinogen to the DNA of the healthy cells.

Lees verder


Einstein researchers discover protein that contributes to cancer spread

In an important finding published online in Developmental Cell, researchers at Albert Einstein College of Medicine of Yeshiva University, along with collaborators at Massachusetts Institute of Technology, have identified a protein likely responsible for causing breast cancer to spread. Metastatic cancer occurs when cancer cells from the original tumor travel to distant sites via the blood system. Most cancer deaths are due to cancer that has spread to other organs. Trying to stop cancer before it metastasizes is the main goal of cancer treatments. Upon diagnosis, 6 out of 10 breast cancer patients have cancer that is still in its primary location making the potential discovery of a marker for invasive cancer of tremendous value that could better inform treatment options. Until now, early markers of metastatic breast cancer have been hard to find. However, in the Einstein-led study, researchers have identified a protein that is a promising candidate for a metastatic breast cancer marker.

Lees verder


Pathway links inflammation, angiogenesis and breast cancer

A well-known inflammatory protein spawns an enzyme that inactivates two tumor-suppressing genes, ultimately triggering production of new blood vessels to nourish breast cancer cells, researchers at the University of Texas M. D. Anderson Cancer Center report in the August edition of the journal Cell.

Lees verder


Mayo researchers find potential links between breast density and breast cancer risk

Having dense breasts -- areas that show up dark on a mammogram -- is strongly associated with increased breast cancer risk, but "why" remains to be answered. Now, by examining dense and non-dense tissue taken from the breasts of healthy volunteers, researchers from Mayo Clinic have found several potential links.

Lees verder


Study firmly ties hormone use to breast cancer

Taking menopause hormones for five years doubles the risk for breast cancer, according to a new analysis of a big federal study that reveals the most dramatic evidence yet of the dangers of these still-popular pills.

Lees verder


Study examines the mechanisms that silence the estrogen receptor gene alpha during breast cancer

The mechanisms that silence the estrogen receptor gene alpha (ER-?) in certain breast cancer cell lines may be closer to being unlocked, according to a study by researchers at Temple University's Sbarro Institute for Cancer Research and Molecular Medicine.

Lees verder


UCSB scientists show how certain vegetables combat cancer

Women should go for the broccoli when the relish tray comes around during holiday celebrations this season. While it has been known for some time that eating cruciferous vegetables, such as broccoli, cauliflower, and cabbage, can help prevent breast cancer, the mechanism by which the active substances in these vegetables inhibit cell proliferation was unknown — until now. Scientists in the UC Santa Barbara laboratories of Leslie Wilson, professor of biochemistry and pharmacology, and Mary Ann Jordan, adjunct professor in the Department of Molecular, Cellular, and Developmental Biology, have shown how the healing power of these vegetables works at the cellular level. Their research is published in this month's journal Carcinogenesis. "Breast cancer, the second leading cause of cancer deaths in women, can be protected against by eating cruciferous vegetables such as cabbage and near relatives of cabbage such as broccoli and cauliflower," said first author Olga Azarenko, who is a graduate student at UCSB. "These vegetables contain compounds called isothiocyanates which we believe to be responsible for the cancer-preventive and anti-carcinogenic activities in these vegetables. Broccoli and broccoli sprouts have the highest amount of the isothiocyanates.

Lees verder


Hormone Use Likely Cause of Decline in Breast Cancer Incidence

A decline in breast cancer incidence among women who received regular mammograms implicates hormone use as the most likely cause of a widely-reported drop in breast cancer incidence in the United States.

Lees verder


American Researchers Question Effect of Scandinavian Mammography Debate

A public row is taking place among some European investigators over a 22-year-old study that helped lay the foundation for mammography screening worldwide. Some experts question if it could—or even should—affect current practice in the United States

Lees verder


Newly created cancer stem cells could aid breast cancer research

Scientists have created breast cancer stem cells in culture by isolating and transforming a particular population of cells from normal human breast tissue. After being injected with just 100 of these transformed cells, mice develop tumors that metastasize. When scientists performed the same transformation process on a slightly different population of cells from the identical human breast tissue, the resulting cancer cells were 10,000 times less potent as tumor initiators and could not move to other tissues.

Lees verder


Dense breasts, hormone levels are 2 separate, independent risk factors for breast cancer

The density of a woman's breast tissue and her level of sex hormones are two strong and independent risk factors for breast cancer, according to a team of researchers from Harvard and Georgetown universities. The finding dispels the common belief that the risk associated with dense breasts merely reflects the same risk associated with high levels of circulating sex hormones, they say.

Lees verder


Breast cancer - How tumor cells break free and form metastases

When tumor cells acquire the capacity to move around and invade other tissues, there is a risk ofmetastases and cancer treatment becomes more difficult. At the Institut Curie, CNRS Director of Research Philippe Chavrier and his group have just discovered how breast cancer cells break the bonds that tether them to the tumor. The basement membrane around the mammary gland is a barrier to the spread of cancer cells. Three proteins in the tumor cells transport enzymes needed to perforate this barrier, and another protein puts these enzymes in the right place. These discoveries, published in the 16 June 2008 issue of The Journal of Cell Biology and in Current Biology on 8 July 2008, shed light on the early mechanisms of the formation of metastases in certain breast cancers. These findings constitute an essential step in the quest for the early identification of highly invasive tumors, or even the blocking of formation of metastases.

Lees verder


New link between estrogen and breast cancer

the female sex hormone estrogen turns on a gene linked to breast cancer, according to new research by Brisbane scientists. The cancer biology team from UQ's Diamantina Institute for Cancer, Immunology and Metabolic Medicine, believe their finding will help explain the link between breast cancer and high levels of estrogen. “What we've shown is that the ability of estrogen to switch this gene on is important for the growth of breast cancer cells,” Diamantina cancer biology research leader Professor Tom Gonda said. The gene they studied, known as MYB, is found in about 70 percent of all breast cancers and is one of several dozen genes called oncogenes that promote cancer growth. “What's important in breast cancer is the ability of estrogen to turn on MYB rather than there being a mutation in the gene itself,” Professor Gonda said.

Lees verder


HWI scientist first in world to unravel structure of key breast cancer target enzyme

The molecular details of Aromatase, the key enzyme required for the body to make estrogen, are no longer a mystery thanks to the structural biology work done by the Ghosh lab at the Hauptman-Woodward Medical Research Institute (HWI) in Buffalo, New York. Dr. Debashis Ghosh's solution of the three-dimensional structure of aromatase is the first time that scientists have been able to visualize the mechanism of synthesizing estrogen. In fact, the Ghosh lab has determined the structures of all three of the enzymes involved in controlling estrogen levels that can serve as drug targets for estrogen-dependent tumors in breast cancer. This work is so significant, the world-renowned journal Nature will be publishing the structure of aromatase at 2.90 angstrom resolution in an upcoming issue. The other two enzyme structures determined by the Ghosh lab as part of this project were estrone sulfatase (2003) and 17beta-hydroxysteroid dehydrogenase type 1 (1996). All three enzymes control the levels of estradiol in different tissues. "This is a dream come true," Dr. Debashis Ghosh, an HWI senior research scientist and a principal investigator who also holds a joint faculty appointment at the Roswell Park Cancer Institute (RPCI), said. "Scientists worldwide have been trying for 35 years to crystallize this membrane-bound enzyme and we are the first to succeed. Now that we know the structures of all three key enzymes implicated in estrogen-dependant breast cancers, our goal is to have a personalized cocktail of inhibitors customized to the specific treatment needs of each patient. Our knowledge about these three enzymes will enable us to develop three mutually exclusive inhibitors customized to each patient's needs which will work in harmony together with minimal side effects."

Lees verder


Dense Breasts, Hormone Levels Are Two Separate, Independent Risk Factors For Breast Cancer

The density of a woman’s breast tissue and her level of sex hormones are two strong and independent risk factors for breast cancer, according to a team of researchers from Harvard and Georgetown universities.

Lees verder


Herceptin targets breast cancer stem cells

A gene that is overexpressed in 20 percent of breast cancers increases the number of cancer stem cells, the cells that fuel a tumor’s growth and spread, according to a new study from the University of Michigan Comprehensive Cancer Center. The gene, HER2, causes cancer stem cells to multiply and spread, explaining why HER2 has been linked to a more aggressive type of breast cancer and to metastatic disease, in which the cancer has spread beyond the breast, the researchers say. Further, the drug Herceptin, which is used to treat HER2-positive breast cancer, was found to target and destroy the cancer stem cells. Results of the study appear online in the journal Oncogene.

Lees verder


High insulin levels raise risk of breast cancer in postmenopausal women

Higher-than-normal levels of insulin place postmenopausal women at increased risk of breast cancer, researchers at Albert Einstein College of Medicine of Yeshiva University report. Their findings, published in the January 7 issue of the Journal of the National Cancer Institute, suggest that interventions that target insulin and its signaling pathways may decrease breast cancer risk in these women. Breast cancer is the most common cancer among women in the United States. Last year, approximately 182,000 women were diagnosed with breast cancer and more than 40,000 died from the disease. The majority of breast cancers arise in women past the age of menopause. Obesity is a well-established risk factor for postmenopausal breast cancer, but just how obesity and breast cancer are connected is unclear. Many researchers have assumed that the link is estrogen—a hormone that is known to increase breast-cancer risk and is found at higher-than-average levels in obese women. But obese women also have other hormonal imbalances that may play a role in triggering breast cancer. One such imbalance is elevated levels of insulin, which stimulates the growth of breast cells in tissue culture. The Einstein study is the first to prospectively identify insulin's role in breast cancer while controlling for estrogen levels. The multi-year Women's Health Initiative (WHI)—the largest study of postmenopausal women ever funded by the National Institutes of Health—followed health outcomes in more than 93,000 postmenopausal women. At enrollment, each participant donated blood samples that were stored for later analysis.

Lees verder


High-fat Diet Linked to Increased Breast Cancer Risk

A diet high in fat significantly increases a woman's risk of developing invasive breast cancer, according to a study conducted by researchers at the National Cancer Institute in Bethesda, Maryland, and published in the Journal of the National Cancer Institute.

Lees verder


Jefferson Researchers Show Antibody to Breast Cancer-Secreted Protein Blocks Metastasis

Scientists at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia have made a key discovery about the mechanism of breast cancer metastasis, the process by which cancer spreads. Focusing on a gene dubbed “Dachshund,” or DACH1, they are beginning to pinpoint new therapeutic targets to halt the spread of cancer.

Lees verder


Researchers identify cancer preventive properties in common vitamin supplement

Early laboratory research has shown that resveratrol, a common dietary supplement, suppresses the abnormal cell formation that leads to most types of breast cancer, suggesting a potential role for the agent in breast cancer prevention. Resveratrol is a natural substance found in red wine and red grapes. It is sold in extract form as a dietary supplement at most major drug stores.

Lees verder


Bras Shown to Cause Cancer

Is it possible that wearing a bra can actually cause cancer? Studies show that this is a very real possibility. The reason is that regularly wearing a bra prevents lymph drainage and circulation, which can greatly increase the possibility of developing breast cancer. The lymphatic and circulatory systems are responsible for both delivering vital nutrients and clearing out toxins. When the body does not have access to nutrients or when it is under the attack of toxins, cancer may develop.

Lees verder


Reduced breast cancer risk - Physical activity after menopause pays off

Several studies had previously suggested that regular physical exercise reduces the breast cancer risk of women. However, it had been unknowned just how much exercise women should take in which period in life in order to benefit from this protective effect. Moreover, little was known about which particular type of breast cancer is influenced by physical activity. Answers to these questions are now provided by the results of the MARIE study, in which 3,464 breast cancer patients and 6,657 healthy women between the ages of 50 and 74 years were questioned in order to explore the connections between life style and breast cancer risk. Participants of the study, which was headed by Professor Dr. Jenny Chang-Claude and conducted at the German Cancer Research Center and the University Hospitals of Hamburg-Eppendorf, were questioned about their physical activity during two periods in life: from 30 to 49 years of age and after 50. A comparison between control subjects and breast cancer patients showed that women in the control group had been physically more active than patients. The scientists calculated the relative breast cancer risks taking account of the effect of other risk factors. Results show that the risk of developing breast cancer after menopause was lower by about one third in the physically most active MARIE participants compared to women who had generally taken little physical exercise.

Lees verder


Less Swedish women getting breast cancer

The Swedish government says a reduction in hormonal therapy has resulted in fewer cases of breast cancer among women 45 and older.

Lees verder


Researchers identify new protein that triggers breast cancer

Canadian researchers have identified a new protein in the progression of breast cancer. According to a recent study from the Universitť de Montrťal and the University of Alberta, published in the Journal of Biological Chemistry, the protein ARF1 plays a critical role in cancer cell growth and the spread of tumours. Targeting this protein with drug therapy may provide hope to women with breast cancer."Until now, ARF1 has been associated with harmless albeit important housekeeping duties of cells," says senior author Audrey Claing, a professor of pharmacology at the Universitť de Montrťal. "The Universitť de Montrťal and the University of Alberta team is the first to characterize the role of ARF1 in breast cancer."Dr. Claing and her colleagues used invasive breast cancer cell lines to study ARF1's role. These cells are sensitive to a particular growth factor, called epidermal growth factor or EGF, which has previously been shown to stimulate tumour growth and invasion. Their findings suggest that EGF works through ARF1 in these cells. In addition, when ARF1 activity was chemically blocked, breast cancer cell migration and growth was reduced. Conversely, when ARF1 was overproduced in these cells, their movement was enhanced.

Lees verder


Dental student designs possible treatment for facial and breast reconstruction

Someday, patients disfigured by cancer, birth defects or trauma could benefit from the research of Michael Stosich, a third-year student at the Maurice H. Kornberg School of Dentistry at Temple University. In a paper published in the September issue of the journal Tissue Engineering, Stosich and Jeremy Mao, associate professor of orthodontics at Columbia University, found promise in a technique that would use a patient’s own stem cells to regrow soft tissue damaged by facial tumors, breast cancer, injury or a congenital abnormality, such as cleft lip and palate.

Lees verder


Vitamin A pushes breast cancer to form blood vessel cells

Researchers at Georgetown University Medical Center have discovered that vitamin A, when applied to breast cancer cells, turns on genes that can push stem cells embedded in a tumor to morph into endothelial cells. These cells can then build blood vessels to link up to the body's blood supply, promoting further tumor growth. They say their findings, published in the July 16 online issue of PLoS ONE, is a proof of principle of the new – and controversial – "vasculogenic mimicry" theory, proposing that, as needed, tumors build their own blood pipelines. This is very different from the well-accepted role of tumor angiogenesis, when tumors send signals to blood vessels to grow toward the cancer. The study's senior author, Stephen W. Byers, Ph.D., a professor of oncology and cell biology at Georgetown's Lombardi Comprehensive Cancer Center, also says that this study helps explain why retinoids-- natural or synthetic vitamin A agents--have had mixed results in treating cancer. "Finding that vitamin A may cause some breast cancer cells to form blood vessels brings up the rather disturbing notion that treatment with these drugs may actually stimulate tumor growth," says Byers.

Lees verder


New breast cancer test under study

Whether a painless, portable device that uses electrical current rather than X-ray to look for breast cancer could be an alternative to traditional mammograms is under study at the Medical College of Georgia. MCG is one of 20 centers internationally studying new technology developed by Z-Tech Inc., to compare traditional mammograms to impedence scanning, a technique based on evidence that electrical current passes through cancerous tissue differently than through normal tissue.

Lees verder


McGill researchers link enzyme to breast cancer malignancy

McGill University researchers have uncovered the crucial role played by the enzyme focal adhesion kinase in the onset of breast cancer. The research, led by Dr. William Muller -- along with colleagues from McGill and the Beatson Institute for Cancer Research in Scotland -- was published the week of November 26 in the Proceedings of the National Academy of Sciences. The study's first author is Dr. Hicham Lahlou, a post-doctoral fellow in Dr. Muller's lab.

Lees verder


Breast MRI spots other cancers, may alter treatment plan

MRI, which is not routinely administered to women who plan to undergo a lumpectomy, can find additional cancerous areas in the breast that previously evaded detection, discover cancer in the opposite breast that standard imaging tests such as mammography and ultrasound missed, or determine a tumor is actually larger than expected.

Lees verder


Household chemical may affect breast development

A chemical found in household fittings has been found to affect the development of the mammary gland in rats and further studies will be required to determine if the presence of this chemical could lead to breast cancer. New research published in the online open access journal BMC Genomics is the first to show that this chemical can affect the breasts' genomic profile.

Lees verder


Hip bone density helps predict breast cancer risk

Bone density provides information that may help more accurately determine the risk of developing breast cancer.

Lees verder


Device zeroes in on small breast tumors

A new medical imager for detecting and guiding the biopsy of suspicious breast cancer lesions is capable of spotting tumors that are half the size of the smallest ones detected by standard imaging systems, according to a new study. The results of initial testing of the PEM/PET system will be published in the journal Physics in Medicine and Biology on Feb. 7.

Lees verder


Breast Cancer Deception

Breast Cancer Deception, an eye-opening special report by Mike Adams, the Health Ranger. This is a shocking, tell-all report that exposes the scam of today's breast cancer industry, revealing how conventional breast cancer detection and treatment programs are actually designed to ensnare women into a very harmful (but highly lucrative) system of toxic treatments that will only cause permanent damage to her health.

Lees verder


Chemical in Nail Polish, Lipstick Linked to Breast Cancer

A chemical commonly used to soften plastic and in lipstick, nail polish and other household items has been found to interfere with the development of healthy breast tissue, which could lead to breast cancer, according to a new study.

Lees verder


Researchers find breast cancer trigger

Now researchers claim today in the journal Nature Genetics that they have solved this puzzle. Their finding sheds new light on the cause of a particularly aggressive kind of breast cancer, which may represent a target for a new generation of treatments focused on holding the growth of tumour cells in check.

Lees verder


CSHL scientists identify and repress breast cancer stem cells in mouse tissue

By manipulating highly specific gene-regulating molecules called microRNAs, scientists at Cold Spring Harbor Laboratory report that they have succeeded in singling out and repressing stem-like cells in mouse breast tissue -- cells that are widely thought to give rise to cancer.

Lees verder


First step towards switching off breast cancer and leukaemia

Australian scientists have identified a way to ‘switch off’ a molecule, a key player in the molecular processes that trigger breast cancer and certain forms of leukaemia. The molecule, known as Gab2, operates downstream of a major breast cancer oncogene, HER2, the target of the drug Herceptin. A research team from the Garvan Institute of Medical Research, led by Professor Roger Daly, has found a novel way of blocking signals to and from Gab2, preventing it from fulfilling its role in cell proliferation. The finding is published online today in the EMBO Journal.

Lees verder


The Relationship Between Root Canals and Cancer

Dr. Thomas Rau, who runs the Paracelsus Clinic (cancer clinic since 1958) in Switzerland recently checked the records of the last 150 breast cancer patients treated in his clinic. He found that 147 of them (98%) had one or more root canal teeth on the same meridian as the original breast cancer tumor. His clinic has a biological dentist section where all cancer patients, on reporting in, have their mouth cleaned up first -- especially all root canal teeth removed.

Lees verder


Vet medicine researcher examines link between cancer, Down syndrome

There's new hope for breast cancer research, and it's coming from a very unlikely place. Researchers at the Texas A&M University College of Veterinary Medicine & Biomedical Sciences recently published articles in the journals Molecular and Cellular Biology and Carcinogenesis indicating that a protein long suspected to play a role in Down Syndrome may also contribute to treating this devastating disease.

Lees verder


U.S. researchers regenerate lost breast tissue

U.S. researchers have successfully tested the method of mixing a woman's stem cells with her body fat to partly-regenerate breasts after partial masectomies, it was announced on Sunday.

Lees verder


Breast Cancer Deception

Breast Cancer Deception, an eye-opening special report by Mike Adams, the Health Ranger. This is a shocking, tell-all report that exposes the scam of today's breast cancer industry, revealing how conventional breast cancer detection and treatment programs are actually designed to ensnare women into a very harmful (but highly lucrative) system of toxic treatments that will only cause permanent damage to her health.You've never read anything like this about breast cancer. It's the report the industry would prefer to censor, because it contains startling truths about how the cancer industry actually feeds upon the continuation of this disease while censoring natural cancer prevention strategies that could halt 90 percent of all future cancers starting right now.

Lees verder


Vitamin D & Cardiovascular Health, Vitamin D & Breast Cancer, Green Tea & Cancer

When comparing the women with the highest blood levels of Vitamin D against the women with the lowest levels, the results were rather striking. Having the highest levels of Vitamin D in the blood was associated with a nearly 70% reduction in the risk of breast cancer, in this population of Northern European women, when compared to similar women with low Vitamin D levels.

Lees verder


Phoenix lab develops blood test for breast cancer

Provista Life Sciences LLC developed a blood test that can detect breast cancer early, when patients have a much higher survival rate.

Lees verder


How DDT metabolite disrupts breast cancer cells

Research has shown that the main metabolite of the insecticide DDT could be associated with aggressive breast cancer tumors, but there has been no explanation for this observation to date. Now a report published in the open access journal Breast Cancer Research shows how DDT could act to disrupt hormone-sensitive breast cancer cells.

Lees verder


Does hormone treatment predispose patients to breast cancer?

Breast cancer, the leading cause of death among women in France, is the most commonly occurring cancer in women. Sporadic breast cancer, which is non-hereditary, turns out to be the most widespread, representing 85 to 90% of all cases, but remains the least well-known. Researchers at CNRS and CEA (1), working with a team from HŰpital Saint-Louis (2), have just discovered the cause of 50% of sporadic breast cancers. The results should also explain epidemiological studies which suggest that hormone treatment predisposes patients to breast cancer. The work is published in 'Cancer Research'.More than four out of five breast cancers are not related to hereditary factors. These cancers, which are called sporadic, are due to causes which were until recently considered complex and poorly understood. On the other hand, hereditary forms of cancer, which represent only 10 to 15% of breast cancers, have for years been the subjects of studies, work which has resulted in the identification of ten genes whose mutation increases the risk of cancer in an individual. Among these genes, nine are involved in the DNA damage response system, which is the collection of cell mechanisms that optimize the repair of DNA. The tenth gene codes for a protein which inhibits the action of the AKT1 enzyme. And among these ten genes, two are responsible for 50% of hereditary breast cancers: BRCA1 and BRCA2. Researchers from the "Radiobiologie molťculaire et cellulaire" (CNRS / CEA) lab took these data on hereditary cancers as the starting point for their research into non-hereditary forms.

Lees verder


The Breast Cancer Gene in Men Carries Increased Risks

Men who have a BRCA-1 or -2 gene mutation have twice the normal risk of prostate cancer, triple the normal risk of pancreas cancer, and 7 times more likely to develop breast cancer (it can happen in men, too.)

Lees verder


CSHL scientists show how a protein that determines cell polarity prevents breast cancer

A team of scientists at Cold Spring Harbor Laboratory has found that a protein called Scribble, originally discovered as a cell-shape regulator in fruit flies and worms, is an important regulator of breast cancer. They report that Scribble normally directs breast epithelial cells to form the structures that give breast tissue its shape and thereby resist cancer formation. When Scribble stops functioning, the tissue loses its shape and cancers ensue.

Lees verder


Eating eggs when pregnant affects breast cancer in offspring

A stunning discovery based on epigenetics (the inheritance of propensities acquired in the womb) reveals that consuming choline—a nutrient found in eggs and other foods—during pregnancy may significantly affect breast cancer outcomes for a mother's offspring. This finding by a team of biologists at Boston University is the first to link choline consumption during pregnancy to breast cancer. It also is the first to identify possible choline-related genetic changes that affect breast cancer survival rates. "We've known for a long time that some agents taken by pregnant women, such as diethylstibesterol, have adverse consequences for their daughters," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "But there's an upside. The emerging science of epigenetics has yielded a breakthrough. For the first time, we've learned that we might be able to prevent breast cancer as early as a mother's pregnancy." The researchers made the discovery in rats by studying females whose mothers were fed varying amounts of choline during pregnancy. Different groups of pregnant rats received diets containing standard amounts of choline, no choline at all, or extra choline. Then the researchers treated the female offspring with a chemical that causes cancer of the mammary gland (breast cancer). Although animals in all groups developed mammary cancer, the daughters of mothers that had received extra choline during pregnancy had slow growing tumors while daughters of mothers that had no choline during pregnancy had fast growing tumors.

Lees verder


Angled gantry technique reduced breast radiation exposure by 50 percent

A novel angled gantry approach to coronary CT angiography reduced radiation exposure to the breast by more than 50%, according to Thomas Jefferson University researchers. Ethan Halpern, M.D., associate professor of Radiology at Jefferson Medical College of Thomas Jefferson University in Philadelphia, presented the research at the 94th Scientific Assembly and Annual Meeting of the Radiological Society of North America. "Radiation dose to the breast during coronary CT is especially a concern for young women as the dose may increase the risk for breast cancer," Dr. Halpern said. "Physicians are working diligently to reduce the patient radiation dose related to coronary CT."Dr. Halpern and colleagues retrospectively reviewed 100 consecutive coronary CT angiography images that were obtained with a 64 detector helical scanner. They evaluated sagital images to: 1) define the position of the breasts and the gantry angulation required to perform a CT examination parallel to the long axis of the heart; and 2) determine the reduction in breast exposure to radiation that might be accomplished by imaging the heart with an angled gantry acquisition.

Lees verder


Broccoli compound targets key enzyme in late-stage cancer

An anti-cancer compound found in broccoli and cabbage works by lowering the activity of an enzyme associated with rapidly advancing breast cancer, according to a University of California, Berkeley, study appearing this week in the online early edition of the journal Proceedings of the National Academy of Sciences. The compound, indole-3-carbinol, is already undergoing clinical trials in humans because it was found to stop the growth of breast and prostate cancer cells in mice. The new findings are the first to explain how indole-3-carbinol (I3C) stops cell growth, and thus provides the basis for designing improved versions of the chemical that would be more effective as a drug and could work against a broader range of breast as well as prostate tumors. "I think one of the real uses of this compound and its derivatives is combining it with other kinds of therapies, such as tamoxifen for breast cancer and anti-androgens for prostate cancer," said coauthor Gary Firestone, UC Berkeley professor of molecular and cell biology. "Humans have co-evolved with cruciferous vegetables like broccoli and Brussels sprouts, so this natural source has a lot fewer side effects."

Lees verder


New Breast Imaging Technology Targets Hard-to-Detect Cancers

Breast-specific gamma imaging (BSGI) is effective in the detection of cancers not found on mammograms or by clinical exam, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA). "BSGI can identify the most difficult to detect breast cancer—invasive lobular carcinoma," said lead author Rachel F. Brem, M.D., professor of radiology and director of the Breast Imaging and Interventional Center at The George Washington University Medical Center in Washington, D.C. "It also can help us detect additional lesions of all types of breast cancer in women whose mammograms show only one suspicious lesion." Breast cancer affects more women than any other non-skin cancer and, according to the American Cancer Society, accounts for more than 40,000 deaths annually in the U.S. Most experts agree that the best way to decrease breast cancer mortality is through early detection using mammography and clinical breast exam. However, some cancers are difficult to detect with mammography and clinical exam, particularly in the earliest stage when treatment is most effective. While mammography findings are characterized by the difference in appearance between normal and suspicious breast tissue, BSGI findings are based on how cancerous cells function.

Lees verder


Combined HRT increases risk of lobular breast cancer fourfold after just 3 years of use

Postmenopausal women who take combined estrogen/progestin hormone-replacement therapy for three years or more face a fourfold increased risk of developing various forms of lobular breast cancer, according to new findings by researchers at Fred Hutchinson Cancer Research Center.

Lees verder



 

 

 


View My Stats